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Abstract 
Hypoxia signalling pathway acts in all mammalian cells to try and avert damage occurring 
during periods of limited oxygen availability (hypoxia). The cellular response to a low 
oxygen environment is mediated by the transcription factor hypoxia-inducible factor (HIF), 
which activates the transcription of genes that aid cell survival and act to restore oxygen 
homeostasis. The heterodimeric transcription factor consists of a constitutively expressed 
beta subunit (HIF-1β) & an alpha subunit (HIF-1α / HIF-2α). The alpha subunits are 
regulated in an oxygen-dependent manner.  
The main aim of this thesis was to elucidate if the spatial localisation and/or the temporal 
fluctuations of HIF-1α and HIF-2α are altered in response to hypoxia and participate to the 
regulation of HIF activity. The experimental strategy focused on studying HIF at several 
scales ranging from single cell to single molecule level. I first investigated the temporal and 
spatial dynamics of the HIF-α subunits in living cells using time-lapse imaging. This was part 
of a larger study, which was initiated before the start of this thesis. It was published in 
January 2014 in the Journal of Biological Chemistry. We demonstrated that HIF-α 
accumulates transiently in the nucleus in response to hypoxia and this was necessary to 
ensure cell survival. We further demonstrated using a combination of mathematical 
modelling and knock-down experiments that the negative feedback loop involving PHD2 
has an essential role in these dynamics. Secondly, we observed that HIF-2α exhibits a non-
homogenous sub-nuclear localisation, whereas HIF-1α is distributed homogenously within 
the nucleus. Since protein localisation is commonly linked to function we sought to 
elucidate the purpose of this heterogeneous distribution using a combination of live cell 
imaging, co-localisation and photo-bleaching experiments. Lastly, to avoid molecule 
averaging errors, we planned to employ single molecule tracking to elucidate sub-cellular 
dynamics of HIF-2α and gain further insight into the movement of HIF-2α between the 
speckles and the rest of the nucleus. Our aim was to image and monitor gold nanoparticles 
(GNPs) conjugated to HIF-2α in real time in living cells, using photo-thermal microscopy. In 
collaboration with Prof. D. G. Fernig and Dr. R. Levy’s research groups, we developed a 
protocol using the Halotag (an engineered enzyme that reacts with a substrate (Halo-
ligand) to form a covalent bond) to label a protein of interest with gold nanoparticles. This 
was achieved by: immobilising the Halotag ligand on the surface of GNPs and producing 
purified recombinant Halotag-fusion protein. We have obtained positive results by using 
ii 
the fibroblast growth factor 2 as proof of principle. Due to difficulties in expression and 
purification of recombinant Halotag-HIF-2α single molecule tracking of HIF-2α has not been 
achieved yet, but this work is still on-going.  
Overall my results show that:  (1) the temporal dynamics of HIF-1α elicited by hypoxia have 
a critical role in HIF activity and function, (2) the non-homogenous speckle localisation of 
HIF-2α is associated with a slow diffusion time within the nucleus, 7-10X (depending on 
condition) slower than the homogeneous HIF-1α. Finally, using single molecule 
measurements, we did not observe any significant difference in speckle organisation or 
HIF-2α mobility, so single molecular tracking will be required to provide a non-average 
quantitative measurement of HIF-2α movement between the speckles and inter-speckle 
space. 
iii 
Contents 
 
ABSTRACT                i 
CONTENTS              iii 
LIST OF FIGURES             vii 
LIST OF TABLES            viii 
LIST OF SUPPLEMENTAL DATA            ix 
ABBREVIATIONS               x 
 
CHAPTER 1: INTRODUCTION....................................................................................................... 1 
1.1 Cell signalling ............................................................................................................................... 2 
1.2 Oxygen and metabolism .............................................................................................................. 2 
1.3 Hypoxia ........................................................................................................................................ 4 
1.3.1 Maintaining oxygen homeostasis ......................................................................................... 5 
1.4 Hypoxia-inducible factor (HIF) ..................................................................................................... 5 
1.4.1.1 HIF-α .............................................................................................................................................. 6 
1.4.1.2 HIF-β .............................................................................................................................................. 6 
1.4.2 Oxygen-Dependent regulation of HIF ................................................................................... 7 
1.4.3 Oxygen-independent regulation of HIF ................................................................................ 9 
1.5 HIF-1α versus HIF-2α.................................................................................................................. 10 
1.5.1 Differential regulation of the HIF-α isoforms ..................................................................... 11 
1.5.2 Differential roles of HIF-1α and HIF-2α in physiological processes .................................... 16 
1.5.3 Differential role of HIF-1α and HIF-2α in disease ............................................................... 19 
1.5.4 Tissue distribution .............................................................................................................. 21 
1.5.5 Cellular localisation............................................................................................................. 21 
1.6 The Cell Nucleus ......................................................................................................................... 22 
1.7 Microscopy ................................................................................................................................. 26 
1.7.1 A brief history of fluorescent confocal microscopy ............................................................ 26 
1.7.1.1 Fluorescence microscopy and labelling methods ........................................................................ 28 
1.7.2 Probing the dynamics of proteins further .......................................................................... 29 
1.7.2.1 FCS ............................................................................................................................................... 30 
1.7.2.2 FRET ............................................................................................................................................. 30 
1.7.2.3 FRAP ............................................................................................................................................ 31 
1.7.3 Super-resolution microscopy.............................................................................................. 32 
1.7.4 Single molecule tracking (SMT) .......................................................................................... 33 
1.8 Project aims ............................................................................................................................... 34 
CHAPTER 2: MATERIALS AND METHODS .................................................................................. 35 
2.1 Chemicals and reagents ............................................................................................................. 36 
2.2 Molecular Biology ...................................................................................................................... 36 
2.2.1 Plasmids .............................................................................................................................. 36 
2.2.2 Propagation of Expression Plasmid DNA ............................................................................ 36 
iv 
2.2.2.1 Transformation............................................................................................................................ 36 
2.2.2.2 Small scale Plasmid DNA purification (Mini-prep) ....................................................................... 37 
2.2.2.3 Large Scale Plasmid DNA purification (Maxi-Prep) ...................................................................... 37 
2.2.3 Polymerase Chain Reaction (PCR) ...................................................................................... 38 
2.2.4 Restriction Digests .............................................................................................................. 39 
2.2.5 Plasmid Cloning .................................................................................................................. 39 
2.3 Cell Culture................................................................................................................................. 42 
2.3.1 Cell line propagation ........................................................................................................... 42 
2.3.2 Cell treatments ................................................................................................................... 43 
2.3.3 Transient Transfection ........................................................................................................ 43 
2.4 Stable cell line production ......................................................................................................... 44 
2.4.1 Lentivirus ............................................................................................................................ 44 
2.4.1.1 Viral particle production ............................................................................................................. 44 
2.4.1.2 Transduction of HeLa cells .......................................................................................................... 44 
2.4.2 Bacterial artificial Chromosome (BAC) ............................................................................... 45 
2.5 Microscopy ................................................................................................................................. 46 
2.5.1 Overview of Microscopes used .......................................................................................... 46 
2.5.2 Immunofluorescence (IF) .................................................................................................... 48 
2.5.3 Imaging Fixed samples ........................................................................................................ 49 
2.5.4 Live cell imaging.................................................................................................................. 49 
2.5.4.1 LSM 510 ....................................................................................................................................... 49 
2.5.4.2 Epifluorescent microscope .......................................................................................................... 49 
2.5.5 Analysis ............................................................................................................................... 49 
2.5.5.1 Co-localisation analysis ............................................................................................................... 49 
2.5.5.2 Cell Tracker .................................................................................................................................. 50 
2.5.5.3 Characterisation of EGFP-HIF-2α Speckles .................................................................................. 50 
2.5.5.4 Analysis of EGFP-HIF-2α Speckle Dynamics ................................................................................. 50 
2.5.6 Advanced Microscopy Techniques ..................................................................................... 51 
2.5.6.1 Fluorescence Recovery After Photobleaching (FRAP) ................................................................. 51 
2.5.6.2 Fluorescence Loss in Photobleaching (FLIP) ................................................................................ 52 
2.6 Bulk cell analysis ........................................................................................................................ 53 
2.6.1 Western Blot ....................................................................................................................... 53 
2.6.2 Real-time qPCR (RT-qPCR) .................................................................................................. 54 
2.7 Recombinant protein and nanoparticle work ............................................................................ 56 
2.7.1 Bacterial transformation for recombinant protein expression .......................................... 56 
2.7.2 Assessing recombinant protein expression ........................................................................ 57 
2.7.3 Assessing recombinant protein solubility ........................................................................... 57 
2.7.4 Purification of Recombinant protein .................................................................................. 57 
2.7.5 Labelling bacterial cell lysates with Fluorescent Halotag Ligand for SDS PAGE ................. 58 
v 
2.7.6 Fluorescent labelling of Halotag-Fusion protein for microscopy ....................................... 58 
2.7.7 in vitro Protein Expression .................................................................................................. 59 
2.7.8 Expression of recombinant protein in Mammalian Cells.................................................... 59 
2.7.9 Gold Nanoparticles ............................................................................................................. 60 
2.7.9.1 Synthesis and Functionalisation of Gold Nanoparticles .............................................................. 60 
2.7.9.2 Gold nanoparticle conjugation .................................................................................................... 60 
2.7.9.3 UV-visible spectroscopy .............................................................................................................. 61 
2.7.9.4 Stripping Gold Nanoparticles ...................................................................................................... 61 
2.7.9.5 Dot Blot ....................................................................................................................................... 61 
2.7.9.6 Microinjection ............................................................................................................................. 61 
CHAPTER 3: INVESTIGATING THE TEMPORAL DYNAMICS OF HIF- AT THE SINGLE CELL LEVEL 62 
3.1 Investigating Protein Dynamics ................................................................................................. 63 
3.2 Tight Control of HIF-α Transient Dynamics Is Essential for Cell Survival in Hypoxia .................. 64 
3.3 Additional work .......................................................................................................................... 83 
3.3.1 Improving molecular tools for imaging: HIF-1α-GFP stable cell line .................................. 83 
3.3.1.1 HIF-1α-GFP BAC stable cell line ................................................................................................... 84 
3.4 Conclusion .................................................................................................................................. 88 
3.4.1 Imaging tools ...................................................................................................................... 88 
CHAPTER 4: INVESTIGATING THE SPATIAL LOCALISATION OF HIF-1 AND HIF-2 .................... 90 
4.1 Is the non-homogenous nuclear localisation of HIF-2α functionally relevant? ......................... 92 
4.1.1 Characterisation of HIF-2α speckles ................................................................................... 92 
4.1.2 Speckle mobility.................................................................................................................. 93 
4.1.3 Protein co-localisation ........................................................................................................ 98 
4.1.3.1 Other nuclear bodies ................................................................................................................... 99 
4.1.4 Molecular Mobility ........................................................................................................... 103 
4.1.4.1 Nuclear proteins and FRAP ........................................................................................................ 103 
4.1.4.2 Molecular mobility of HIF-2α .................................................................................................... 103 
4.1.4.3 Molecular mobility of HIF-2α compared to HIF-1α ................................................................... 108 
4.2 Conclusion ................................................................................................................................ 111 
CHAPTER 5: DEVELOPMENT OF TOOLS FOR SINGLE MOLECULE TRACKING IN LIVING CELLS ... 113 
5.1 Can the Halotag be used for conjugation of a protein to a gold nanoparticle? ....................... 118 
5.1.1 Testing the Halotag approach for labelling a protein of interest with gold nanoparticles118 
5.1.1.1 Expressing recombinant Halotag-FGF2 ..................................................................................... 118 
5.1.1.2 Optimisation of Halotag-FGF2 purification protocol ................................................................. 120 
5.1.1.3 Testing the functionality of purified Halotag-FGF2 ................................................................... 123 
5.1.1.4 Labelling Halotag-FGF2 with gold nanoparticles via the Halotag ligand ................................... 124 
5.2 Expression & purification of Halotag-HIF-2α ........................................................................... 125 
5.2.1 Expressing Halotag-HIF-2α in bacteria ............................................................................. 127 
5.2.1.1 Bacterial Expression System: Troubleshooting.......................................................................... 131 
5.2.1.2 Expression of Halotag-HIF-2α in E.coli: Conclusion ................................................................... 133 
vi 
5.2.2 Cell-free protein expression ............................................................................................. 134 
5.2.3 Mammalian expression system ........................................................................................ 135 
5.2.3.1 in vivo conjugation .................................................................................................................... 136 
5.2.3.2 in vitro conjugation ................................................................................................................... 137 
5.2.3.3 Anti-GFP Nanobodies: A compromise? ..................................................................................... 140 
5.3 Conclusion ................................................................................................................................ 141 
CHAPTER 6: DISCUSSION ........................................................................................................ 144 
6.1 Utilising fluorescent confocal microscopy to investigate protein dynamics in living cells: 
Reflection and future prospects .................................................................................................... 145 
6.1.1 Stable cell lines ................................................................................................................. 145 
6.1.2 Data analysis ..................................................................................................................... 146 
6.1.3 Investigating molecular dynamics .................................................................................... 146 
6.2 HIF-1α versus HIF-2α................................................................................................................ 147 
6.2.1 Normoxic stabilisation of HIF-2α ...................................................................................... 147 
6.2.2 Not just a backup system ................................................................................................. 148 
6.3 Final remarks............................................................................................................................ 149 
 
 REFERENCES          150 
APPENDICES          173 
 
 
  
vii 
List of Figures 
Figure 1.1 Cellular metabolism 
Figure 1.2 Examples of the partial pressure of oxygen in different organs and tissues 
Figure 1.3 Domain structure of HIF-1α and HIF-1β 
Figure 1.4 Oxygen dependent regulation of HIF-α subunit 
Figure 1.5 Comparison of HIF-1α and HIF-2α domains. 
Figure 1.6 Differential effect of HIF-a levels on nitrous oxide production 
Figure 1.7 Differential role of HIF in disease 
Figure 1.8 Nuclear localisation of HIF-1α and HIF-2α in HeLa cells 
Figure 1.9 Structure of the nucleus 
Figure 1.10 Lightpath of an epi-fluorescence microscope 
Figure 1.11 Fluorescence recovery after photobleaching 
Figure 2.1 Overview of FRAP EGFP-HIF-2α analysis 
Figure 3.1 Validation of HIF-1α-GFP stable cell line 
Figure 3.2 HIF-1α-GFP BAC time-lapse experiments 
Figure 3.3 Comparison of HIF-1α dynamics in hypoxia 
Figure 4.1 Sub-nuclear localisation of HIF-2α 
Figure 4.2 Measurement of HIF-2α speckles 
Figure 4.3 Analysis of the HIF-2α trajectories 
Figure 4.4 Speed of individual HIF-2α speckles 
Figure 4.5 Schematic representation of the different types of diffusion 
Figure 4.6 Diffusion mode of the HIF-2α speckles 
Figure 4.7 Co-localisation of HIF-2α.with HIF-1β and RNAPII 
Figure 4.8 Co-localisation HIF-2α and other nuclear proteins 
Figure 4.9 EGFP-HIF-2α FRAP 
Figure 4.10 Comparing EGFP-HIF-2α mobility in different conditions 
Figure 4.11 Molecular mobility of HIF-2α measured using FLIP 
Figrue 4.12 Comparing EGFP-HIF-2α and HIF-1α-EGFP mobility 
Figure 5.1 Overview of GNP-Halotag plan 
Figure 5.2 Halotag-FGF2 recombinant protein expression test 
Figure 5.3 Trial purification of Halotag-FGF2 
Figure 5.4 Halotag-FGF2 purification tests 
Figure 5.5 Testing the activity of Halotag-FGF2 
Figure 5.6 Photothermal images of FGF2-Halotag-nanoparticles 
Figure 5.7 Halotag-HIF-2α recombinant protein in HeLa cells 
Figure 5.8 HIS-Halotag-HIF-2α expression in bacteria 
Figure 5.9 Induction of protein expression from different pETM-11 constructs 
Figure 5.10 BL21.pLysS DE3 E. coli expression and solubility test 
Figure 5.11 HIS-Halotag-HIF-2α expression in Rosetta DE3 E. coli 
Figure 5.12 PureExpress in vitro Protein Expression System (NEB) 
Figure 5.13 Plan for conjugation of mammalian expressed Halotag-HIF-2α 
Figure 5.14 Halotag-HIF-2α-IRES-dTomato 
Figure 5.15 Halotag-HIF-2α expressed in HEK293T cells 
Figure 5.16 Conjugation of HL-GNPs to Halotag-HIF-2α from mammalian cell lysate 
Figure 5.17 Labelling cells expressing EGFP-HIF-2α with anti-GFP nanobodies 
Figure 5.18 Microinjection of anti-GFP nanobodies into cells ectopically expressing 
EGFP-HIF-2α 
Figure 5.13 Plan for conjugation of mammalian expressed Halotag-HIF-2α 
Figure 5.14 Halotag-HIF-2α-IRES-dTomato 
Figure 5.15 Halotag-HIF-2α expressed in HEK293T cells 
viii 
Figure 5.16 Conjugation of HL-GNPs to Halotag-HIF-2α from mammalian cell lysate 
Figure 5.17 Labelling cells expressing EGFP-HIF-2α with anti-GFP nanobodies 
Figure 5.18 Microinjection of anti-GFP nanobodies into cells ectopically expressing 
EGFP-HIF-2α 
Figure 6.1 PHD enzymatic reaction. 
Figure 6.2 Theory of normoxic stabilisation of HIF-2α 
 
List of Tables 
Table 1.1 Examples of cellular processes that are up-regulated during hypoxia 
Table 1.2 Examples of protein-protein interactions that regulate transcription and 
translation of HIF-1α and HIF-2α mRNA in an O2-independent manner 
Table 1.3 Examples of post-translation modifications and protein-protein interactions 
that regulate protein stability and transcriptional activity of HIF-1α and HIF-2α 
in an O2-independent manner 
Table 1.4 Examples of target genes unique to HIF-1α or HIF-2α 
Table 1.5 Differential roles of HIF-1α and HIF-2α in cancer 
Table 1.6 Timeline of key events in the history of light microscopy 
Table 1.7 Key landmarks of FRET 
Table 2.1 Antibiotic concentrations used 
Table 2.2 Standard set up for PCR reaction 
Table 2.3 Standard conditions used for PCR reaction 
Table 2.4 Standard set up for restriction digest 
Table 2.5 Components used to create plasmids via Infusion HD cloning method 
Table 2.6 Primers used for infusion cloning 
Table 2.7 Sequencing primers 
Table 2.8 Cell lines and culturing conditions 
Table 2.9 Definition of different cell treatments 
Table 2.10 Volumes of reagents used for different vessels for transient transfection of 
HeLa cells 
Table 2.11 Microscopes used and the application used for 
Table 2.12 Details of settings used for different fluorophores on each microscope 
Table 2.13 Antibodies used for immunocytochemistry 
Table 2.14 Antibodies used for immunoblotting 
Table 2.15 Cycle parameters for RT-qPCR 
Table 2.16 Primers used for RT-qPCR 
Table 2.17 Details of the variations in protocols for transforming pET-M11-Halotag-HIF-
2α into different strains of competent cells 
Table 2.18 Antibiotics used for recombinant protein expression 
Table 4.1 Colocalisation analysis 
  
 
 
  
ix 
List of Supplemental Data 
Available on the attached CD 
Movies 
M1 HIF-1α-GFP BAC nuclear accumulation in hypoxia 
M2 HIF-2α speckles 
M3 Speckle trajectory 1 
M4 Speckle trajectory 2 
M5 FRAP - Tracking HIF-2α speckles in bleached region 
M6 FRAP - Tracking individual HIF-2α speckle in bleached region 1 
M7 FRAP - Tracking individual HIF-2α speckle in bleached region 2 
  
x 
List of Abbreviations 
aa Amino acid 
ADP Adenosine diphosphate 
aka Also known as 
APS Ammonium persulphate 
ARNT Aryl receptor nuclear transporter 
ATP Adenosine triphosphate 
BAC Bacterial artificial chromosome 
bHLH Beta helix loop helix 
bp nucleotide basepairs 
BSA Bovine serum albumin 
CBP CREB binding protein 
CCI Centre for cell imaging 
CM Carboxymethyl 
CMV Cytomegalovirus 
CREB cAMP response element-binding protein 
Da Daltons 
 DAEA Diethylaminoethanol  
ddH2O Ultrapure water / double distilleds water 
DM Double mutant 
DMEM Dulbecco’s modified medium 
DMOG Dimethyloxaloylglycine 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
dTOM  dTomato fluorescent protein 
DTT  Dithiothreitol  
xi 
e-  Electron 
 EDTA Ethylenediaminetetraacetic acid 
EGFP Enhanced green fluorescent protein 
EPAS  Endothelial PAS domain protein 1 
EPO Erythropoietin  
FADH Flavin adenine dinucleotide 
FBS Fetal Bovine serum (cell culture) 
FCS Fluorescence correlation spectroscopy 
FGF Fibroblast growth factor 
FIH Factor inhibiting HIF 
FLIP Fluorescence loss in photobleaching 
FRAP Fluorescence recovery after photobleaching 
FRET Förter / fluorescence resonance transfer 
GFP Green fluorescent protein 
GLUT Glucose transporter 
GNP Gold nanoparticles 
h Hours 
 HAF Hypoxia associated factor 
HDAC5 Histone de-acetylase 5 
HIF Hypoxia-inducible factor 
His Histadine 
 HisTag Poly-Histadine tag 
HIV Human immunodeficiency virus 
HL Halotag ligand 
HRE Hypoxia response element 
HT Halotag 
 IF Immunofluorescence 
xii 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IRES internal ribosome entry site 
Lab Laboratory 
LB Lysogeny broth aka Luria-Bertani medium 
LSM Laser scanning microscope 
MEM Modified eagle medium 
min Minute  
 mRNA Messenger RNA 
MSD Mean squared displacement 
MW Molecular weight 
NADH Nicotinamide adenine dinucleotide 
NiNTA Nickel nitrilotriacetic acid 
NLS Nuclear localisation signal 
OD600 Optical density measured at a wavelength of 600 
ODD Oxygen dependent degradation 
PAS PER-ARNT-SIM domain 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PEG Polyethylene glycol 
PEI Poly(ethylenimine) 
PER Period circadian protein 
PFA Paraformaldehyde 
PHD Prolyl hydroxylase domain protein 
pI Isoelectric point 
PML Promyelocytic leukemia protein 
POI Protein of interest 
PTM Post-translational modification 
xiii 
RNA Ribonucleic acid 
RNAPII RNA polymerase II 
ROI Region of interest 
RPM Revolutions per minute 
RT-qPCR Real time quantitative polymerase chain reaction 
SD Standard deviation 
SDS PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sec Seconds 
 SFC Splicing factor compartments 
sh Short hairpin RNA  
SIM Single minded protein 
SMSS Slope of the moment scaling factor 
SMT Single molecule tracking 
SR Super-resolution 
SUMO Small ubiquitin-like protein 
TAD Trans-activation domain 
TEMED Tetramethylethylenediamine 
TEV Tobacco etch virus 
TF Transcription factor 
TMR Tetramethylrhodamine 
Tris Tris(hydroxymethyl)aminomethane 
UV Ultraviolet light 
VEGF Vascular endothelial growth factor 
VHL von Hippel Lindau protein 
vs Versus 
WT Wild type 
YFP Yellow fluorescent protein 
 Chapter 1: Introduction 
  
Introduction 
2 
 1.1 Cell signalling 
Cell to cell communication is vital in multi-cellular organisms for coordination of cellular 
events such as metabolism and growth. Cell signalling is orchestrated by several factors 
such as signalling molecules (e.g. hormones and cytokines), that are detected via receptors 
that trigger a chain of events whereby proteins are sequentially activated / deactivated 
leading to the up / down regulation of genes and a change in protein expression.  
As well as signalling molecules, cells can sense changes in their environment. They 
relentlessly monitor and respond to environmental cues causing the activation / 
deactivation of signalling pathways. For example extreme temperatures, changes in pH and 
exposure to toxins trigger stress response pathways that orchestrate a change in gene 
expression facilitating cellular protection.  
In addition to this, cells monitor the levels of oxygen, a vital component for life, and it is the 
signalling pathway that facilitates cells to sense and adapt to low oxygen (hypoxia) that is 
the focus of this study.  
 1.2 Oxygen and metabolism 
As obligate aerobes, humans cannot survive without oxygen. Homo sapiens (and many 
other living organisms) require oxygen to generate chemical energy in the form of 
Adenosine triphosphate (ATP) to fuel energetically unfavourable processes and biochemical 
reactions at the cellular level. It is generated via a number of mechanisms in eukaryotic 
cells, but the greatest yield of ATP comes from aerobic respiration, a process involving the 
oxidation of organic compounds such as sugars (Figure 1.1).  
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Figure 1.1 ǀ Cellular metabolism. A simplified schematic of the three stages of cellular metabolism. Glucose 
is broken down into pyruvic acid in the cytosol. This product is transported into the mitochondria where it is 
converted into acetyl CoA. Acetyl CoA enters the Krebs cycle (aka citric acid cycle) which produces high energy 
electrons that are passed onto the electron transport chain (ETC), situated in the inner membrane. As the 
electrons travel down the ETC, it creates a proton gradient which drives ATP synthase to create ATP from ADP 
and Pi. Oxygen acts as the electron acceptor at the end of ETC and is split to create two molecules of water. *Net 
gain is 32 or 34 ATP molecules depending on which electron shuttle transports the electrons from the cytosol 
into the mitochondria.  
 
Glycolysis literally means “lysis of sugar”. One molecule of glucose is converted to two 
pyruvate molecules in a ten step process to yield a net gain of two ATP molecules. It is a 
primitive form of ATP production and is present in nearly all organisms including anaerobes 
as it does not require molecular oxygen. 
The pyruvate molecules produced are transported in the mitochondrial matrix where they 
are converted to acetyl CoA, the substrate of the Krebs cycle (citric acid cycle). Although the 
Krebs cycle is part of “aerobic metabolism”, this process does not itself require molecular 
oxygen. It does however produce high energy electrons, transported in the form of NADH 
and FADH, which are required for the subsequent oxygen-dependent step in aerobic 
respiration. These electrons pass down the electron transport chain and eventually 
combine with oxygen. The proton gradient created during this process drives ATP synthase 
which produces a net value of 32 (or 34) molecules of ATP. Meaning that in presence of 
sufficient oxygen, a cell can produce 36 (or 38) molecules of ATP per one molecules of 
glucose in total. 
Introduction 
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 1.3 Hypoxia 
Hypoxia occurs when oxygen levels fall below the threshold of a particular tissue. Figure 1.2 
highlights the partial pressures of a selection of organs and tissues. In simple terms, organs, 
tissues and cells require delivery of sufficient oxygen to meet their particular metabolic 
needs and when the demand for oxygen becomes greater than the supply, they become 
hypoxic.  
 
Figure 1.2 ǀ Examples of the partial pressure of oxygen in different organs and tissues. Values taken 
from Wiener et al. (1976) and Carreau et al. (2011). Image source http://media.tumblr.com/tumblr_m5z390bpp
P1qmovzi.jpg 
Hypoxia results from pathological conditions where the oxygen supply is reduced or 
impeded such as anaemia, sleep apnoea and ischemic events. Hypoxia has been shown to 
play a role in physiological and developmental processes, such as wound healing (Brahimi-
Horn & Pouyssegur, 2009), embryogenesis (Dunwoodie, 2009) and maintenance of 
pluripotent stem cells (Forristal et al., 2010).  
Introduction 
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 1.3.1 Maintaining oxygen homeostasis 
Hypoxic events trigger a highly conserved canonical signalling pathway that results in the 
up-regulation of genes that aid cell survival by restoring oxygen levels, improving tissue 
oxygenation and/or increasing anaerobic respiration (Table 1.1).  
For example, hypoxia triggers an increase in the levels of the hormone erythropoietin (EPO) 
that controls the maturation of red blood cells. This results in an increase in the number of 
red blood cells and therefore increases the oxygen carrying capacity of the blood. There is 
also an increase in vascular endothelial growth factor (VEGF). This protein stimulates 
angiogenesis (development of new blood vessels), which restores or increases blood supply 
to tissues. Together, these responses contribute towards re-establishing sufficient tissue 
oxygenation. 
Table 1.1 ǀ Examples of cellular processes that are up-regulated during hypoxia. 
Process HIF target gene(s) Reference 
Erythropoiesis EPO Wang & Semenza (1993)     
Angiogenesis VEGF Forsythe et al. (1996)     
Switching cellular 
metabolism to glycolysis 
GLUT1 
GLUT3 
GAPDH 
Wolfe and Voelkel (1983),                    
Chen et al. (2001)     
Iron metabolism 
Transferrin 
Transferrin receptor 
Ferroxidase 
Rolfs et al. (1997), Tecchini et al. 
(1999), Lok & Ponka (1999),              
Mukhopadhyay et al. (2000)     
 
 1.4 Hypoxia-inducible factor (HIF) 
In 1995 it was determined that the protein responsible for the hypoxic induction of 
erythropoietin (EPO) was hypoxia-inducible factor (HIF) (Wang et al., 1995). Subsequent 
studies found that HIF is a heterodimeric transcription factor that is composed of an alpha 
subunit, which is tightly regulated in an oxygen-dependent manner, and a constitutively 
expressed beta subunit (HIF-1β) (Wang & Semenza, 1995;Reyes et al., 1992;Huang et al., 
1996).  
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 1.4.1.1 HIF-α 
There are three isoforms of the alpha subunit (HIF-1α, -2α and -3α). HIF-1α was discovered 
by Gregg Semenza in 1992 (Semenza & Wang, 1992). It was determined that this basic 
helix-loop-helix (bHLH) protein was made up of the following domains: PER/ARNT/SIM 
(PAS) domains, the oxygen-dependent degradation (ODD) domain and two transactivation 
domain (TAD) (Figure 1.3) (Depping et al., 2008;Jiang et al., 1996;Wang et al., 1995;Lee et 
al., 2004).  
Five year after the discovery of HIF-1α, several laboratories published reports on an HIF-1α 
isoform, HIF-2α. The simultaneous discovery led to its publication under several names: 
endothelial PAS domain protein-1 (EPAS1), HIF-1α-like factor (HLF) or members of PAS 
superfamily 2 (MOP2) (Wenger & Gassmann, 1997;Tian et al., 1997;Ema et al., 
1997;Hogenesch et al., 1997). This, like HIF-1α, is a beta-helix-loop-helix protein that 
heterodimerises with HIF-1β, recognises the HRE DNA consensus sequence and activates 
transcription of hypoxia inducible genes (Tian et al., 1997).  
The third isoform, HIF-3α, has numerous splice variants. The resulting proteins range from 
667 to 7 amino acids, with some splice variants having an ODD and an N-terminal TAD like 
HIF-1α and HIF-2α (Maynard et al., 2003;Gu et al., 1998). Although the role of HIF-1α and -
2α in the cellular adaptation to low oxygen is well established, the function of this third 
isoform is complex, with some splice variants have been shown to act as negative or 
positive regulators in the hypoxia response (Hara et al., 2001;Maynard et al., 2005;Maynard 
et al., 2003;Gu et al., 1998).  
 1.4.1.2 HIF-β 
Otherwise known as aryl hydrocarbon nuclear translocator (ARNT), this member of the 
bHLH-PAS superfamily was first described in 1991 as the binding partner of the aryl 
hydrocarbon receptor (AhR / dioxin receptor) (Hoffman et al., 1991;Reyes et al., 1992). 
When hetero-dimerised, this transcription factor is responsible for regulating xenobiotic 
(chemicals foreign to the body) metabolism. It was later discovered that ARNT also forms 
heterodimers with HIF-1α and HIF-2α, thus acquiring the name HIF-β (Wang et al., 
1995;Wang & Semenza, 1995). There are two isoforms: HIF-1β and HIF-2β (HIF-1β2 / 
ARNT2). Both isoforms can mediate the hypoxic response, but HIF-2β has a more limited 
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tissue expression compared to the ubiquitous HIF-1β (Hirose et al., 1996;Drutel et al., 
1996;Maltepe et al., 2000).  
  
 
Figure 1.3 ǀ Domain structure of HIF-1α and HIF-1β. PAS = PER/ARNT/SIM domains, ODD = oxygen-
dependent degradation domain, TAD = transactivation domains. 
 
 1.4.2 Oxygen-Dependent regulation of HIF 
The availability of oxygen regulates both the stability and transcriptional activity of HIF, via 
two independent processes. HIF-α subunits are continually synthesised but they are rapidly 
degraded in normoxia (Figure 1.4A). This is regulated by members of the Fe (II) and 2-
oxoglutarate-dependent dioxygenase superfamily: the prolyl-4 hydroxylase domain (PHD1, 
2 and 3) proteins (Bruick & McKnight, 2001;Kallio et al., 1999). These proteins use oxygen 
as a co-substrate, thus the availability of oxygen regulates their enzymatic activity and 
enables them to sense local or general hypoxia (Steinhoff et al., 2009;K et al., 2004;Epstein 
et al., 2001). Under normoxic conditions, the PHD proteins catalyse the hydroxylation of 
specific prolyl residues located within the oxygen dependent degradation (ODD) domain of 
the alpha subunit (Figure 1.4B) (Bruick & McKnight, 2001;Epstein et al., 2001). 
Hydroxylation initiates the association of von Hippel-Lindau (VHL) tumour suppressor 
protein (an E3 ubiquitin ligase) with the alpha subunit and targets it for proteasomal 
degradation (Maxwell et al., 1999;Kallio et al., 1999;Ivan et al., 2001). During periods of 
hypoxia, the lack of oxygen leads to a marked reduction in the activity of the PHD proteins, 
resulting in fewer prolyl residues being hydroxylated and the stabilisation of the alpha 
subunit (Epstein et al., 2001).  
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Figure 1.4 ǀ Oxygen dependent regulation of HIF-α subunit. A) During periods of sufficient oxygen 
(normoxia) the HIF alpha subunits are degraded. Reduced oxygen (hypoxia) causes a decrease in PHD activity, 
allowing HIF-α subunits to accumulate and dimerise with HIF-1β to form active HIF in the nucleus. There it binds 
to a highly conserved consensus sequence, (A)CGTG, located within the enhancer domain. This sequence is 
termed the hypoxic response element (HRE) and leads to transcription of hypoxia-inducible genes (Luo & 
Shibuya, 2001).  pVHL = Von Hippel-Lindau tumour suppressor protein. Negative feedback highlighted in orange. 
B) Schematic representation of the domain structures of HIF-1α highlighting the key protein interactions in 
normoxia and hypoxia. PER/ARNT/SIM (PAS-A & PAS-B) domains, oxygen-dependent degradation domain (ODD) 
and N-terminal / C-terminal transactivation domain (NTAD / CTAD) are shown. The proline residues highlighted 
in the oxygen degradation dependent domain are hydroxylated by Prolyl Hydroxylase Domain (PHD) enzymes 
and the asparagine residues at the C-terminus is hydroxylated by factor-inhibiting HIF (FIH). Adapted from Lee et 
al.(2004). Illustration of the key interactions that take place between the alpha subunit and other proteins, 
highlighting the domain through which they occur. HIF-1β = Hypoxia Inducible Factor Beta, PHD = Prolyl 
Hydroxylase Domain, FIH = Factor Inhibiting HIF, CBP = CREB Binding Protein, pVHL = Von Hippel-Lindau tumour 
suppressor protein.  
 
Factor Inhibiting HIF (FIH) is an asparaginyl hydroxylase and regulates the transcriptional 
activity of HIF. During normoxia, factor inhibiting HIF (FIH) catalyses the hydroxylation of an 
asparagine residue which blocks the interaction of HIF with its co-activators CREB-binding 
protein (CBP)/p300 through the transactivation domain (TAD, Figure 1.4B) (Kallio et al., 
1998;Zhang et al., 2010). In hypoxia, the asparagyl residues are not hydroxylated, allowing 
the interaction of HIF with CBP/p300 and therefore the transcription of HIF target genes. 
Therefore in hypoxia, the impaired activity of the PHD and FIH enzymes leads to the alpha 
subunit evading degradation allowing it to form transcriptionally active heterodimers with 
HIF-1β via the PAS domains in the nucleus.  
 1.4.3 Oxygen-independent regulation of HIF 
HIF is not only activated in response to low oxygen. For example, HIF-1α levels increase in 
proliferating cells, because the resulting daughter cells require more oxygen than the single 
parent cell. It is likely that growth factors increase synthesis of HIF-1α in a pre-emptive 
move to maintain oxygen-homeostasis. This increase in HIF switches ATP production to 
glycolysis and increased VEGF expression to ensure the oxygen needs for the cells are met 
(Brand & Hermfisse, 1997;Seagroves et al., 2001;Jiang et al., 1997). It has been shown that 
HIF can be regulated by the PI3K/AKT/mTOR pathway, a regulator of the cell cycle. The 
activation of this signalling pathway leads to an increase in translation of a subset of mRNAs 
including HIF-1α and HIF-2α (Laughner et al., 2001;Hudson et al., 2002;Toschi et al., 
2008;Hay & Sonenberg, 2004).  
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Non-hypoxic stimulation of HIF has also been observed in cells responsible for the immune 
response such as macrophages (Blouin et al., 2004). For example cells exposed to the 
endotoxin lipopolysaccharide (LPS) have been shown to have increased levels of active HIF-
1 and this regulation is believed to be at the transcriptional level as HIF-1α mRNA increase 
significantly in the presence of LPS (Blouin et al., 2004). 
Several other components regulate the stability of the alpha subunit in an oxygen-
independent manner. For example all of the following lead to the alpha subunits evading 
proteasomal degradation in normoxia: inhibition of PHD proteins by intermediaries of the 
Kreb’s cycle, sequestration of pVHL in nucleoli due to increased acidity and overexpression 
of a deubiquitase (DUB) called pVHL protein-interacting deubiquitinating enzyme 2(VDU2 
aka USP20) (Fong & Takeda, 2008;Mekhail et al., 2004;Li et al., 2005). Stability of HIF-1α is 
also regulated by protein-protein interaction. For example, HSP90 and RACK1 actively 
compete to bind to HIF-1α and have antagonistic effects on protein stability (Hogenesch et 
al., 1997;Liu et al., 2007;Isaacs et al., 2002).  
 1.5 HIF-1α versus HIF-2α 
This study focuses on the spatial and temporal dynamics of HIF-1α and -2α. Even though 
these two isoforms have been implicated in activating and regulating the hypoxic response, 
it has become clear that they do not have redundant roles and do have many differences. 
Here I discuss some of the key differences that have been described so far.  
Firstly, HIF-1α and HIF-2α are encoded by different genes, HIF1A and EPAS1, which are 
located on chromosome 14 (14q23.2) and chromosome 2 (2p21-p16), respectively. The 
translated proteins differ slightly in length (826 and 870 amino acids, respectively) with an 
overall sequence similarity of 48%. They have a similar domain structure (Figure 1.5) with 
the greatest amount of similarity within the bHLH, PAS-A and PAS-B domains (Table 1.2). 
Both isoforms have an ODD domain where residues 549-572 and 517-534 are vital for the 
VHL-dependent degradation of HIF-1α and HIF-2α, respectively (Huang et al., 
1998;O'Rourke et al., 1999;Ema et al., 1999;Ohh et al., 2000;Cockman et al., 2000;Tanimoto 
et al., 2000;Kamura et al., 2000). Additionally, both alpha subunits have nuclear localisation 
signals. Lys737, Arg738 and the surrounding amino acid sequence, function as the nuclear 
localisation for HIF-2α and residues 718-721 for HIF-1α (Hara et al., 1999). 
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Figure 1.5 ǀ Comparison of HIF-1α and HIF-2α domains. A) Schematic representation of the domain 
structures of HIF-1α and HIF-2α. A) Highlighted are the key residues and their position that are hydroxylated in 
hypoxia. (p = proline, n = asparagine). B) The size and location of domains, regions and motifs found within the 
protein sequence of HIF-1α and HIF-2α. Sequence similarities were calculated by performing sequence alignment 
using BlastP. 
§
Data obtained from Uniprot, 
#
Fedele et al. (2002). C) Alignment of the ODD sequences using BlastP 
Three regions are similar. The highlighted amino acids are those that are identical.  
 
 1.5.1 Differential regulation of the HIF-α isoforms 
The two alpha subunits are regulated at all levels: transcription of the HIF1A and EPAS1 
genes, mRNA translation, protein stability and transcriptional activity of the isoforms 
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themselves. Here are some examples of regulation that is unique to one isoform or an 
event that targets both isoforms but has a different effect.  
TRANSCRIPTION – As previously discussed LPS has been shown to upregulate transcription 
of HIF-1α in an oxygen-independent manner. But cytokines have been shown to 
differentially regulate HIF-1α and HIF-2α mRNA expression. Takeda et al. (2010) 
demonstrated that interferon gamma (IFNγ) increases HIF-1α but significantly decreases 
HIF-2α mRNA expression. Conversely, interleukin-4 (IL-4) initiates prolonged increase in 
HIF-2α mRNA expression, but has no effect on HIF-1α (Takeda et al., 2010). 
TRANSLATION – As mentioned previously, HIF-α can be regulated independently of oxygen 
levels by the PI3K/AKT/mTOR pathway (see chapter 1.3.2) however there is discrimination 
between the two HIF-α isoforms. Toschi et al. (2008) demonstrated that in renal cell 
carcinoma cell lines HIF1A translation is regulated by mTORC1 and mTORC2 but EPAS1 
translation is regulated by mTORC2 only (Toschi et al., 2008). They also looked at Akt, a 
substrate of mTORC2, and found that the expression of HIF-1α and HIF-2α was dependent 
on different Akt isoforms (Toschi et al., 2008).  
In addition to this, HIF-2α is regulated at the post-transcriptional level by iron-response 
element binding protein 1 (IREBP1). This protein specifically inhibits the translation of HIF-
2α when bound to the iron response element within the EPAS1 transcript (Sanchez et al., 
2007). 
It has also been suggested that HIF-1α protein synthesis is regulated by antisense HIF-1α 
(αHIF1, a transcript that is complementary to the 3’ untranslated region (3’-UTR)).  Upon 
hypoxic stimulation, in addition to an increase in HIF1A mRNA expression, there is an 
increase in the αHIF1 which associates with and destabilises the HIF1A mRNA transcript, 
thus preventing further translation (Uchida et al., 2004). It is unknown whether a similar 
mechanism exists for HIF-2α. 
PROTEIN STABILITY – It is well established that the protein stability of both alpha subunits 
is regulated via the hydroxylation of specific prolyl residues (Ivan et al., 2001;Lando et al., 
2002) and that this leads to degradation following VHL-dependent poly-ubiquitination 
(Maxwell et al., 1999;Kallio et al., 1999;Ivan et al., 2001). However, it has been shown that 
there are differences in the specificity of the PHD enzymes, for instance PHD3 preferentially 
hydroxylates HIF-2α (Appelhoff et al., 2004). Furthermore, it appears that there are 
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differences in the stabilisation of HIF-1α and HIF-2α in hypoxia. Firstly, it has been shown 
that, in HeLa and other cell lines, HIF-2α stabilises at oxygen levels of 2-5% but levels need 
to be lower for HIF-1α stabilisation (0-2% O2) (Nilsson et al., 2005;Holmquist-Mengelbier et 
al., 2006;Li et al., 2009). Secondly, a difference in the duration of protein stabilisation has 
been observed. Holmquist-Mengelbier et al. (2006) found that in prolonged hypoxia, high 
levels of HIF-2α levels were maintained whereas levels of HIF-1α decline after several hours 
in neuroblastoma cells (Holmquist-Mengelbier et al., 2006;Uchida et al., 2004). This will be 
discussed further in chapter 3. 
There are a number of mechanisms that specifically regulate HIF-1α stability. For example, 
Heat shock protein 70 (HSP70) and carboxyl terminus of HSP70-interaction protein (CHIP) 
have been shown to bind HIF-1α in prolonged hypoxia and target the subunit for 
proteasomal degradation (Luo et al., 2010). Secondly, arrest defective 1 (ARD1) has been 
shown to specifically acetylate HIF-1α, which results in the destabilisation of the protein 
(Jeong et al., 2002;Yoo et al., 2006). And finally heat shock protein 90 (HSP90) and receptor 
for active kinase 1 (RACK1), previously mentioned in section 1.4.3 (Hogenesch et al., 
1997;Liu et al., 2007;Isaacs et al., 2002).  
TRANSCRIPTIONAL ACTIVITY – FIH regulates both HIF-1α and HIF-2α in an oxygen-
dependent manner, however Bracken et al. (2006) demonstrated that FIH preferentially 
hydroxylates HIF-1α (Bracken et al., 2006). In addition to this, several kinases (CK1, MAPK, 
ATM) have been identified to phosphorylate HIF-1α and increase its activity (Kalousi et al., 
2010;Mylonis et al., 2006;Cam et al., 2010). However, it is yet to be determined whether 
these kinases also modify HIF-2α. Sirtuin1 (SIRT1) has been shown to de-acetylate both HIF 
isoforms, but with differential effects. The removal of the acetyl group results in the 
transcriptional repression of HIF-1α and the transcriptional activation of HIF-2α (Dioum et 
al., 2009;Lim et al., 2010). 
More interestingly, HIF associated factor (HAF aka SART1), fits into several categories. HAF 
promotes VHL-independent degradation of HIF-1α in acute hypoxia but upregulates HIF-2α 
transcriptional activation in chronic hypoxia, which has led to this molecule being put 
forward as a differential regulator that switches cells from HIF-1α to HIF-2α dependent 
signalling in prolonged hypoxia (Koh et al., 2008).  
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Table 1.2 ǀ Examples of protein-protein interactions that regulate transcription and translation of 
HIF-1α and HIF-2α mRNA in an O2-independent manner. 
 Protein Isoform Outcome Reference 
Tr
an
sc
ri
p
ti
o
n
 
IFNγ 
HIF-1α   
Takeda et al. (2010)      
HIF-2α   
IL-4 
HIF-1α  - 
HIF-2α   
Tr
an
sl
at
io
n
 
Antisense 
HIF1A 
HIF-1α   
Uchida et al. (2004)     
HIF-2α  - 
IREBP1 
HIF-1α  - 
Sanchez et al. (2007)     
HIF-2α   
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Table 1.3 ǀ Examples of post-translation modifications and protein-protein interactions that 
regulate protein stability and transcriptional activity of HIF-1α and HIF-2α in an O2-independent 
manner. 
 Protein PTM / interaction Isoform Outcome Reference 
P
ro
te
in
 s
ta
b
ili
ty
 
ARD1 PTM 
HIF-1α   
Jeong et al. (2002),           
Yoo et al. (2006)     
HIF-2α  - 
HSP70 PTM 
HIF-1α   
Luo et al. (2010)     
HIF-2α  - 
HAF PTM 
HIF-1α   
Koh et al. (2011),              
Koh et al. (2008)      
HIF-2α  - 
HSP90 Interaction 
HIF-1α   Liu et al. (2007),       
Hogenesch et al. 
(1997), Isaacs et al. 
(2002)     HIF-2α  - 
Rack1 Interaction 
HIF-1α   
Liu et al. (2007)     
HIF-2α  - 
Tr
an
sc
ri
p
ti
o
n
al
 a
ct
iv
it
y 
HAF Interaction 
HIF-1α  - 
Koh et al. (2011),             
Koh et al. (2008)      
HIF-2α   
SUMO-
1/2/3 
PTM 
HIF-1α  
 
van Hagen et al. 
(2010), Berta et al. 
(2007)    HIF-2α  
SIRT1 PTM 
HIF-1α   
Dioum et al. (2009),          
Lim et al. (2010)     
HIF-2α   
CHFs Interaction 
HIF-1α  - 
Chin et al. (2000)     
HIF-2α   
 
It should be noted that there is far less known about mechanisms that specifically regulate 
HIF-2α largely due to HIF-1α being the more popular focus of research in the field of 
hypoxia. But it is clear that the two isoforms are differentially regulated at all levels.  
  
Introduction 
16 
 1.5.2 Differential roles of HIF-1α and HIF-2α in physiological 
processes 
HIF-1α and HIF-2α exhibit some redundancy in function. However, there are some 
processes that are either differentially regulated or uniquely regulated by one of the two 
isoforms. 
HYPOXIA INDUCIBLE GENES – Hundreds of HIF target genes have been identified so far 
(Mole et al., 2009) and there is increasing evidence that some genes are specifically 
regulated by either HIF-1α or HIF-2α (Table 1.4). Genomic studies have found that 
generally, but not exclusively, HIF-1α regulates genes involved in the metabolic response 
and HIF-2α target genes control the respiratory response to oxygen deprivation (Mole et 
al., 2009;Hu et al., 2003). There is substantial evidence that HIF-2α is solely responsible for 
regulating erythropoiesis (reviewed in Haase, 2013), iron homeostasis (Haase, 2013) and 
lipid metabolism (Schoenenberger et al., 2015).  
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Table 1.4 ǀ Examples of target genes unique to HIF-1α or HIF-2α.  Adapted from Keith et al. (2012). 
 Gene Process Reference 
H
IF
-1
α
 t
ar
ge
t 
ge
n
e
s 
BNIP3 (BNIP3) 
Autophagy and 
apoptosis 
Raval (2005)  
HK1 (hexokinase 1) 
Glycolysis 
Iyer (1998), Ryan et al. 
(1998)      
HK2 (hexokinase 2) 
Hu et al. (2003), Iyer (1998), 
Ryan et al. (1998)      
PFK (phosphofructokinase) 
Hu et al. (2003), Iyer (1998), 
Ryan et al. (1998)      
ALDOA (ALDA) 
Hu et al. (2003), Iyer (1998), 
Ryan et al. (1998)      
PGK1 (PGK1) 
Hu et al. (2003), Ryan et al. 
(1998)     
LDHA (LDHA) 
 Hu et al. (2003), Ryan et al. 
(1998)     
H
IF
-2
α
 t
ar
ge
t 
ge
n
e
s 
EPO (erythropoietin) Erythropoiesis 
Scortegagna et al. (2003), 
Gruber (2007), Rankin et al. 
(2007), Kapitsinou (2010)  
ANGPT2 (angiopoietin 2) 
Blood vessel 
remodelling
 
 
Skuli (2009)  
POU5F1 (OCT4) Stem cell identity Covello et al. (2006)  
SCGB3A1 (secretoglobin 3A1) 
Growth-inhibitory 
cytokine 
Mazumdar (2010)  
TGFA (TGFα) Growth factor 
Raval (2005), Gunaratnam 
(2003)  
CCND1 (cyclin D1) Cell cycle progression Raval (2005)  
 
ACUTE VS CHRONIC HYPOXIA – It has also been hypothesised that the response to 
different types of hypoxia is differentially controlled by the two isoforms i.e. HIF-1α is the 
mediator of the response to acute hypoxia, but during periods of prolonged hypoxia control 
switches to HIF-2α (Holmquist-Mengelbier et al., 2006;Koh et al., 2011).  
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CELL CYCLE – The HIF-α isoforms regulate components of other signalling pathways. For 
example, HIF-1α has been shown to up-regulate p53 and down-regulate c-Myc, mTOR and 
β-catenin, whereas induction of HIF-2α has the converse effect on these signalling 
molecules, suggesting that HIF-1α suppresses cell proliferation and HIF-2α promotes cell 
cycle progression (Koshiji et al., 2004;Koshiji et al., 2005;Gordan et al., 2007;Florczyk et al., 
2011)  
NO PRODUCTION – The two alpha subunits are regulated by the levels of interferon gamma 
(IFNγ) resulting opposing effects on nitrous oxide (NO) production. Low levels of IFNγ result 
in high levels of HIF-2α and reduced NO production due to an increase in arginase, the 
enzyme that catalyses the conversion of aginine (the substrate required for NO production) 
to ornithine and urea (Figure 1.6). Whereas high levels of IFNγ leads to HIF-1α domination 
and increased NO productions (Figure 1.6)(Takeda et al., 2010).  
 
 
Figure 1.6 ǀ Differential effect of HIF-α levels on nitrous oxide production. A) Reaction catalysed by 
nitrous oxide synthase (iNOS). B) Reaction catalysed by arginase. C) The antagonistic effect of interferon gamma 
(IFNγ) levels on NO production. 
 
 
EMBRYONIC DEVELOPMENT – Knockout mice experiments have shown that the loss of the 
HIF-1α or HIF-2α gene is embryonic lethal. However, lethality is due to defects in the heart 
and impaired lung formation, respectively (Loboda et al., 2010). Thus, indicating that both 
play vital yet different roles in embryonic development (Peng et al., 2000;Tian et al., 
1998;Iyer et al., 1998;Ryan et al., 1998). 
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 1.5.3 Differential role of HIF-1α and HIF-2α in disease 
The involvement of HIF in a range of disease makes it an interesting and promising 
therapeutic target. However, depending on the disease, HIF can have a protective role or 
can contribute to the pathogenesis (Figure 1.7).  
 
Figure 1.7 ǀ Differential role of HIF in disease. 
 
There is particular focus on the relationship between HIF and cancer, as many HIF target 
genes are related to tumour progression and metastasis (Gilkes & Semenza, 2013). 
Furthermore, it has been shown that a hypoxic tumour microenvironment is associated 
with aggressiveness and resistance to treatment (Liu et al., 2008;Nardinocchi et al., 2009). 
However, the role of HIF in cancer is complex. Both HIF-1α and HIF-2α can be over-
expressed in many different cancers with HIF-2α being generally seen as a tumour 
promoter and HIF-1α a tumour suppressor; a classic example being clear cell renal cell 
carcinoma (ccRCC). However, this characterisation is not always true and in some cancers 
HIF-2α has a tumour suppressive role. For example, Mazumdar et al. (2010) demonstrated 
that knocking out HIF-2α in the KRAS mouse model led to increased tumour growth due to 
the down regulation of the tumour suppressor gene Scgb3al (Mazumdar et al., 2010).  
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To complicate matters further, not only does the prognostic role of HIF-1α and HIF-2α vary 
between cancers, they even vary within the same types of cancer e.g. hepatocellular cancer 
(Table 1.5).  
Table 1.5 ǀ Differential roles of HIF-1α and HIF-2α in cancer.  
Cancer / Model 
HIF 
isoform 
Up/down 
regulated 
Prognosis Reference 
Breast Cancer HIF-1α  Poor Gilkes and Semenza (2013)     
Neuroblastoma HIF-1α 
 Good Keith et al. (2012)     
 Poor Dungwas et al. (2012)     
Renal Cell 
Carcinoma 
HIF-1α  Good Qing and Simon (2009)     
Soft Tissue 
Sarcoma 
HIF-1α  Poor 
Eisinger-Mathason et al. (2013)     
HIF-2α  Good 
Gastric cancer HIF-2α  Poor Wang et al. (2010), Yoon (2014)     
Hepatocellular 
cancer (HCC) 
HIF-2α 
 Poor 
Talks et al. (2000), Bangoura et al. (2007), 
Yang et al. (2014), Zhao et al. (2014)  
 Poor Sun et al. (2013)     
 Good Menrad et al. (2010)     
Pancreatic cancer HIF-2α  Poor 
Talks et al. (2000), Criscimanna et al. 
(2013)     
Colorectal cancer HIF-2α 
 Poor 
Talks et al. (2000), Hui et al. (2002),      
Franovic et al. (2009), Cleven et al. 
(2008), Koukourakis et al. (2006)     
 Poor Imamura et al. (2009)  
 
Although HIF is of great interest as a potential therapeutic target and it is evident that there 
is a link between deregulation of HIF and therapeutic outcome, there is not a clear cut 
relationship.  
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 1.5.4 Tissue distribution 
As with cancer, the expression of the alpha subunits differs in tissues. HIF-1α is ubiquitously 
expressed throughout the body in all cell types; however HIF-2α is limited to distinct 
populations on cells in certain tissues or organs (Wiesener et al., 2003). For example: in the 
liver, HIF-2α accumulates in the nuclei of hepatocytes, i.e. parenchymal distribution; in the 
kidneys, pancreas and brain, HIF-2α nuclear accumulation is predominantly in non-
parenchymal cells; and, in myocardial tissue equal distribution is observed (Wiesener et al., 
2003).  
 1.5.5 Cellular localisation 
Within our research group, single cell imaging of HIF-1α and HIF-2α has revealed that the 
two proteins exhibit different nuclear localisation patterns. HIF-1α is only observed in cells 
that have been subjected to hypoxia or treated with an inhibitor of the PHD enzymes, 
Dimethyloxalylglycine (DMOG).  Approximately 2-4 hours after oxygen levels fall, 
homogenous extra-nucleolar accumulation of HIF-1α is observed in the nucleus. Whereas, 
in cells expressing EGFP-HIF-2α, punctate foci are observed (see Figure 1.8). Moreover, 
some HIF-2α stabilisation is observed without subjecting cells to hypoxia or DMOG 
treatment, therefore hinting that HIF-2α may evade oxygen-dependent degradation.  
 
 
 
 
 
 
Figure 1.8 ǀ Nuclear localisation of HIF-1α and HIF-2α in HeLa cells. HeLa cells transiently transfected 
with HIF-1α-EGFP (right) and HIF-2α-EGFP (left) showing different nuclear sub-localisation patterns. HIF-1α 
shows a homogenous nuclear localisation during hypoxia, whereas HIF-2α localises in sub-nuclear foci or 
“speckles”. 
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These observations strongly correlate with previous findings:  
1) Hypoxic accumulation of HIF-1α in the nucleus was first described by Huang et al (1996). 
They also observed the translocation of HIF-1α from the cytoplasm into the nucleus when 
in hypoxia. However, they too observed that HIF-2α tagged with GFP was stabilised in the 
nucleus regardless of oxygen levels (Hara et al., 1999).  
2) Takahashi et al also noticed that in Bovine aortic endothelial cells HIF-2α localised in the 
nucleus (excluded from the nucleoli) in “dots” and they too found that hypoxia or 
treatment with a hypoxia mimic (CoCl2) did not affect the nuclear localisation of HIF-2α 
(Takahashi et al., 2004). 
 1.6 The Cell Nucleus 
The nucleus was first described by Franz Bauer in 1802. It holds the majority of the cells 
genetic material and controls the activities of the cell by regulating gene expression. As 
with the cytoplasm, spatial organisation plays an important role within the nucleus to 
contain, regulate and streamline processes. However, unlike the cytoplasm, where 
processes are contained within organelles, nuclear functions are compartmentalised into 
domains. The different nuclear bodies can be distinguished by their size, shape, number 
and presence of particular proteins. Some examples follow. 
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Figure 1.9 ǀ Structure of the nucleus. Schematic diagram of the nucleus, highlighting key domains and sub-
compartments. (Taken from http://www.fli-leibniz.de/www_imaging/structure_en.php)  
 
NUCLEOLUS – The nucleolus is the largest and most well studied substructure in the 
nucleus. Many processes relating to ribosome biosynthesis takes place here such as 
transcription of ribosomal DNA and assembly of the ribosomes (Cmarko et al., 2008;Busch 
& Smetana, 1970). Although it is mainly seen as a “ribosome factory” it has recently come 
to light that it may also have a role in the regulation of cell cycle, proliferation and lifespan 
of a cell (Pederson, 1998;Carmo-Fonseca et al., 2000;Visintin & Amon, 2000;Takemura et 
al., 2002;Chestukhin et al., 2002). 
CAJAL BODIES – Also known as coiled bodies (CBs) due to being composed of tangled 
fibrillar strands (Almeida et al., 1998;Pombo et al., 1999;Iborra et al., 2001), there are 
between 1-5 of these spherical compartments per nucleus but this can change depending 
on cell cycle stage and disease state (Brasch & Ochs, 1992;Boudonck et al., 1999;Gall, 
2000). They are highly mobile and dynamic and have been observed: moving throughout 
the nucleoplasm; merging with and travelling through the nucleolus; and, going through 
joining and separation events, to make larger or smaller CBs (Platani et al., 2000;Lyon et al., 
1997). Although reasonably well studies, the function of CBs has not been clearly defined as 
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yet, but there is some evidence to suggest that they are involved in the storage of  small 
nuclear ribonucleic proteins (snRNPs) and may deliver these to the nucleolus (Lamond & 
Earnshaw, 1998;Matera, 1999;Spector, 2001;Zhou et al., 2002). It has also been suggested 
that the transcription machinery assembles within CBs before relocating to transcription 
factories (Platani et al., 2002). 
PML BODIES – PML bodies get their name from the distinguishing presence of 
promyelocytic leukemia (PML) protein. They are donut shaped nuclear bodies, typically 
0.25-0.5 μm in diameter and number around 10-30 per nucleus (Ascoli & Maul, 
1991;Stuurman et al., 1992). As well as PML, many other proteins such as CBP, SP100, p53, 
NRF2 and eIF-4E have been shown to localise at these nuclear bodies (LaMorte et al., 
1998;Lai & Borden, 2000;Sternsdorf et al., 1999;Fogal et al., 2000;Ben-Dor et al., 2005). The 
function of the PML bodies is not clearly defined but based on the additional occupants it 
has been suggested that they may play a role in transcriptional regulation or translational 
regulation. They have also been linked to viral replication (Maul, 1998). 
TRANSCRIPTION FACTORIES – It was previously thought that RNA polymerase II (RNAPII) is 
recruited to the promoters of genes that are to be transcribed, however it is now believed 
that active loci migrate to domains where the transcriptional machinery is located (Iborra et 
al., 1996;Jackson et al., 1998). Different genes, even genes that are separated by great 
distances, in the genome have been shown to concurrently occupy the same transcription 
factories (Osborne et al., 2004;Jackson et al., 1993;Jackson et al., 1998). 
SPLICING FACTOR COMPARTMENTS – Pre-mRNA splicing occurs co-transcriptionally. 
Splicing factors continuously exchange between splicing factor compartments (SFCs) and 
sites of transcription. SFCs are irregular in shape but following inhibition of transcription 
these nuclear speckles increase in size and change shape, indicating further these are 
storage sites of inactive splicing factors (Sinclair and Brasch, 1978).  
There is little known about how nuclear bodies are formed as they are not delineated by a 
lipid bilayer (like the nucleus itself). The lack of intra-nuclear membranes has led to 
suggestions that they form via “self-organisation”, whereby the architecture and function 
of the structure is determined via the physical interaction of its components (Misteli, 2001).  
There is some evidence that there is a sub-nuclear framework, similar to the cytoskeleton, 
which is composed of a mixture of proteins such as lamin B (Stuurman et al., 1990;Berezney 
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& Coffey, 1977). It has been suggested that this nuclear matrix may play a role in the 
orchestrating nuclear processes and is likely to act as a “substratum” for nuclear bodies 
(Mitchell & Fraser, 2008;Ascoli & Maul, 1991;Stuurman et al., 1992).  
The discovery and study of the heterogeneous localisation of nuclear proteins and nuclear 
domains has been facilitated by the advancements in microscopy and protein labelling 
techniques made over the last century. 
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 1.7 Microscopy 
 1.7.1 A brief history of fluorescent confocal microscopy 
1595 saw the invention of the first instrument that facilitated the visualisation of objects 
that could not be seen by the naked eye but it wasn’t until 1911 that the first successful 
fluorescent microscope was constructed by the physicist, Oskar Heimstädt (Heimstadt, 
1911). This design was reconfigured by Ellinger and Hirt (1929) so that the light source was 
on the same side of the specimen as the objective, resulting in both the emission and 
excitation light passing through the objective (Figure 1.10), creating the epi-fluorescence 
microscope (Ellinger & Hirt, 1929). 
 
Figure 1.10 ǀ Lightpath of an epi-fluorescence microscope. Schematic representation of the basic setup of 
an inverted epifluorescence microscope. 
 
The problem of “out of focus light” associated with epi-fluorescence microscopes was 
circumvented by Minsky’s confocal microscope, which incorporated pinhole apertures to 
block this non-specific fluorescence from reaching the detector (Minsky, 1961). He also 
introduced “raster scanning”, whereby an image is created by systematically illuminating 
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the field of interest line by line, to reduce the amount of the specimen that is illuminated at 
any one time. Minksy’s design was further improved by the addition of dichroic mirrors 
(Ploem, 1967) and upgrading the light source to a laser beam (White et al., 1987;Van Meer 
et al., 1987) resulting in the basis of the modern laser scanning confocal microscope.  
Table 1.6 ǀ Timeline of key events in the history of light microscopy.  
1595 Invention of microscope 
1911 First fluorescent microscope 
1929 First epi-fluorescence microscope 
1942 First example of immunofluorescence 
1961 Minsky’s patent of confocal microscope accepted 
1972 Development of Fluorescence correlation spectroscopy (FCS) 
1976 
Development of Fluorescence recovery after photobleaching (FRAP) 
Försters / fluorescence resonance transfer (FRET) experimentally proven 
1987 Laser scanning confocal microscope 
1993 
Light sheet microscopy 
Single molecule microscopy 
1992-1996 Cloning and development of GFP 
1999 Cloning of red fluorescent proteins 
2000 Development of super-resolution method - STED & SIM 
2002 Photoactivatable fluorescent proteins 
2006 Development of Super-resolution methods - PALM / fPALM / STORM 
2008 
Nobel prize for chemistry awarded to researchers involved in the cloning and 
development of GFP 
2014 Nobel prize for chemistry awarded to developers of super-resolution imaging 
Introduction 
28 
 1.7.1.1 Fluorescence microscopy and labelling methods 
Fluorescence refers to the ability of a substance to absorb light at a certain wavelength and 
emit light at a higher wavelength (Figure 1.11) and was first described in 1852 by Sir George 
Stokes. However, the earliest recorded use of fluorescence in biological investigations 
wasn’t until almost a century later. However, when the fluorescent microscope was first 
invented, scientists relied upon autofluorescence (the natural emission of light from a 
specimen) until Ellinger and Hirt pioneered the use of “secondary fluorescence”, whereby 
they introduced an exogenous fluorescent substance (fluorescein) to improve contrast of 
the sample (Ellinger & Hirt, 1929).  
 
Figure 1.11 ǀ Overview of fluorescence. A) Schematic representation of the principle of how fluorescence occurs. 
Briefly, an orbital electron of a molecule or atom is electronically excited by absorbing photons from higher 
energy light (e.g. blue). As the electron relaxes through energy levels (orange lines) to its ground state, photons 
of a lower energy wavelength (e.g. green) are emitted. B) Example excitation - emission spectra of enhanced 
green fluorescent protein (EGFP). 
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It was only in the 1940’s that immunofluorescence, a technique that permits specific 
labelling of cells, structures and proteins with fluorescent probe, emerged. Coons et al took 
antibodies raised against strains of pneumococcus and attached a fluorescent molecule 
(Coons et al., 1941). They labelled tissue from patients positive and negative for this 
bacteria and observed a clear difference in the signal between the two samples (Coons et 
al., 1942). However, the biggest breakthrough for fluorescence microscopy came in 1994 
when Chalfie et al. demonstrated how the green fluorescent protein (GFP), from the 
jellyfish Aequorea victoria, could be used to visualise proteins in living organisms (Chalfie et 
al., 1994). The cloning of GFP opened the door for the creation of genetically labelled 
proteins of interest facilitating the study of intracellular localisation and dynamic behaviour 
of proteins of interest in real time in vivo.  
Further developments were made when Roger Tsien and colleagues conducted exploratory 
mutagenesis of GFP creating enhanced GFP (EGFP), a derivative that is 30x brighter than 
the wildtype, and derivatives with a shift in the excitation / emission spectra: BFP (blue), 
CFP (cyan) and YFP (yellow) (Heim & Tsien, 1996). To add to these tools, the orange-red 
fluorescent protein, dsRED, that emits at 583 nm following excitation at 558 nm, was 
cloned from a reef coral Discosoma sp in 1999 (Matz et al., 1999). The availability of these 
different fluorescent proteins (only a subset mentioned here) has meant that genetically-
encoded spectrally-discrete reporters can be created, thus facilitating the simultaneous 
study of several proteins of interest in situ. Furthermore, it has permitted the non-invasive 
study of protein kinetics and interactions in living cells. The invaluableness of GFP (and its 
variants) and the genetic tagging of biomolecules to scientific research was recognised by 
the award of the Nobel Prize in chemistry in 2008. 
 1.7.2 Probing the dynamics of proteins further 
In the 1970s, it was proposed that fluorescence microscopes could be utilised for more 
than just imaging, but could also be used to study reaction kinetics, diffusion and 
intermolecular interactions. Some examples include: fluorescence correlation spectroscopy 
(FCS), Förster / fluorescence resonance electron transfer (FRET) and fluorescence recovery 
after photobleaching (FRAP). 
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 1.7.2.1 FCS  
This technique measures fluctuations in fluorescent signal coming from labelled molecules 
moving in and out of a defined region. These measurements can be used to determine the 
concentration and diffusion rate of the molecule being studied. Advancements in detection 
methods led to the quantification of the dynamics of single molecules, with Rigler and 
Widengren being the first to demonstrate this in 1990.  
In principle, FCS can be used to measure intermolecular interactions of a fluorescently 
labelled protein as the diffusion rate would slow upon binding to a larger molecule. 
However, the development of two-colour FCS (fluorescence cross-correlation spectroscopy 
/ FCCS) has meant the interaction of any two molecules, regardless of size, can be studied 
(Schwille et al., 1997). 
 1.7.2.2 FRET  
This technique is based on the principle, proposed by Theodor Förster in the 1940s (Förster, 
1946) and confirmed experimentally in 1967 (Stryer & Haugland, 1967), that the energy 
generated from electronic excitation can be passed from one fluorophore (donor) to 
another (acceptor) when the two chormophores are within close enough proximity 
(10 nm). However, it wasn’t until the development of GFP variants CFP and YFP, that FRET 
was utilised to study protein-protein interactions in vivo (Bacskai et al., 1993). Shortly after, 
FRET-sensors were developed that act as biological indicators. Examples include calcium 
(Miyawaki et al., 1997;Romoser et al., 1997;Emmanouilidou et al., 1999), cyclic AMP 
(Zaccolo et al., 2000), apotosis (Xu et al., 1998) and synaptic activity (Vanderklish et al., 
2000).  
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Table 1.7 ǀ Key landmarks of FRET 
Year Event Reference 
1993 
First application of FRET to study molecular 
interactions in situ. 
Bacskai et al. (1993)   
1995 
Development and application of fluorescence 
lifetime imaging (FLIM)-FRET to study the 
dimerization of cell surface receptors in single cells. 
Gadella and Jovin (1995)   
1998 Confirmation of the existence of ‘lipid rafts’. 
Kenworthy and Edidin (1998), 
Varma and Mayor (1998)   
1997> Development of FRET-sensors  See text 
 
 1.7.2.3 FRAP  
This fluorescence perturbation technique involves irreversible bleaching of fluorescently 
labelled proteins. The redistribution of non-bleached molecules (or “recovery”) into the 
bleached region is monitored (Figure 1.12) and subsequent analysis of the recovery of 
fluorescent molecules provides information on mobility.  
 
Figure 1.12 ǀ Fluorescent recovery after photobleaching. A) Schematic of time-lapse imaging to capture 
recovery of fluorescence. B) Schematic of molecular redistribution following photobleaching. Black broken circle 
= bleached region, black circles = bleached molecules, green circles = non-bleach molecules.  
 
Although FCS can be used to measure diffusion of single molecules, for answering certain 
biological questions FRAP is more advantageous as the whole cell can be monitored and it 
can detect the presence of immobile populations of molecules.  
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Due to ease of labelling, FRAP was first utilised to study the movement of protein within the 
cell membrane (Peters et al., 1974) as these could be easily labelled. However, today, 
genetic labelling enables the study of protein trafficking anywhere within the cell. 
It may seem surprising that these aforementioned techniques were all invented before the 
realisation of the laser scanning confocal microscope and the cloning of GFP (Table 1.7). 
However, these later developments only broadened the applications of these techniques by 
facilitating the non-invasive study of real-time diffusion and interactions of fluorescently 
labelled protein in living cells. 
 1.7.3 Super-resolution microscopy  
The diffraction limit theory was conceived in 1873 and states that the smallest resolvable 
distance between two points is half the wavelength of the light used for illumination (Abbe, 
1873), which essentially means that objects less than 150-200 nm apart cannot be resolved 
with conventional light microscopy. Now, over 100 years later, with the arrival of super-
resolution we are able to see beyond the diffraction limit, with distances down to tens of 
nanometres being resolved. Up until recently, to resolve structures that were closer than 
200 nm, either electron microscopy (Ruska, 1987) or total internal reflection (TIRF) 
microscopy (Axelrod, 1981) were used. Although modern electron microscopes are capable 
of achieving more than 1 nm resolution (Erni et al., 2009), they cannot be used to image 
living cells and there is an intensive sample preparation protocol. TIRF is also limited to 
certain applications as only structures that are no more than 100 nm away from the 
coverslip can be studied. However, the last twenty years has seen the emergence of new 
super-resolution (SR) imaging techniques which can be divided into two categories: 
illumination-based such as stimulation emission depletion (STED) (Hell & Wichmann, 1994) 
or structured illumination (SIM) microscopy (Gustafsson, 2000); and, single-
molecule / probe-based e.g. photo-activated localisation (PALM) (Betzig et al., 2006;Hess et 
al., 2006) or stochastic optical reconstruction (STORM) microscopy (Rust et al., 2006). These 
methodologies mean that structures can be visualised in living cell at the molecular level 
and have already been utilised in discerning the three-dimensional organisation of 
molecules in the nuclear pore complex (Schermelleh et al., 2008) and the distribution of 
proteins in structures such as microtubules (Huang et al., 2008) and lysosomes (Betzig et 
al., 2006). SR has also been utilised to study dynamic processes such as the formation of 
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macromolecular complexes e.g. focal adhesions (Shroff et al., 2008). The recent ground-
breaking developments to surpass the diffraction limit of conventional fluorescence 
microscopy resulted in E. Betzig, S. Hell and W. Moerner being awarded the Nobel Prize in 
chemistry in 2014.  
 1.7.4 Single molecule tracking (SMT) 
Although perturbation (e.g. FRAP) and correlation (e.g. FCS) techniques can provide 
information on diffusion, this information is based on the average behaviour of the protein 
of interest meaning that, as with any population technique, any heterogeneity within the 
population will be masked (Brameshuber & Schuetz, 2008). Single molecule tracking (SMT) 
is a technique that allows the elucidation of the spatial and temporal dynamics of individual 
molecules by direct monitoring of said molecules in real time. 
Several techniques have been developed for SMT of fluorescently labelled proteins 
(reviewed in Meuller et al., 2013) and have been implemented in tracking RNA polymerase 
II in three dimensions (Abrahamsson et al., 2013) and deciphering how transcription factors 
search target binding sites (Chen et al., 2014). 
One alternative to fluorescence microscopy, which can be utilised for SMT in living cells, is 
photothermal imaging of protein labelled with gold nanoparticles, which is discussed in 
Chapter 5.  
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 1.8 Project aims 
The aim of my project is to study the spatial and temporal regulation of the main 
intracellular effectors of the hypoxia signalling pathway.  
The specific aims of my project were: 
 Improving molecular and cellular tools for imaging HIF-1/2α.  
 Investigating the temporal dynamics of HIF-1/2α at the single cell level 
 Investigating the sub-nuclear spatial localisation of HIF-2α at the single cell and single 
molecule levels 
I have employed live cell imaging techniques to elucidate the spatial and temporal 
dynamics of the key mediators of the hypoxia signalling pathway at the cellular level. I have 
also utilised confocal microscopy to study sub-cellular localisation and perturbation 
techniques to elucidate molecular dynamics. All of this was done with a view to 
contributing to the understanding of the mechanisms of cellular responses and adaptation 
to environmental stress but also toFR potentially provide insight into improving therapeutic 
strategies developed to either inhibit (e.g. cancer) or enhance (e.g. stroke) the hypoxic 
response.
 Chapter 2: Materials and Methods 
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In this chapter, the general materials and methods used during this project are described. 
For some areas, such as recombinant protein expression and purification, specific details 
can be found in the respective chapters.  
 2.1 Chemicals and reagents 
All chemicals and reagents were from Sigma Aldrich (MO, USA) unless stated otherwise. 
With the exception of cell culture regents which were from Life Technologies (CA, USA) and 
all plastic ware was Corning® (Corning Inc., NY, USA), unless stated otherwise.  
 2.2 Molecular Biology 
 2.2.1 Plasmids 
Plasmids encoding fluorescent HIF-1α and HIF-2α fusion proteins were as described in 
Bagnall et al. (2014). pLNT-Ubc-HIF-2α-Venus was created by replacing the region encoding 
HIF-1α in pLNT-Ubc-HIF-1α-Venus (a generous gift from J. Bagnall, University of 
Manchester, UK) with a fragment encoding HIF-2α using Infusion HD cloning protocol (see 
Plasmid Cloning). pCMX-PL1-YFP-mHDAC5 was a generous gift from R. M. Evans Laboratory, 
(The Salk Institute, CA, USA). CMV-Halotag-HIF-2α (pFN21AB4384) was purchased from 
Kazusa DNA Research Institute, Japan. pET-M11-His-Halotag-HIF-2α was created by 
inserting the Halotag-HIF-2α coding region (from CMV-Halotag-HIF-2α) and inserting this 
into the pETM-11-His plasmid (obtained from G. Stier, EMBL. See Plasmid Cloning). 
 2.2.2 Propagation of Expression Plasmid DNA  
 2.2.2.1 Transformation 
50 μL commercial competent DH5α E. coli cells (Invitrogen, CA, USA) were thawed on ice 
and transferred to pre-chilled 14 mL BD Falcon 17x100 mm round-bottom polypropylene 
tube (Becton Dickinson, NJ, USA). 5 ng of plasmid DNA was added to the competent cells 
and were incubated on ice for 30 min. The cells were then heat-shocked at 42 °C for 45 sec 
in a water bath, followed by a second incubation on ice for 2 min. 950 μL pre-warmed SOC 
medium (Invitrogen, CA, USA) was added and the culture was incubated for 1 hour at 37 °C 
in an orbital shaker (225 rpm). The cells were diluted 1:10-1:100 in pre-warmed SOC 
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medium and 100 μL spread onto LB agar (Merck KGaA, Germany; prepared according to 
manufacturer’s instructions) plates containing the appropriate antibiotic (at a final 
concentration as stated in Table 2.1) and incubated overnight at 37 °C. 
Table 2.1 ǀ Antibiotic concentrations used 
Antibiotic Final Concentration (μg mL
-1
) 
Ampicillin 100 
Kanamycin 50 
Chloramphenicol 34 
 2.2.2.2 Small scale Plasmid DNA purification (Mini-prep) 
A single colony was selected from the agar plate for mini-culture using aseptic techniques 
and added to 5 mL LB broth (Merck KGaA, Germany; prepared according to manufacturer’s 
instructions) containing the appropriate antibiotics. Following incubation for 6 h-8 h at 
37 °C in an orbital shaker (225 rpm), 2 mL of the bacterial culture was processed and the 
plasmid DNA extracted using the GeneJET Plasmid Miniprep Kit (Thermo Scientific, Ma, 
USA) following the manufacturers guidelines. 
 2.2.2.3 Large Scale Plasmid DNA purification (Maxi-Prep) 
Using aseptic technique, 2 mL of bacterial mini-culture was transferred to a 1 L flask 
containing 200 mL LB broth & selective antibiotic(s). This was then incubated overnight at 
37 °C in the orbital shaker (225 rpm). Cells were harvested using a Sorvall centrifuge, they 
were spun at 4 °C, 6800 × g for 15 min. DNA was isolated from bacterial cells using Purelink 
TM HiPure Plasmid Filter Purification Kit (Invitrogen, CA, USA), following the protocol 
provided by manufacturer. The purified DNA was diluted to 1 μg μL-1. 
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 2.2.3 Polymerase Chain Reaction (PCR) 
PCR was used to amplify gene inserts for In-Fusion cloning (see below). KOD Hot Start DNA 
polymerase (Novagen, Germany) was used according to Table 2.2. PCR was carried out in a 
Px2 Thermal Cycler (Thermo Scientific, MA, USA). The standard PCR conditions used are 
stated in Table 2.3. 
Table 2.2 ǀ Standard set up for PCR reaction  
Component Volume / amount 
MgSO4 3 μl 
2mM dNTPs 5 μl 
10x PCR buffer 5 μl 
10 μM Forward-primer 1.5 μl 
10 μM Reverse-primer 1.5 μl 
Template DNA 20 ng 
KOD hot start polymerase 1 μl 
ddH2O Up to final volume of 50 μl 
 
Table 2.3 ǀ Standard conditions used for PCR reaction  
Stage Temperature (°C) Time Cycles 
1 94 5 min 1 
2 
94 20 seconds 
30 50-70 1 min / 1kb Thyb 
72 3 min 
3 72 10 min 1 
Hold 4 - - 
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 2.2.4 Restriction Digests 
Digests were set up according to Table 2.4. The 10x buffer used was dependent on the 
restriction enzyme used and chosen based upon manufacturers guidelines. Total reaction 
volume made up to 20 μL with ddH2O and incubated at 37 °C (or the temperature 
recommended by the manufacturer) for a minimum of 2 h followed by enzymes 
inactivation (if required) by heating to 65 °C for 15 min. Digests were validated via gel 
electrophoresis.  
Table 2.4 ǀ Standard set up for restriction digest  
 Component Volume / amount 
Single digest 
Enzyme 1 1 μl 
10x Buffer 2 μl 
DNA 1μg 
Double digest 
Enzyme 1 1 μl 
Enzyme 2 1 μl 
10x Buffer 2 μl 
DNA 1 μg 
 
 2.2.5 Plasmid Cloning 
The constructs listed in Table2.5 were created using the Clontech In-Fusion® HD cloning 
protocol. Inserts were amplified using specifically designed primers that have 20 bp insert 
specific regions and 15 bp that are homologous to the destination vector (Table 2.6). The 
destination vectors were linearised using the protocol in Table 2.4 using the enzymes listed 
in Table 2.5 Both the PCR product and linearised vector were run on a 1% agarose gel at 
100 V for 1 h and excised. These DNA fragments were purified using E.Z.N.A. gel extraction 
kit (Omega Biotek, GA, USA) according to manufacturer’s instruction.  
The In-Fusion® (Clontech, Canada) reaction was carried out according to the manufacturer’s 
instructions. The volume of linearised vector and insert were calculated based on the mass 
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of each required, as determined by the In-Fusion® Molar Ratio Calculator 
(http://bioinfo.clontech.com/infusion/molarRatio.do; insert:vector ratio = 2). Briefly, 2 μL 
of 5X In-Fusion HD Enzyme was added to make a total reaction volume of 10 μL. The 
reaction was incubated in a heat block at 50 °C for 15 min. In order to reduce toxicity and 
improve the number of transformants the In-fusion enzyme was digested via incubation 
with 1 μL Proteinase K (Invitrogen, CA, USA) for 10 min at 37 °C prior to transformation into 
Stellar™ competent cells (Clontech, Canada). 50 μL of cells were thawed on ice and 
transferred to pre-chilled 14 mL BD Falcon 17x100 mm round-bottom polypropylene tube 
(Becton Dickinson, NJ, USA). Approximately 5 ng of DNA was added. The cells were 
incubated on ice for 30 min, heat shocked at 42 °C for 45 sec and returned to ice for 2 min. 
450 μL pre-warmed SOC medium was added and the culture was incubated in an orbital 
shaker for 1 h at 37 °C (225 rpm). 200 μL was then spread onto selective LB agar plates and 
incubated for 16 h at 37 °C. DNA from isolated colonies was purified (see mini-prep) and 
screened using restriction digest and imaging of transiently transfected cells. The best 
candidate was sent away for sequencing (GATC, Germany) before large scale DNA 
purification (maxi-prep). 
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Table 2.5 ǀ Components used to create plasmids via Infusion HD cloning method 
Plasmid Destination Vector 
Restriction 
Enzymes 
Insert 
Insert amplified 
from 
pETM-11-HIS-
HaloTag- HIF-2α 
pETM-11-HIS
*
 
NcoI & EcoRI 
(Roche, UK) 
Halotag- 
HIF-2α 
CMV-Halotag-
HIF-2α 
CMV-HaloTag-HIF-
2α-IRES-dTomato 
CMV-Halotag-
HIF-2α 
NotI & XbaI 
(Roche,Uk) 
IRES-
dTomato 
pHIV-EGFP-HIF-
2α-IRES-dTOM 
pLNT-Ubc-HIF-2α-
Venus 
pLNT-Ubc-HIF-1a-
Venus
#
 
XbaI & BamHI (New 
England Biolabs, 
MA, USA) 
HIF-2α pG-EGFP-HIF-2α 
[*G. Stier, EMBL; #J. Bagnall, University of Manchester] 
 
Table 2.6 ǀ Primers used for infusion cloning. 20 bp are specific for the insert and 15 bp (red) are specific to 
the destination vector, this creates overhangs allows the amplified insert to be directionally ligated into the 
linearised destination vector.  
Plasmid Primer Sequence (5’ to 3’) 
pETM-11-HIS-
HaloTag- HIF-2α 
Forward GACGGAGCTCGAATTCAACGGTGGCCTGGTCCAGG 
Reverse TTTCAGGGCGCCATGGGCAGAAATCGGTACTGGC 
CMV-HaloTag-
HIF-2α-IRES-
dTomato 
Forward TACCCGGGGATCCTCTAGAAGTACCCGGGCTAGGATC 
Reverse TCATGTCTGCTCGAAGCGGCCGCCGATTTACTTGTACAGCTCGT 
pLNT-Ubc-HIF-2α-
Venus 
Forward GGGCTGCAGGTCGACTCTAGAATGACAGCTGACAAGGAG 
Reverse GGTGGCGACCGGTGGATCCGCGGTGGCCTGGTCCAGGGCTC 
 
Table 2.7 ǀ Sequencing primers 
Plasmid Primer Sequence (5’ to 3’) Details 
pETM-11-HaloTag-
HIF-2α 
TCAAGACCCGTTTAGAGG; 
ATACATGGACTGGCTGCAC; 
CATCAGCAAGTTCATGGGAC; 
TCATCTCTCTGGATTTCGG; 
CTCTCCAACAAGCTGAAGC 
Covered full Halotag- HIF-2α insert 
CMV-HaloTag-HIF-2α-
IRES-dTomato 
Same as those used for 
cloning (Table 2.6) 
Covered IRES and dTOM insert 
pLNT-Ubc-HIF-2α-
Venus 
CATGAAGTTCACCTACTG 
Binds in the middle of EPAS1 and 
sequences towards 3’ end 
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 2.3 Cell Culture 
 2.3.1 Cell line propagation 
All cell lines were maintained in humidified air at 37 °C in a Sanyo CO2 (CO2 set at 5%) 
incubator (SANYO Electric Biomedical Co., Japan). 
Table 2.8 ǀ Cell lines and culturing conditions 
Cell Line Growth Conditions 
Comments 
Name Details Medium Supplements 
HeLa             
Human cervix 
epitheloid 
carcinoma 
MEM 
10% v/v FCS, 1% 
v/v NEAA 
ECACC no: 93021013 
shPHD2 HeLa 
Stable cell line 
knocked down 
for PHD2 via 
small hairpin 
RNA (shRNA) 
MEM 
10% v/v FCS, 1% 
v/v NEAA, 
10 µg mL
-1
 
Puromycin 
(Invitrogen, CA, 
USA). 
generous gift from D 
Hoogewijs, D Stiehl and R 
Wenger, University of Zürich, 
Switzerland 
shPHD3 HeLa 
Stable cell line 
knocked down 
for PHD3 via 
small hairpin 
RNA (shRNA) 
MEM 
10% v/v FCS, 1% 
v/v NEAA, 
10 µg mL
-1
 
Puromycin 
(Invitrogen, CA, 
USA). 
HeLa cells transduced with 
shPHD3 lenti virus. shPHD3 
plasmid from D Stiehl and R 
Wenger, University of Zürich, 
Switzerland 
PML-YFP HeLa 
cell line that 
stably express 
PML-YFP 
construct 
MEM 
10% v/v FCS, 
1% v/v NEAA, 
1 μg mL
-1 
Blasticidin, 
1% v/v 
Penicillin/Strept
romycin 
generous gift from E. G. 
Jaffrey, University of Dundee 
HEK 293TN 
Human 
embryonic 
kidney 
DMEM 10% v/v FCS. 
#LV900A-1; System 
Biosciences, Inc., CA, USA 
HIF-1α-GFP 
BAC HeLa 
HeLa cells stably 
expressing 
HIF-1α-GFP 
MEM 
10% v/v FCS, 1% 
v/v NEAA, 
400 μg mL
-1
 
geneticin 
Stably cell line created by 
transfection of HIF-1α-GFP 
BAC (generous gift from Prof 
R van de Water, Leiden 
University) 
C2C12 
Mouse 
myoblasts 
– – 
Provided by Dr J Ankers, 
University of Liverpool, UK 
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 2.3.2 Cell treatments 
Hypoxic incubation was carried out either directly on the microscope stage or incubated in 
a H35 Hypoxysation (Don Whitley, UK). DMOG was used as a hypoxia mimic at a final 
concentration of 0.5 mM used (Enzo Life Sciences; NY, USA).  
Table 2.9 ǀ Definitions of different cell treatments 
 
 2.3.3 Transient Transfection 
The transfection reagent, FuGene®6 (Roche, Switzerland) was used for delivery of plasmids 
into cells. Transfection of cell was carried out 24 h before imaging or other analysis, 
following the manufacturer’s protocol and using a ratio of 2:1 (transfection reagent: 
plasmid DNA mass).  
Table 2.10 ǀ Volumes of reagents used for different vessels for transient transfection of HeLa cells.  
Vessel 
Volume of Serum Free 
Medium (μL) 
Volume of Fugene 
(μL) 
Total Mass of 
DNA (μg) 
12 well plate 50 1.5 0.75 
35 mm glass bottom dish 100 2 1 
60 mm culture dish 200 6 3 
10 cm culture dish 1700 34 17 
  
Treatment Name Description 
Normoxia 19% O2, 5% CO2, 37 °C 
Hypoxia 1% O2, 5% CO2, 37 °C 
Dimethyloxalylglycine (DMOG) 2OG-hydroxylase (PHD) inhibitor 
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 2.4 Stable cell line production  
 2.4.1 Lentivirus 
The shPHD3 and ODD-EGFP stable cell lines were made via lenti-viral transduction. The 
pLKO.1.shPHD3 construct was obtained from D Hoogewijs and R Wenger (University of 
Zürich). The pHIV-ODD-EGFP-IRES-dTomato lentiviral construct was cloned by Amelie 
Schober (Erasmus Masters student). This was done by amplifying the ODD-EGFP coding 
region from pG-ODD-EGFP (Bagnall, 2011) and ligating this into a pHIV-IRES-dTomato 
plasmid (plasmid 21374; Addgene, MA, USA). 
 2.4.1.1 Viral particle production 
HEK 293TN cells were plated in 10 cm at a density of 1.5 × 106. The lentiviral construct was 
transfected into HEK 293TN cells using FuGene®6 (Roche Applied Science, UK) along with 
packaging plasmids psPAX2 (plasmid 12259; Addgene, MA, USA) and pMD2.G (plasmid 
12260; Addgene, MA, USA). The three plasmids were mixed in the ratio of 4:2:1 
respectively and transfected using a ratio of 2:1 (Fugene®6 volume: total DNA mass). 16 h 
post transfection, the media was aspirated and replaced with fresh media. The media was 
then collected 72 h after transfection and the viral particles concentrated by 
ultracentrifugation, following the protocol in Kutner et al. (2009). In brief, the 20 ml of viral-
particle containing medium was placed in sterilized Ultra-clear SW28 centrifuge tubes with 
a 4 mL 20% sucrose solution (20 g of ultrapure sucrose dissolved in 100 mM NaCl, 20 mM 
Hepes pH 7.5 and 1 mM EDTA) at the bottom. Ultracentrifugation was carried out as stated 
in protocol. Viral particles were resuspended in 100 μL PBS and were combined to make a 
total of 200 μL.  
 2.4.1.2 Transduction of HeLa cells 
Wt HeLa cells were seeded in a 24 well plate and grown to approximately 60% confluency. 
The concentrated virus was added to the cells along with polybrene (8 μg mL-1; Sigma, MO, 
USA). The media was changed after 16 h. When confluent, the transduced cells were 
transferred to a 25 cm3 flask and eventually maintained in 75 cm3 flask. The ODD-EGFP and 
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shPHD3 HeLa cell lines were grown in MEM (10% FCS, 1% NEAA). The shPHD3 medium was 
supplemented with 10 µg mL-1 puromycin (Invitrogen, CA, USA). 
 2.4.2  Bacterial artificial Chromosome (BAC) 
Bacteria containing the HIF-1α-GFP BAC (generous gift from Dr S Le Dévédec, Leiden 
University; RP11-867-L15, http://www.mitocheck.org/cgi-bin/BACfinder) were streaked 
onto an LB agar plate (containing 31.25 μg mL-1 Kanamycin and 12.5 μg mL-1 
Chloramphenicol) and incubated at 37 °C overnight. Isolated colonies were picked and 
grown in 4 mL of LB broth (containing 31.25 μg mL-1 Kanamycin and 12.5 μg mL-1 
Chloramphenicol) at 37 °C in an orbital shaker (225 rpm) for 8 h. Five hundred microlitres of 
this culture was transferred to 500 mL LB broth (containing 31.25 μg mL-1 Kanamycin and 
12.5 μg mL-1 Chloramphenicol) and incubated at 37 °C in an orbital shaker (225 rpm) for 
16 h. The bacteria were harvested via centrifugation (Sorvall RC-5B Refrigerated 
Superspeed Centrifuge; GSA rotor) at 6000 rpm, 4 °C for 10 min. The supernatant was 
discarded and the BAC was extracted and purified from the pellet using a NucleoBond Bac 
100 kit (Macherey-Nagel GmbH, Germany) following the manufacturers protocol (BAC 100 
Maxi).  
One million HeLa cells were seeded in 10 cm dishes 24 h hours before transfection. 
HIF-1a-GFP BAC was transfected into HeLa cells using polyethylenimine (PEI) ‘‘Max’’ 
(Polysciences Inc., PA, USA) in a ratio of 2:1 (PEI:BAC) following the same protocol as used 
for Fugene6® (see section 2.3.3). A second plate was left non-transfected as a selection 
control. After 72 h, the medium was replaced with medium containing 400 μg mL-1 
geneticin (Sigma Aldrich, MO, USA). The medium was changed every 48 h until all cells on 
control plate had died and colonies had started to form on the transfected plate.  
Isolated colonies were picked and transferred to a 96 well plate (one colony per well). Cells 
were kept under selection until confluent enough to be transferred into a larger vessel. This 
process was repeated until there were enough cells to create frozen stocks. Expression of 
HIF-1α-GFP was verified by western blot and microscope experiments.    
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 2.5 Microscopy 
 2.5.1 Overview of Microscopes used 
Table 2.11 ǀ Microscopes used and the application used for 
Microscope Application 
Zeiss, LSM 510 
EGFP-HIF-2α FRAP 
HIF-1α-EGFP FRAP 
Zeiss, LSM 710 
Co-localisation of HIF-2α 
TMR-Halotag-FGF2 
Zeiss, LSM 780 
EGFP-HIF-2α FLIP 
HIF-1α-EGFP BAC imaging 
Epifluorescence 
Speckle characterisation 
Microinjection 
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Table 2.12 ǀ Details of settings used for different fluorophores on each microscope 
 Fluorophore Laser Filter set up Objective 
Image capture 
software 
LS
M
 5
1
0
 
EGFP 
488 nm laser 
5% power 
output 
Emitted light 
reflected by a 
540 nm dichroic 
mirror through a 
505-550 nm 
bandpass filter 
and detected 
through a 530 nm 
longpass filter. 
Plan-
apochromat 63× 
1.4 oil 
LSM510 version 
3 software 
dTomato 543 nm laser 
Emitted light was 
detected through 
a 560 nm 
longpass filter 
LS
M
 7
1
0
 
AlexaFluor488 
/ YFP 
488 nm laser 
5% power 
output 
MBS 488/561/633 
Plan-Fluar 100× 
/ 1.40 oil 
Zen 2010 
software 
AlexaFluor555 
561 nm laser 
2.4% power 
output 
MBS 458/561 
Topro-3-
Iodide 
633 nm laser 
2% power 
output 
MBS 488/561/633 
TMR 
561 nm laser 
2.6% power 
output 
MBS 561 / 633 
C-apochromat 
63x/1.20 Oil 
LS
M
 7
8
0
 
EGFP 
Argon ion laser 
at 488 nm 
2% power 
output 
488 MBS, 
detection range 
493-598 nm. 
Plan-
apochromat 63× 
1.4 oil DIC 
Zen 2012 
software 
                                                                                                                    MBS = main beam splitter 
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 2.5.2 Immunofluorescence (IF) 
Cells were seeded at a density of 1 × 105 / glass cover slip, 24 h before treatment. Following 
treatment, cells were rinsed three times with PBS and subsequently fixed for 15 min with 
4% paraformaldehyde at room temperature, followed by three 10 min PBS washes. To 
reduce auto-fluorescence, 50 mM NH4CL was added for 20 min, removed and the cells were 
blocked for 20 min (blocking buffer: 1% w/v BSA, 0.1% v/v Triton X-100, and 0.4% v/v 
Tween 20 in PBS). Cells were then incubated for 1 h with primary antibody (see table). Cells 
were washed three times in blocking buffer and then incubated for 30 min with the 
secondary antibody. All steps were carried out at room temperature and antibodies were 
diluted in blocking buffer according to table. Cover slips were mounted onto glass 
microscope slides with Dako Fluorescent Mounting Medium (Dako UK Ltd., UK). Precautions 
were taken throughout to ensure minimal exposure of samples to light. 
Table 2.13 ǀ Antibodies used for immunocytochemistry 
 
Reactive 
against 
Species Source Reference Dilution 
Primary 
Anti-HIF-2α Rabbit Abcam, UK ab20654 1:500 
Anti-HIF-2α Rabbit Abcam, UK ab179825 1:100 
Anti-HIF-1α Mouse 
BD Biosciences,      
NJ, USA 
610959 1:1000 
Anti-HIF-1β Mouse 
Novus Biologicals, 
CO, USA 
NB100-124 1:100 
Anti-RNAPII 
(phospho ser5) 
Mouse Abcam, UK ab24759 1:50 
Anti-SC35 Mouse Abcam, UK ab11826 1:1000 
Anti-Sart1 Mouse Abcam, UK ab88583 10 μg / mL 
Secondary 
Anti-rabbit-
AlexaFluor555 
Goat 
Invitrogen,               
CA, USA 
A-21428 
1:500-
1:1000 
Anti-mouse-
AlexaFluor488 
Goat 
Invitrogen,               
CA, USA 
A-11008 
1:500-
1:1000 
Nanobodies 
Anti-GFP-
Atto594 
Alpaca 
ChromoTek GmbH, 
Germany 
gba594 1:200 
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 2.5.3 Imaging Fixed samples 
Fixed samples were imaged with a Plan-Fluar 100× / 1.30 oil immersion objective on a LSM 
710 confocal microscope (Zeiss, Germany). Z-stacks were taken through the nucleus of 
single cells, with a distance of 0.5 μm between each slice. 1024x1024 pixel images were 
acquired using a 100x oil-immersion objective with a numerical aperture >1.40, zoom x2 
and the pinhole set at 70 μm. Images were captured using the Zen 2010 software (Zeiss, 
Germany). 
 2.5.4 Live cell imaging 
 2.5.4.1 LSM 510  
Twenty four hours before each experiment, 1.5 × 105 cells were seeded in a 35 mm glass 
bottom dish (Greiner Bio One, UK). Cells were transiently transfected at the time of 
seeding. Imaging dishes were placed in a PeCon O2 controller incubator (PeCon GmbH, 
Germany) mounted on the confocal microscope stage. Conditions were as described in 
Table 2.9.  
 2.5.4.2 Epifluorescent microscope 
Imaging dishes were prepared as described above and mounted on the stage of an Axio 
Observer Z.1 Epifluorescent microscope (Zeiss, Germany) fitted with an incubation system. 
Conditions were as described in Table 2.9. Cells expressing EGFP-HIF-2α were imaged for 
1000 frames with an Andor iXon 879 (16 μm pixels 512×512) camera (Andor, UK). To 
achieve high magnification a 63× objective and 2.5× optovar lens were used.  
 2.5.5 Analysis 
 2.5.5.1 Co-localisation analysis 
Post-acquisition processing and co-localisation analysis was carried out using ImageJ 
(Schneider et al., 2012). The middle slice from each z-stack was analysed. The background 
was subtracted for both the red and green channel (pixel size of 5 for HIF-2α, 5 for RNAPII, 
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10 for HDAC5-YFP). Analysis was performed with an ImageJ plugin for co-localisation 
analysis (http://fiji.sc/Colocalization_Threshold).  
 2.5.5.2 Cell Tracker 
For each time lapse the fluorescence intensities, for a number of cells, was determined 
using Cell Tracker version 0.6 software (software website: www.dbkgroup.org/celltracker/) 
(Shen et al., 2006). Using this software, EGFP positive cells were manually tracked by 
drawing a circle in the cell and adjusting it accordingly to ensure it remained within the cell 
boundaries through each frame. Cells were tracked from the start of imaging up to point of 
cell death or until the end of the experiment. For any cell division, the parent cell was 
tracked up to point of division and after division tracking continued following one of the 
daughter cells. Any cells that started outside of the frame or moved out of the frame during 
the time course were not tracked. All data was exported as the mean intensity of 
fluorescence.  
 2.5.5.3 Characterisation of EGFP-HIF-2α Speckles 
Analysis was performed in Fiji (Schindelin et al., 2012) on calibrated image stacks (1000 
frames). The image stack was duplicated: one was processed as follows. Background was 
subtracted using a 5 pixel filter and a mask applied (threshold type Li, dark background). To 
separate touching objects a watershed was applied and any holes were filled (using Fill 
Holes option). The masked images was analysed (size of pixel = 10-infinity) and 
measurements were redirected to the original (unprocessed) image. The results output 
gave the number, size, total area etc.  
 2.5.5.4 Analysis of EGFP-HIF-2α Speckle Dynamics 
Image stacks (1000 frames) were analysed with the plugin Particle Tracker 2D/3D 
(Sbalzarini & Koumoutsakos, 2005; parameters using radius = 5, cut-off = 1, percent = 5, 
link = 1, displacement = 5) in ImageJ. The trajectory coordinates were exported to Excel 
(Microsoft Corporation, WA, USA). Analysis of trajectories of individual speckles was 
performed using a macro written by Dr D Mason (Image Analyst, Centre for Cell Imaging, 
University of Liverpool, UK). The velocity and slope of the moment scaling spectrum 
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(corresponds to diffusion mode) were calculated based on formulas in Ewers et al. (2005), 
Sbalzarini & Koumoutsakos (2005) and Scheweizer (2007). 
 2.5.6 Advanced Microscopy Techniques 
 2.5.6.1 Fluorescence Recovery After Photobleaching (FRAP)  
FRAP was performed on an Axiovert 200M LSM510 (Zeiss, Germany) confocal microscope. 
Ten pre-bleach and 290 post-bleach images were acquired every 300 ms, using a 63× oil 
immersion objective. Bleaching of a region of interest (ROI) was performed with an Argon 
ion laser (488 nm) at 100% output power for 50 iterations for EGFP-HIF-2α. The pinhole was 
set at ~3 airy units. Data was captured by LSM510 version 3 software (Zeiss, Germany).  
 
Figure 2.1 ǀ Overview of FRAP EGFP-HIF-2α analysis. A) Example of the three regions acquired for analysis 
Region of interest (ROI) 1 = bleached region, ROI2 = whole fluorescent region / acquisition bleach control, ROI3 = 
background fluorescence. B) Schematic of the quantitative data obtained from the three regions in B plotted 
against time. C) Schematic of a normalised recovery curve and the different information that can be 
extrapolated. D) Example of final recovery curve after background subtraction and normalisation from a single 
bleached cell. Half time and mobile fraction calculated from the fitted curve. All performed in Matlab (see 
methods).  
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For each FRAP experiment, fluorescent intensities for the bleached region (ROI1), 
non-bleached region (acquisition control; ROI2) and background (ROI3) were extracted 
using the LSM510 software (Figure 2.1). ROI1 and ROI2 were background subtracted 
(average) and normalised to their respective pre-bleach values (average). The resulting 
ROI1 values were normalised to the ROI2 values (ROI1 / ROI2). This ratio was then 
corrected for any non-specific bleaching during acquisition using the following equation: 
(     )
(    )
 
Where Rt is the bleach value at a given time point and Rp is the first post-bleach value. 
These values were plotted against time and the curves were fitted using the following 
equation:  
(   )          
Where a= Value of Y intercept, b= Value of Y at infinity, c= rate constant for graph. 
Both the normalisation and curve fitting was performed in Matlab (Mathworks, UK) using a 
code written by SiSeet Chan (Honours project student, Violaine See Group, University of 
Liverpool, UK). Using the curves the mobile fraction and half time for each FRAP experiment 
was calculated.  
Due to the rapid recovery exhibited by HIF-1α-EGFP, the experimental set-up was altered 
slightly whereby a strip across the nucleus was bleached and was performed at 100% 
output power for 50 iterations. 
 2.5.6.2 Fluorescence Loss in Photobleaching (FLIP) 
FLIP was performed on a LSM780 (Zeiss, Germany) confocal microscope. Following the 
acquisition of 10 images, cells expressing EGFP-HIF-2α were bleached within a region of 
interest with an Argon ion laser (488 nm) for 100 iterations at 100% output power. Twenty 
post-bleach images were captured before bleaching was repeated. Cycles of imaging and 
bleaching were carried out until fluorescence in the non-bleached region was lost. For 
acquisition of images, Images were captured by Zen 2012 software (Zeiss, Germany).  
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For each FLIP experiment, the fluorescent intensities for the bleached region (ROI1), 
non-bleached region (ROI2) and background (ROI3) were extracted using Fiji. The average 
of the background fluorescence over the course of the time-lapse was subtracted from 
each ROI2 value. These background corrected values were then normalised to average of 
the pre-bleach fluorescence values. This data was plotted against time. The half time for 
each experiment was calculated by fitting each FLIP curves with a one component 
exponential decay curve in Matlab. 
 2.6 Bulk cell analysis 
 2.6.1 Western Blot 
Cells were plated at a density of 4 x 105 – 5 x 105 per 60 mm culture dish (Corning, NY, USA) 
24 h before the experiment. Following the respective treatment, samples were washed 
with PBS and 350 µL lysis buffer (50 mM Tris-HCl pH 7.5, EDTA 1 mM, EGTA 1mM, Na3VO4 
1 mM, 1% v/v Triton X-100, 50 mM Sodium Fluoride, 5 mM Sodium pyrophosphate, 19 mM 
sodium B-glycerophosphate, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 10 µl / mL 
Phosphatase Inhibitor Cocktail) added. Cells were detached with a cell scraper and 
collected in 1.5 mL eppendorf tubes. Samples were rotated for 45 min at 4 °C and then 
centrifuged at 14000 g (≈10,000 rpm) for 15 min at 4 °C and the supernatant was collected. 
The protein concentration of the supernatant was measured using the BCA Protein Assay 
Kit (Thermo Scientific Pierce) according to manufacturer’s instruction. Protein samples were 
mixed in a 1:1 ratio with Laemmli (2×) buffer (25% v/v 0.5 M Tris base pH 6.8, 20% v/v 
glycerol, 10% w/v SDS, 5% v/v β-mercaptoethanol and 0.1% w/v bromophenol blue) and 
boiled for 5 min prior to loading. Samples were resolved on 10% SDS-PAGE resolving gel 
(0.4 M Tris base pH 8.8, 0.1% w/v SDS, 10% acrylamide, 0.25 ng/μl APS and 0.125% v/v 
Temed) and 4% stacking gels (0.4 M Tris base pH 6.8, 4% acrylamide, 0.65 ng/μl APS  and 
0.325% v/v Temed). 30 µg of protein was loaded per well and 8 µL of protein ladder 
(Precision Plus Protein All Blue Standards; Biorad, CA, USA) was loaded in one well. Gels 
were run at 130 V in running buffer 1× (25 mM Tris, 192 mM glycine and 3.4 mM SDS) until 
adequate separation achieved. Protein was transferred for 1.5 h (4 °C, 300 mA) onto a 
nitrocellulose membrane (Biorad, CA, USA) in transfer buffer (20% v/v ethanol, 25 mM Tris, 
192 mM glycine). Membranes were blocked with 5 % w/v milk (in TBST; 0.2 M Tris pH 7.6, 
0.14 M NaCl, 0.1% v/v Tween 20) for 1 h and incubated with primary antibody (prepared in 
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5 % w/v BSA in TBST) for 16 h at 4 °C. Following three TBST washes, membranes were 
incubated with the secondary antibody (prepared in 5% w/v skimmed milk powder in TBST) 
for 1 h. Protein bands were visualised with Amersham ECL western blotting detection 
reagent (GE Healthcare, UK) and membranes imaged on the Syngene G-box (Geneflow, UK).  
Table 2.14 ǀ Antibodies used for immunoblotting. 
 Antibody Species Source Reference Dilution 
P
ri
m
ar
y 
HIF-1α Mouse 
BD Biosciences, NJ, 
USA 
610959 1:1000 
HIF-2α Rabbit Abcam, UK ab20654 1:1000 
PHD3 Rabbit 
Novus Biologicals, 
CO, USA 
NB100-139 1:1000 
GFP Rabbit Abcam, UK ab290 1:1000 
Beta-Actin Mouse Abcam, UK ab8226 1:1000 
Cyclophillin A Rabbit Abcam, UK ab3563 1:1000 
Se
co
n
d
ar
y 
Anti-mouse HRP 
conjugated 
Horse 
Cell Signalling, MA, 
USA 
7073S 1:5000 
Anti-rabbit HRP 
conjugated 
Goat 
Cell Signalling, MA, 
USA 
7074S 1:3000 
 2.6.2 Real-time qPCR (RT-qPCR) 
Cells were plated 24 hours before treatment at a density of 4-5 x 106 cells in 60 mm culture 
dishes. Following treatment cells were rinsed with PBS and lysed with 350 µL of RLT buffer 
(provided in the RNeasy kit; QIAGEN, Netherlands) with 1% v/v β-mercaptoethanol, cells 
were scraped and collected in eppendorf tubes and stored at -80 °C. When all samples were 
collected, the lysates were homogenised using QIAshredder mini spin columns (QIAGEN, 
Netherlands). RNA extraction was carried out according to manufacturer’s instruction. RNA 
was eluted in 30 µL RNase free water and concentration was measured using a 
spectrophotometer (Nanodrop 2000; Thermo Scientific, MA, USA).1 µg of extracted RNA 
was converted to cDNA using SuperScript® VILO cDNA Synthesis Kit (Invitrogen, CA, USA) 
according to manufacturer’s instruction. RT-qPCR reactions were ran in triplicates and 
carried out in a 96 well plate. Each reaction consisted of 18 µL master mix (10 µL 1x SYBR 
Green PCR master mix, 1 µL 5 µM forward primer, 1 µL 5 µM reverse primer, 6 µL RNase 
Methods 
55 
free H2O) and 2 µL cDNA sample. Temperature cycling was performed using a LightCycler® 
480 (Roche, UK) using the parameters stated in Table 2.15. Results were analysed using the 
LightCycler® 480 software (version 1.5.0.39; Roche, UK). Target genes were normalised to 
the house-keeping gene cyclophillin A, with control sample used as the calibrator.  
Table 2.15 ǀ Cycle parameters for RT-qPCR 
 
Table 2.16 ǀ Primers used for RT-qPCR 
 
 
  
Stage Temperature Time Ramp Rate (°C/s) No. Of Cycles 
Pre-Incubation 95 °C 5 min 4.4 1 
Amplification 
95 °C 10 s 4.4 
45 
60 °C 30 s 2.2 
Melt Curve 
95 °C 5 s 4.4 
1 65 °C 61 s 2.2 
97 °C Continuous 0.11 
Cooling 40 °C 10 s 1.5 1 
Gene Sequence 
Cyclophillin A (forward) gctttgggtccaggaatgg 
Cyclophillin A (reverse) gttgtccacagtcagcaatggt 
PHD2 (forward) tgcagatgagagagcacg 
PHD2 (reverse) ttagcgaccgaatctgaagg 
PHD3 (forward) agatcgtaggaacccacacg 
PHD3 (reverse) ttctgccctttcttcagcat 
VEGF (forward) gggcagaatcatcacgaagt 
VEGF (reverse) cacacaggatggcttgaaga 
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 2.7 Recombinant protein and nanoparticle work 
 2.7.1 Bacterial transformation for recombinant protein 
expression 
Fifty microlitres of C41 (DE3) E. coli, were thawed on ice and 5 ng of Halotag-FGF2 were 
added. The cells were incubated on ice for 20 min, heat shocked at 42 °C for 1 min and 
returned to ice for 2 min. 950 μL pre-warmed SOC medium was added and the cells 
incubated for 1 h at 37 °C in an orbital shaker (225 rpm). Following this, the cells were 
centrifuged at 8000 g for 1 min, the supernatant removed and the pellet re-suspended in 
200 μL of pre-warmed SOC medium. 20-50 μL transformed cells were spread on selective 
LB agar plates (for antibiotics used see Table 2.1, note: BL21.pLysS also required 50 μg mL-1 
Chloramphenicol) and incubated at 37 °C overnight. See Table 2.17 for the variations in the 
transformation protocol for each strain of E. coli used.  
Table 2.17 ǀ Details of the variations in protocols for transforming pET-M11-Halotag-HIF-2α into 
different strains of competent cells 
Strain of E. coli Mass of DNA Time on ice Heat shock Return to ice 
BL21(DE3) 5 ng 30 min 10 sec at 42 °C 2 min 
C41 (DE3) 5 ng 30 min 45 sec at 42 °C 2 min 
BL21(DE3).pLysS 10 ng 10 min 45 sec at 42 °C 2 min 
Rosetta(DE3) 5 ng 5 min 30 sec at 42 °C 2 min 
Lemo21 5 ng 30 min 10 sec at 42 °C 5 min 
SoluBL21 5 ng 15 min 45 sec at 42 °C - 
 
Table 2.18 ǀ Antibiotics used for recombinant protein expression 
Plasmid Antibiotic Final Concentration 
pET-14b-Halotag-FGF2 Ampicillin 
As in Table 2.1 
pETM-11-Halotag-HIF-2α Kanamycin 
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 2.7.2 Assessing recombinant protein expression 
Single colonies of transformed bacteria were picked using aseptic techniques and added to 
10 mL LB broth (Merck KGaA, Germany; prepared according to manufacturer’s instructions) 
containing respective antibiotic. The 10 mL cultures were incubated at 37 °C in an orbital 
shaker (240 rpm). When the OD600 (optical density / absorbance measured at a wavelength 
of 600 nm) reached 0.6-0.8 protein expression was induced by the addition of 1 mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG; Bioline, MA, USA). Cultures were then 
incubated at different temperatures for varying times in an orbital shaker (240 rpm). From 
this point all samples were kept on ice. Cells were pelleted via centrifugation at 4 °C, 8000 x 
g for 30 min and the supernatant discarded. The pellet was re-suspended in PBS and the 
centrifugation step repeated. The supernatant was discarded and samples were taken for 
analysis via SDS PAGE.  
 2.7.3 Assessing recombinant protein solubility 
10 mL culture was inoculated with a single colony and incubated overnight at 37 °C, 225 
rpm. 5 mL of the overnight culture was transferred to 200 mL LB broth (100 µg mL-1 
Ampicillin) and incubated at 37 °C, 225 rpm. When the OD600 reached 0.6-0.8, 1 mM IPTG 
added and incubated for a further 4 h. Bacteria was pelleted via centrifugation at 8000 rpm, 
16 min, 4 °C (RC6+ Centrifuge). Pellets re-suspended in 20 mL PBS and centrifuged again.  
Cells were lysed via sonication. Each pellet was thawed on ice, resuspended in 30 mL 
resuspension buffer (30 mM Tris, 0.6 mM EDTA, 0.5 M NaCl, 3 mM MgCl2, 6% v/v Glycerol) 
and transferred to a pre-chilled 50 mL beaker. The cells were sonicated for 30 s (DAWE 
Ultrasonic Generator 7533A, pulsed sonication, 40-50% duty of cycles, output 10) followed 
by 60 s on ice. This was repeated five times. The sample was transferred to a 50 mL tube 
and centrifuged at 18000 rev / min for 30 min at 4 °C. The supernatant (soluble fraction) 
was transferred to a new tube and samples from the pellet and supernatant were analysed 
via SDS-PAGE and coomassie staining.  
 2.7.4 Purification of Recombinant protein 
Preliminary purification described in Chapter 5. Final purification protocol as described in 
Sun et al. (2015).  
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 2.7.5 Labelling bacterial cell lysates with Fluorescent Halotag 
Ligand for SDS PAGE  
Purified protein: 10 µL of protein was incubated with 2 µL 50 µM Oregon Green Halotag 
Fluorescent Ligand for 15 min at room temperature. 4 x loading buffer was added and 
samples heated to 80 °C for 2 min. 15 µL of sample was analysed via SDS PAGE.  
Bacterial lysate: Bacterial cell pellets were re-suspended in 1 mL 50 mM Hepes buffer (Life 
Technologies, CA, USA) and 1 mL lysis buffer (1x Fast Break Cell lysis reagent (Promega, WI, 
USA) diluted in PBS, 2 mg mL-1 Lysozyme (Sigma Aldrich, MO, USA), 0.02 units RQ1 RNase 
Free DNase (Promega, WI, USA)). Samples were rotated for 30 mins at 4 °C, followed by 
centrifugation for 30 min. 100 µL of supernatant, 45 µL 50 mM Hepes buffer and 5 µL 
Oregon Green Halotag ligand (50 µM) were incubated for 20 min at room temperature in a 
1.5 mL Eppendorf tube. Appropriate volumes of each sample were mixed with 5x loading 
buffer (250 mM TrisHCl pH6.8, 10% SDS, 30% Glycerol, 5% β-mercaptoethanol, 0.02% 
bromophenol blue) and heated at 80 °C for 2 min prior to analysis via SDS-PAGE with 
coomassie staining and by western blot.  
Mammalian cell lysate: 20 µL of protein (whole cell lysate) was incubated with 4 µL Oregon 
Green Halotag ligand (50 µM) for 20 min at room temperature. 6 µL 5x loading buffer was 
added, and each sample heated to 80 °C for 2 min. Samples were analysed by SDS PAGE 
and western blot.  
 2.7.6 Fluorescent labelling of Halotag-Fusion protein for 
microscopy 
Purified protein: Two microlitres of recombinant protein (30 µM) was mixed with 3 µL TMR 
Halotag Ligand (50 µM, diluted in DMSO) and made up to a total reaction volume of 20 µL 
with PBS. The reaction was allowed to proceed at room temperature for 30 minutes. The 
labelled protein was passed through a Heparin column. To remove any unbound ligand the 
column was washed with PBS and the TMR-Halotag-FGF2 was eluted with 2x 30 µL 1.5 M 
NaCl. The eluted fraction was diluted to 0.8 µM. Rama-27 cells seeded and fixed in 35 mm 
glass bottom microscope dishes (Greiner Bio-One, UK) were provided by Daniel Nieves 
(Prof. D. G. Fernig's group, University of Liverpool). The cells were incubated for 10 minutes 
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with Ringer BSA (10 mg / mL) buffer (stock Ringer solution: 10 mM Hepes pH 7.4, 140 mM 
NaCl, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 11 mM Glucose. Diluted 1:1 with 20 mg / mL 
BSA prepared in PBS). The cells were incubated for 1 hour in 200 µL incubation buffer 
(TMR-Halotag-FGF2 diluted in Ringer and added in ratio of 9:1 to PBS supplemented with 10 
mg / mL BSA to give final protein concentration of 2 nM). This was followed by 3x 1 mL 
Ringer BSA (10 mg / mL) washes.  
Cells ectopically expressing Halotag-Fusion: HeLa cells were seeded in 35 mm glass bottom 
imaging dishes (Greiner Bio One, UK) and transiently transfected with the CMV-Halotag-
HIF-2α construct as described earlier. Cells were labelled with the Oregon Green or TMR 
Fluorescent Halotag ligand following Promega’s guidelines for live cell imaging (rapid 
protocol). The cells were directly observed on a LSM 710 confocal microscope (For details 
see microscopy).  
 2.7.7 in vitro Protein Expression  
Protein synthesis was carried out using the PURExpress® In Vitro Protein Synthesis kit (NEB, 
MA, USA) following the manufacturers guidelines. 250 ng of pET-M11-Halotag-HIF-2α was 
used per 25 µL reaction. 5 µL of protein was labelled with various concentrations (as stated 
in Figure x) of Oregon Green Halotag ligand for 30 minutes at room temperature. Samples 
were analysed via SDS PAGE and western blot.  
 2.7.8 Expression of recombinant protein in Mammalian Cells 
HeLa cells: 5 x 105 HeLa cells were seeded in 6 cm dishes in a total of 4 mL medium and 
were transiently transfected with CMV-Halotag-HIF-2α using FuGene®6 (as described in 
section X). 24 h post transfection, cells were incubated in normoxia or hypoxia or treated 
with 0.5 mM DMOG for 8 h. Cells were lysed with 150 µL western blot lysis buffer (see 
Western Blot). Samples were labelled with Halotag Oregon Green ligand (Promega, WI, 
USA) following the manufacturer’s guidelines.  
HEK 293TN: cells were seeded in 10 cm dishes at a density of 1 x 107 (total) in 10 mL 
medium. The CMV-Halotag-HIF-2α construct was transiently transfected following the 
protocol in section xx. 48 h post transfection the cells were harvested. The medium was 
carefully aspirated away and cells washed gently with PBS. 500 μL lysis buffer (50 mM Tris 
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HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1x Protease Inhibitor Cocktail (G6521; Promega, WI, 
USA)) was used per 10 cm dish. A sterile cell scraper was used to detach the cells, which were 
collected in pre-chilled 1.5 mL Eppendorf tubes. All following procedures were done on ice 
or at 4 °C. The samples were incubator on a rotator for 1 h to aid cell lysis and then 
centrifuged for 1 h, 13000 rpm (Eppendorf MiniSpin). The supernatant was transferred to 
pre-chilled Eppendorf tubes. Total protein concentration was determined using a BCA assay 
(as described in Section 2.6.1)  
 2.7.9 Gold Nanoparticles 
 2.7.9.1 Synthesis and Functionalisation of Gold Nanoparticles 
Gold nanoparticle synthesis and functionalisation was carried out in collaboration with Dr U 
Shaheen (Dr R Levy’s group, University of Liverpool). Nanoparticles with a gold core 10 nm 
in diameter and a ligand shell comprised of polyethylene glycol (PEG) only or PEG and a 
custom made Halotag ligand (Promega, WI, USA) were synthesised. Briefly, capped 
nanoparticles were made by mixing colloidal gold (Sigma Aldrich, MO, USA) with the 
ligand(s) in a ratio of 9:1, respectively (Duchesne et al., 2012). To make 1 mL of 1% Halotag 
ligand (HL) GNPs 2 μL of Halotag Ligand (1 mM) and 98 μL PEG (2 mM) was used. The 
ligands were added sequentially, the HL ligand first followed by the PEG. In between each 
step the nanoparticles were vortexed gently for 1 min. The nanoparticles were incubated at 
room temperature for 16 h on a rotator. Excess ligands were removed by washing with   
(PBS with 0.2% v/v Tween20), nanoparticles were centrifuged (13200 rpm for 1.5 h) and 
resuspended in PBST four times.  
 2.7.9.2 Gold nanoparticle conjugation 
Nanoparticle (70 nM; PEG-GNPs or 1% HL-GNPs) were incubated with 750  μg protein 
(HaloTag-HIF2α or control HEK-293TN lysate) made up to a final volume of 100 μL with 
PBST. Protein degradation was prevented by inclusion of 1x EDTA-free protease inhibitor 
(Promega, WI, USA). Additional control reactions were set up with nanoparticles or lysate 
only. The nanoparticles were mixed with lysates (Halotag-HIF-2α) and for 18 h at 4 °C with 
mixing to allow conjugation to occur. To remove unbound protein, the nanoparticles were 
pelleted via centrifugation (13200 rpm at 4°C for 1 h) and the supernatant removed. The 
nanoparticles were then resuspended in 500 μL PBST. This was repeated four times and 
after each wash a small volume was taken for analysis by western blot or dot blot. 
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 2.7.9.3 UV-visible spectroscopy 
To monitor loss of nanoparticles following each step (of functionalisation or conjugation), 
samples were taken so the absorption spectrum could be measured. Measurements were 
made at room temperature using a Spectra Max Plus spectrophotometer (Molecular 
Devices, Wokingham, UK) between 450–700 nm. 
 2.7.9.4 Stripping Gold Nanoparticles 
After washing, nanoparticles (PEG-GNPs or 1 % HL-GNPs) incubated with the various lysates 
were incubated in stripping buffer (60 mM TrisHCl, 10 % Glycerol, 50 mM DTT, 2 % SDS, 
0.01 % Bromophenol Blue) with mixing for 36 h and then centrifuged (13200 rpm at 4 °C for 
1 h) to remove the stripped gold nanoparticle cores. The supernatant was then boiled for 
5 min prior to analysis via western blot. 
 2.7.9.5 Dot Blot 
Four microlitres of nanoparticles was added to nitrocellulose membrane and allowed to 
dry. The dot blots were blocked for 1 h in 5 % milk (in TBST) and incubated overnight with 
primary antibody (prepared in 5 % BSA in TBST) at 4 °C. Following three TBST washes, 
membranes were incubated with the secondary antibody (prepared in 5 % milk powder) for 
1 h. Protein was visualised with Amersham ECL Select western blotting detection reagent 
(GE Healthcare UK, UK) and membranes developed on a Syngene G-Box (Geneflow, UK). 
 2.7.9.6 Microinjection 
Cells were plated sparsely (1.5 x 105 / mL, 2 mL total) in 35 mm gridded dishes (Grid500; 
Ibidi GmbH, Germany) 24 h prior to injection. Were required, transfection was carried out 
concurrently.  
Microinjection was performed on a Zeiss Epifluorescent Axio Observer Z.1 (Zeiss, Germany) 
fitted with an incubation system that maintains humidity and allows control of 
temperature, CO2 and O2 levels. The microinjection system was set up in a manner that 
allows injection to occur whilst the imaging dish is mounted on the microscope stage. 
Microinjection was performed by Dr J Wnetrzak (Technician, Centre for Cell Imaging, 
University of Liverpool). Cells were injected into nucleus via microcapillaries (Eppendorf, 
Germany) with the injection time of 1 s, injection pressure of 150 KPa and compensation 
pressure of 30 kPa using the Eppendorf FemtoJet® Microinjector (Eppendorf, Germany). 
 Chapter 3: Investigating the temporal 
dynamics of HIF- at the single cell level 
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This chapter starts with a brief introduction to single cell imaging and its advantages over 
bulk-cell analysis techniques. It is followed by the presentation of a paper published in 
January 2014 and then additional work that I conducted relating to this study.  
 3.1 Investigating Protein Dynamics 
Live cell imaging of fluorescently labelled proteins allows the quantification of protein 
abundance over time as well as allowing the visualisation of intracellular localisation. 
Studies using live cell imaging have revealed that temporal and spatial dynamics play a role 
in regulating the activity of key signalling molecules. For example, Lahav et al.(2004) were 
the first to observe the pulsatile nuclear accumulation of p53 and showed that the 
frequency of pulses positively correlated with the amount of DNA damage. Continually, 
NFκB has been shown to transiently translocate from the cytoplasm into the nucleus upon 
stimulation with TNFα (Nelson et al., 2004). This group also determined that the timing of 
the nuclear-cytoplasmic shuttling directly affected gene expression, highlighting that 
temporal and spatial dynamics of transcription factors has a role in regulating their activity 
(Ashall et al., 2009).  
The aforementioned discoveries were made by utilising live cell imaging, which has 
numerous advantages over other methods used for protein analysis. For example, with 
western blot analysis any spatial information such as sub-cellular localisation is lost and so 
spatial kinetics such as nuclear-cytoplasmic oscillations (such as those observed for NFκB) 
are missed. Also, heterogeneity within cell populations can be obscured when using bulk 
cell techniques such as western blot and quantitative PCR, due to “averaging effects” 
(Spiller et al., 2010). Observations at the single cell level have highlighted that the timing of 
cellular responses are not always synchronised (Nelson et al., 2004;Bagnall et al., 2014) and 
this cell to cell variation can only be detected by observing single cells in real-time. 
Our hypothesis was that HIF-1/2α might have complex/oscillatory dynamics due to their 
regulation by negative feedback loops (Epstein et al., 2001;Stiehl et al., 2006). Our aim was 
to utilised single cell imaging techniques to capture the intracellular dynamics of the HIF-α 
subunits to determine which components are involved in this auto-regulatory mechanism.  
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 3.2 Tight Control of HIF-α Transient Dynamics Is 
Essential for Cell Survival in Hypoxia 
As previously mentioned, live cell imaging has revealed that temporal and spatial dynamics 
play a key role in the regulation of the activity of transcription factors such as p53 and NFκB 
(Lahav et al., 2004;Nelson et al., 2004). At the start of my PhD project, I had the opportunity 
to participate towards an on-going project (initiated by Dr James Bagnall, former PhD 
student in the laboratory) utilising live cell imaging to study the dynamics of HIF-1α/-2α at 
the single cell level. Our findings were published in an article entitled “Tight Control of 
Hypoxia-inducible Factor-α Transient Dynamics Is Essential for Cell Survival in Hypoxia” in 
the Journal of Biological Chemistry (Bagnall et al., 2014). 
We found that in hypoxia HIF-1α accumulates transiently in the nucleus after approximately 
4 hours with a peak in protein levels lasting 2-4 hours. In order to validate these data 
obtained from HeLa cells ectopically expressing HIF-1α-EGFP, a stable cell line was created. 
The ODD-EGFP HeLa were produced via lenti-viral transduction of a construct containing a 
fragment that spans 529aa to 652aa of the HIF-1α protein, i.e. part of the oxygen-
dependent degradation (ODD) domain containing the second hydroxylation site (p564), 
fused with EGFP. Live cell imaging of this cell line revealed a similar transient accumulation 
of the fusion protein in hypoxia, suggesting that the transient accumulation of HIF-1α is not 
an artefact of ectopic expression. 
The oscillatory behaviour observed is indicative of a negative feedback loop and led to the 
hypothesis that there is an auto-regulatory mechanism controlling the levels of HIF-1α in 
hypoxia. Mathematical modelling (performed by Joseph Leedale; Mathematics Department, 
University of Liverpool) based on gene expression data from qPCR and live cell imaging of 
PHD2 and PHD3 led to the proposal that PHD2 was the principal component of the negative 
feedback loop. Simulations based on these mathematical models suggested that the 
transient increase of HIF-1α protein levels would be lost if PHD2 was knocked out and 
knocking out PHD3 would have little effect. Live cell imaging of shPHD2 and shPHD3 HeLa 
cell lines ectopically expressing HIF-1α-EGFP confirmed these predictions.  
Moreover, in the shPHD2 cells, we observed that levels of HIF-1α continued to accumulate 
and eventually lead to the cells undergoing apoptosis, suggesting that prolonged HIF 
activity in hypoxia triggers cell death. To complement this, it was demonstrated that gene 
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expression relating to apoptosis (PUMA and NOXA) was induced in these cells in hypoxia. 
This led to the proposal that the PHD2-negative feedback mechanism is in place to protect 
cells by tightly controlling levels of HIF in hypoxia.  
My specific contributions to this paper:  
 Single cell imaging and analysis of ODD-EGFP HeLa cells (Figure 1I) 
 Analysis of PHD2 and PHD3 gene expression in the ODD-EGFP via qPCR (Figure 1J) 
 Creating the shPHD3 HeLa cell line via lenti-transduction of shRNA  (Figure 6H) 
 Single cell imaging and analysis of shPHD2 and shPHD3 HeLa cell lines transiently 
expressing HIF-1α-EGFP (Figure 6E and 6I, respectively) 
 qPCR experiments looking at the upregulation of VEGF mRNA and genes relating to 
apoptosis (PUMA and NOXA) (Figure 6E, F and G, respectively) 
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 3.3 Additional work 
 3.3.1 Improving molecular tools for imaging: HIF-1α-GFP 
stable cell line 
Most of the studies into the dynamics of the HIF-α subunits performed so far have required 
transient transfection of plasmids encoding HIF-1α / HIF-2α fused with fluorescent proteins 
such as EGFP or dsRed. Transient transfection has many disadvantages such as 
heterogeneity in expression levels, the protocol can be unreliable and the reagents can be 
toxic to the cells. In addition to this, the gene is under the control of a promoter that 
permits constitutive expression, the CMV promoter, which can lead to high levels of 
expression that are not necessarily representative of those observed for the endogenous 
promoter, and expression can vary between cell types (Smith et al., 2000). Therefore, to 
improve the quality of our HIF dynamic studies, we aimed to create stably transfected cell 
lines for both HIF-1α and HIF-2α. 
The initial plan was to create three stable cell lines via lenti-viral transduction, however 
creating cell lines stably expressing HIF-1α-EGFP and EGFP-HIF-2α proved difficult and we 
only had success with the ODD-EGFP construct (mentioned earlier). With this cell line, 
although similar dynamics to HIF-1α-EGFP (ectopically expressed in WT HeLa) in hypoxia 
were observed, the degradation appeared to be slower. This is could be explained by the 
fact that the ODD-EGFP is lacking the DNA binding domain and so is not transcriptionally 
active, resulting in an increase of substrate (ODD domain) in the system with no additional 
activation of PHD2 transcription to compensate. In addition to this, the ODD-EGFP only has 
one prolyl residue for hydroxylation which may result in reduced affinity of pVHL binding, 
thus less efficient targeting of the ODD-EGFP for proteasomal degradation. Although the 
ODD-EGFP cell line provides some valuable information, there was a need for a cell line 
stably expressing fluorescently-labelled full-length HIF-1α and HIF-2α. Given the lack of 
success with the lenti-virus approach to achieve this, I directed my efforts towards 
alternative strategies. I tried to generate a cell line stably expressing fluorescently labelled 
HIF-2α using several methods including zinc finger nucleases (ZFNs), but all were 
unsuccessful (work not shown) and so all work with HIF-2α-EGFP presented in this thesis 
was carried out using transient transfection. However, I had the opportunity to use a 
Bacterial Artificial Chromosome (BAC) for HIF-1α-GFP, thanks to the kind gift from Prof B 
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van de Water’s laboratory (University of Leiden), and was able to create a stable cell line 
expressing HIF-1α-GFP. 
 3.3.1.1 HIF-1α-GFP BAC stable cell line 
A HIF-1α-EGFP cell line was established via stable transfection of HeLa with a BAC encoding 
the fusion protein. In comparison to the ODD-EGFP cell line, this gene is under the control 
of its endogenous promoter and BACs can hold large pieces of mammalian DNA (up to 350 
Kb, compared to 15 Kb for plasmids and 7 Kb for lenti-viral vectors) resulting in the 
inclusion of lengthy flanking regions. Therefore a large proportion of the regulatory 
elements are incorporated and so utilising a BAC provides a more true reflection of 
endogenous expression (Adamson et al., 2011;Casali, 2003). Another advantage of the BAC 
cell line is that it was established from a single cell and is therefore a clonal population and 
so could provide the opportunity to determine whether the heterogeneity observed in 
Bagnall et al. (2014) is a feature of the HIF signalling system or an artefact of transient 
transfection. 
The HIF-1α-GFP BAC cell line was validated via western blot and imaging. Figure 3.1A shows 
a strong induction of wild type HIF-1α following treatment with 0.5 mM DMOG (6 h) and a 
transient induction of endogenous HIF-1α in hypoxia. A second band, approximately 40 kDa 
higher, follows the same pattern of induction and is presumed to be HIF-1α-GFP. The cells 
were imaged on a confocal microscope before and after (6 h) treatment with the hypoxia 
mimic and nuclear accumulation of fluorescent protein was observed (Figure 3.1B). 
Following these validation experiments, this cell line was utilised to repeat time-lapse 
experiments that were performed in Bagnall et al. (2014). 
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Figure 3.1 ǀ Validation of HIF-1α-GFP stable cell line. A) Western blot analysis of HIF-1α-GFP HeLa 
incubated in different conditions (D = 0.5 mM DMOG, 6 h, N = normoxia, H = hypoxia, number indicates number 
of hours incubated in hypoxia).Immunoblot was probed with anti-HIF-1α (top) and anti-β-actin (bottom) 
antibodies. B) HIF-1α-GFP HeLa were imaged on a Zeiss LSM780, before and after treatment with 0.5 mM DMOG 
(i = brightfield, ii = GFP, iii = merge of i and ii). Scale bar = 10 μ. In pre-treatment cells nuclei are outlined in 
white.  
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Figure 3.2 ǀ HIF-1α-GFP BAC time-lapse experiments. A) Confocal images of HIF-1α-GFP BAC cells in 0.5 % 
O2. Cells were subjected to hypoxic conditions from the second time point onwards. Nuclear boundary 
highlighted by white dashed line. White arrow indicates perinuclear autofluorescence. B) Quantification of 
fluorescence signal. Each data series represents the fluorescence measured in the nucleus of a single cell over 
time. 
 
Upon incubation in hypoxia, the cells showed a transient induction of HIF-1-GFP. After 
approximately 1 h the levels of fluorescence started to increase, peaked at 3-3.5 h and then 
started to decrease, reaching levels similar to those at the start of the time-lapse by 6-8 h 
(Figure 3.2B, M1 on supplemental CD).   
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Figure 3.3 ǀ Comparison of HIF-1α dynamics in hypoxia Example traces from single HeLa cell ectopically 
expressing CMV-HIF-1α-EGFP (top) and single HIF-1α-GFP BAC cell line (bottom) in hypoxia. Hypoxic incubation 
starts at 0 h.  
 
Figure 3.3 compares the typical shape of HIF-1α accumulation in hypoxia in a single cell 
ectopically expressing CMV-HIF-1α-EGFP (taken from James Bagnall’s data set) and one 
from the HIF-1α-GFP BAC experiments. In both systems the levels of HIF-1α start to 
increase at around 1-2 hours and peaks around 3-4 hours. Compared to the stable cell line, 
the cell transiently transfected with HIF-1α-EGFP shows a sharper increase in fluorescence, 
reaching much higher levels that then decrease more rapidly. The stable cell line exhibits 
stabilisation of much lower levels and a softer decline in HIF-1α, similar to what was 
observed with the ODD-EGFP cell line. The difference in the accumulation pattern might be 
explained by the difference in HIF-1α levels. The very high HIF levels obtained with 
transient transfection will induce a stronger negative feedback response compared to the 2 
fold increase obtained with the BAC cell line.  
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Although the BAC cell line should be closer to physiological HIF expression at the mRNA 
levels as the transgene is under the control of the endogenous promoter and other 
regulatory elements, the dynamic range of HIF-1α-GFP accumulation in hypoxia is poor i.e. 
the expression of the transgene are much lower than the endogenous protein in the 
western-blot (Figure 3.1A). Therefore the accumulation pattern observed with this cell line 
is unlikely to actually represent the reality any more than transient transfection.  
 3.4 Conclusion 
Here we have utilised live single cell imaging to demonstrate that induction of HIF-1α is 
transient due to an auto-regulatory mechanism. Furthermore we showed that the tight 
control of HIF-1α dynamics in hypoxia is necessary to prevent cell death. To validate these 
findings published in Bagnall et al. (2014) I repeated time-lapse experiments with cells 
stably expressing HIF-1α-GFP. 
 3.4.1 Imaging tools 
The difficulties experienced whilst trying to create a cell line stably expressing fluorescently 
labelled HIF-1/2α via lenti-viral transduction may be due to the final constructs being quite 
large (pHIV- HIF-1α-EGFP-IRES-dTomato is 10950 bp and pHIV-EGFP-HIF-2α-IRES-dTomato is 
11049 bp). It has been shown that constructs containing larger inserts achieve lower viral 
titres (units / mL) than smaller constructs (Al Yacoub et al., 2007). Also, the size of the 
construct can result in reduced recovery of the viral particles following the 
ultracentrifugation step prior to transduction (Al Yacoub et al., 2007).  
These stable cell lines that were successfully made are useful tools for studying the 
temporal and spatial dynamics of HIF-1α at the single cell level. For examples the ODD-
EGFP does not have any PAS domains so cannot heterodimerise with HIF-1β and there are 
no DNA binding domains, therefore there will be no downstream effects of overexpression 
of the ODD-EGFP as it is not transcriptionally active and therefore any dynamics observed 
relates purely to the activity of the PHDs. The HIF-1α BAC cell line has other advantages, as 
the transgene is under the control of the endogenous promoter so any observations take 
into account regulation at the transcriptional level as well as regulation via protein stability. 
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Unfortunately, the fluorescent signal in the ODD-EGFP and the HIF-1α BAC cell lines is very 
dim, which makes quantification of signal difficult and raises issues with acquisition, as 
higher laser power is required and longer exposure, which can lead to photobleaching and 
phototoxicity. This poor signal may be due to integration effects. Stable transfection of both 
lenti-viral vectors and BACs results in the integration of the exogenous reporter gene into 
the host’s genome (Adamson et al., 2011). However, there is little control over where the 
transgene is inserted and if it occurs within regions of densely packed, inactive 
heterochromatin then there will be little or no expression (Dillon & Festenstein, 
2002;Adamson et al., 2011). Another possibility is that the transgene integrates 
downstream of silencing elements. One way around this would be to utilise methods that 
allow targeting integration such a genome editing nucleases (zinc finger nucleases / ZFNs, 
transcription activator-like effector nuclease / TALENs, clustered regularly interspaced short 
palindromic repeats / CRISPR). 
Such low fluorescence levels have prevented me from performing longer time-lapse 
experiments, which would have allowed me to investigate whether there are further 
oscillations in prolonged hypoxia and if there is a link between the HIF dynamics and the 
cell cycle (as mentioned in the publication). 
 Chapter 4: Investigating the spatial 
localisation of HIF-1 and HIF-2 
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When investigating the single cell dynamics of HIF-1α and HIF-2α it became apparent that 
the two alpha subunits exhibit different sub-nuclear localisation.  
 
Figure 4.1 ǀ Sub-nuclear localisation of HIF-2α. A) HeLa cells ectopically expressing HIF-1α and HIF-2α EGFP 
fusions and endogenous HIF-1α and HIF-2α labelled using the immunofluorescent protocol. Images of HIF-1α-
EGFP were taken in the presence of DMOG. Scale bar = 5 μm. B) HeLa cells transiently transfected with plasmids 
encoding clover-HIF-2α (i), dsRED-HIF-2α (ii), HIF-2α-venus (iii) and Halotag-HIF-2α (iv). The cells expressing 
Halotag-HIF-2α were labelled with the fluorescent Oregon Green Halotag ligand to visualise the fusion protein. 
C) Confocal images of C2C12 (mouse myoblast; top) and HEK293T (human embryonic kidney cells; bottom) cells 
ectopically expressing EGFP-HIF-2α. Scale bar = 5 μm. 
 
Figure 4.1 shows the localisation of ectopically expressed EGFP fusions of HIF-1α and HIF-
2α. HIF-1α accumulates in the nucleus in a homogenous manner upon exposure to hypoxia 
or following treatment with a hypoxia mimic (DMOG), whereas HIF-2α localises in punctate 
foci (Figure 4.1A). Immunofluorescent staining of the respective endogenous proteins in 
HeLa cells shows a similar sub-nuclear localisation, highlighting that this difference is 
unlikely to be an artefact of overexpression (Figure 4.1A). Figure 4.1B shows that HIF-2α 
localises heterogeneously regardless of type or orientation (N- or C-terminal of HIF-2α) of 
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the tag. This non-homogenous protein expression is also observed in human embryonic 
kidney, mouse myoblast cells (Figure 4.1C), in neuroblastoma (SK-N-AS), medulloblastoma 
(D283 & Med8) and mouse primary neuronal cell lines (Bagnall, 2011).  
These initial findings suggest that the localisation of HIF-2α is not due to artefacts of ectopic 
expression, the presence of the tag or the model cell line being used. As localisation is often 
associated with function, the heterogeneous distribution of HIF-2α was investigated further 
and is the focus of this study. 
 4.1 Is the non-homogenous nuclear localisation 
of HIF-2α functionally relevant? 
As mentioned previously, spatial organisation within the nucleus is vital for regulating 
processes and protein function. It has been shown that many nuclear proteins localise in 
domains or nuclear speckles, which have function as sites of activity, modification or 
sequestration, for example. Further investigation was carried out to determine the purpose 
of the localisation of HIF-2α into speckles. 
 4.1.1 Characterisation of HIF-2α speckles 
Analysis of images of the HIF-2α speckles revealed that, in normoxia, there is between 10-
200 speckles per nucleus (average 64, n = 25) that are 0.24 (± 0.07) μm in size and take up 
approximately 3% of the nucleus (Figure 4.2A). The size of the speckles did not change in 
either hypoxia or DMOG compared to normoxia (Figure 4.2B). However, the average 
number of speckles did increase significantly following treatment with DMOG (Figure 4.2A).  
These results could be explained by the exaggerated effects usually observed following 
treatment with DMOG i.e. a dramatic increase in HIF protein levels and HIF-dependent 
transcription, far greater than those observed in hypoxia (unpublished observations from 
V.Sée group). This drug inhibits all three PHD isoforms (and other hydroxylases) and so the 
HIF-alpha subunits evade oxygen-dependent degradation.  So if there is an increase in 
stabilised HIF-2α molecules, these must go somewhere and these data suggest that the 
extra HIF-2α localise in additional speckles, either newly formed or speckles that were 
already present but were undetectable due to low levels of protein.  
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Figure 4.2 ǀ Measurement of HIF-2α speckles. HeLa cells transiently transfected with EGFP-HIF-2α were 
imaged on a Zeiss epifluorescent microscope fitted with a very fast and highly sensitive CCD camera (Andor, UK). 
One thousand frames were acquired per cell in normoxia, hypoxia (1% O2, 16 h) or following treatment with 
DMOG (0.5 mM, 6 h). The images were analysed using ImageJ. A) The average (±SD) number of speckles per 
nucleus in each condition was: 64 ± 49 (n=25), 44 ± 24 (n=24) and 96 ± 33 (n=22), respectively. Mean of the 
sample data represented by the red line. B) The average size of speckles per nucleus over the 1000 frames. The 
mean values for each condition were: 0.24 ± 0.09 μm (n=25), 0.21 ± 0.07 μm (n=24) and 0.27 ± 0.09 μm (n=22), 
respectively. The mean values for hypoxia and DMOG were compare to the normoxic values using IBM SPSS 
statistics software (independent t-test, significance value set at 5%). Mean of the sample data represented by 
the red line.  
 
 4.1.2 Speckle mobility 
On closer inspection of EGFP-HIF-2α in time-lapse movies, the HIF-2α speckles could be 
seen to move (M2 on attached CD). We therefore decided to characterise and quantify this 
motion further by tracking the speckles. Briefly, the speckles were identified as features in 
each frame and then these features were linked frame to frame creating trajectories using 
ImageJ (Sbalzarini & Koumoutsakos, 2005)(Figure 4.3, supplemental movies M3 and M4). 
The coordinates of these trajectories were exported to Excel for further analysis. Using a 
macro (see Appendix 1.3) created by Dr David Mason (Image Analyst, CCI, University of 
Liverpool), the speed, diffusion coefficient and diffusion mode (denoted by the slope of the 
moment scaling factor aka SMSS) for each trajectory was calculated.  
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Figure 4.3 ǀ Analysis of the HIF-2α trajectories. A) Schematic of how speckles were tracked using ImageJ 
i.e. features were identified in each frame and then linked frame to frame to create a trajectory map. B) EGFP-
HIF-2α speckle (i) tracked in ImageJ (ii) showing course of speckles over 1000 frames (yellow). Coordinates of 
these trajectories exported to excel and plotted (iii).  
 
 
Figure 4.4 ǀ Speed of individual HIF-2α speckles. Speed at which HIF-2α speckles move. Average (±SD) for 
normoxia = 0.47 ± 0.17 μm s-1 (N=25, n=522), hypoxia = 0.38 ± 0.13 μm s-1 (N=24, n=760) and DMOG = 
0.36 ± 0.10 μm s-1 (N=25, n=1402). Independent t-test, significance level 1%; normoxia compared to hypoxia: 
t1280=11.238, p<0.001; normoxia compared to DMOG: t1922=17.954, p<0.001. 
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The average speed of the speckles was faster in normoxia compared to hypoxia and DMOG, 
dropping from 0.47 μm s-1 to around 0.37 μm s-1. To provide further insight in to the motion 
of the HIF-2α speckles, the SMSS value was determined for each trajectory (see methods). 
This value describes the type of movement exhibited by an object (Figure 4.5). For instance 
a value of 0 indicates that the object is static, 0.5 indicates Brownian diffusion (the 
movement of molecules in a suspension caused by random collisions with other molecules) 
and 1 is indicative of ballistic motion (the object moves in a perfectly straight line). The 
intermediate types of diffusion are “restricted Brownian” (same as Brownian motion, but 
the objects movement is restricted within an area) and “directed Brownian” (diffusion is 
random but has overall directionality e.g. molecular motors transporting vesicles or 
organelles along the cytoskeleton) (Figure 4.5).  
 
Figure 4.5. Schematic representation of the different types of diffusion. Brownian diffusion = random 
movement of an object in solution in any direction (x, y and z). Restricted Brownian = random movement 
confined to a specific region. Directed Brownian = random diffusion with gradual movement in a certain 
direction. 
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Figure 4.6A shows the SMSS values of individual trajectories of speckles across the three 
conditions tested. The arbitrary SMSS value ranges attributed to each type of diffusion are 
depicted on the graph. There was no significant difference between the three conditions, 
with the average SMSS values being 0.12-0.13. Although the average indicates restricted 
Brownian motion there are also speckles that do not move. Figure 4.6B highlights that 63% 
of the speckles fall into the restricted Brownian category, with the remainder being static. 
The proportion of speckles within each type of diffusion category does not change with 
oxygen levels or following the inhibition of prolyl hydroxylase enzymes. 
 
Figure 4.6 ǀ Diffusion mode of the HIF-2α speckles. A) Schematic representations of the types of diffusion. 
SMSS values for individual speckles in normoxia, hypoxia and DMOG. Average SMSS (indicated by red line) was 
0.12 ± 0.07 (N=25, n=522), 0.13 ± 0.07 (N=24, n=760) and 0.12 ± 0.08 (N=22, n=1402), respectively. B) 
Percentage of speckles that fall into each category of diffusion. Average: static = 38%, restricted Brownian = 
62%.  
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These results suggest that these speckles are physically hindered from diffusing out of a 
localised region. It is likely that they are trapped or, like other nuclear bodies (e.g. Hendzel 
et al. 2001), tethered to a physical structure (such as the nuclear scaffold). 
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 4.1.3 Protein co-localisation  
Immunofluorescence imaging and co-localisation analysis were performed to investigate 
the spatial relationship between HIF-2α and other proteins (Figure 4.7). To provide a 
benchmark, we measured HIF-2α co-localisation with its known binding partner HIF-1β, in 
normoxia and upon DMOG treatment. Quantification using a Manders’ analysis (Manders 
et al., 1993) revealed that 33% (standard deviation reported in Figure 4.7B) of HIF-2α co-
localises with HIF-1β in normoxia which increases to 47% following treatment with DMOG 
(Figure 4.7; statistically significant; independent t-test; t95=13.362, p<0.001). As HIF-2α is a 
transcription factor it was logical to then investigate whether HIF-2α is localising at sites of 
active transcription. Immunofluorescence was performed using an antibody against 
phospho(ser5)-RNAPII as a marker for active transcription sites and we found that around 
48% of HIF-2α co-localises with the initiating form of RNAPII in normoxia and 54% in 
hypoxia mimic condition, a marginal yet statistically significant (independent t-test; 
t60=4.242, p<0.001) increase.  
Both of these results make sense given that treatment with DMOG should increase activity 
of HIF-2α by inhibiting all PHD enzymes and FIH. They indicate that half of the signal from 
HIF-2α co-localises with its dimerisation partner HIF-1β in hypoxia mimic conditions 
(DMOG) and that the same level also co-localises with active transcription sites. However, 
this type of co-localisation analysis is based on whether both red and green signal is present 
in the same pixel. It could be worth performing object-based co-localisation analysis to 
determine if the number of speckles that are co-localising changes. It may also be of 
interest to look at HIF-1β, HIF-2α and RNAPII simultaneously.  
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Figure 4.7 ǀ Co-localisation of HIF-2α.with HIF-1β and RNAPII A) First image in each panel (far left) is 
endogenous HIF-2α labelled with Alexa Fluor® 555 (red, psuedocolour). Second image (green, pseudocolour) is a 
nuclear protein labelled with Alexa Fluor-488®. Merge = HIF-2α (red) image superimposed onto the image 
(green) of the adjacent nuclear protein. Coloc = co-localisation channel calculated using ImageJ plugin Co-
localisation Threshold. White indicates pixels where both red and green signal is found i.e. co-localisation. 
Overlay = Merge image with coloc image superimposed. Inlay = magnified region (white square). White arrows 
highlight regions of co-localisation. Scale bar = 5 μm. Abbreviations: RNAPII = RNA Polymerase II phosphor serine 
5. B) Immunofluorescent images were analysed using ImageJ plugin Co-localisation Threshold with uses the 
Coste et al method to automatically create a threshold prior to calculating the Manders coefficient for both 
proteins i.e. the percentage of protein A (HIF-2α) that co-localised with protein B (HIF-1β or RNAPII) and vice 
versa.  
 
 4.1.3.1 Other nuclear bodies 
We then looked at whether HIF-2α co-localised with other nuclear proteins that are known 
to localise into nuclear bodies e.g. PML bodies. Previous studies have shown that 
transcription factors, such as p53 and NRF2, localise into PML bodies leading to the 
suggestion that one function of this nuclear body is the storage of inactive TFs (Fogal et al., 
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2000;Ben-Dor et al., 2005). However, immunofluorescent labelling of HIF-2α in HeLa cells 
stably transfected with PML-YFP show very little co-localisation (Figure 4.8A, top row). In 
the first instance this is not too surprising as PML bodies have been described as typically 
0.5 µm in size and usually 10-30 per cell (Spector, 2001) which does not match the 
characteristics of the HIF-2α speckles. However, as HIF-2α is mainly inactive in normoxia 
one would think that more than 18% (Figure 4.8B) would be localised at PML bodies in 
normoxia, if they are in fact the storage site of inactive transcription factors.  
Other well-studied nuclear bodies are SC35 domains also known as splicing factor 
compartments (SFCs) or interchromatin granule clusters (IGC), which house inactive splicing 
factors, such as SC35.  (Wansink et al., 1993;Phair & Misteli, 2000). It was found that only 
13% of HIF-2α co-localised with SC35, but 48% of SC35 co-localised with HIF-2α. The 
biological relevance of this is unclear.  If SFCs store inactive splicing factors that move to the 
site of transcription when required, it would be logical to assume that, in the interest of 
efficiency, these sites would be within close proximity to these sites. Therefore if the HIF-2a 
speckles are also near to transcription sites then there is an increase chance of them 
occurring in similar locations. Then again, it could be down to the simple fact that there is a 
vast number of HIF-2α and the SFCs take up a large volume, therefore there is an increased 
chance of the two entities occurring next to each other.  
HDAC5 is a histone deacteylase and localises in to domains that have been termed matrix 
associated deacetylase bodies (Downes et al., 2000). Images of this protein published in 
Downes et al. (2000) show a sub-nuclear localisation pattern very similar to that of HIF-2α 
(Figure 4.8A, third row down). We found that 27% of HDAC5-YFP co-localised with HIF-2α 
and 19% of HIF-2α co-localises with HDAC5-YFP (Figure 4.8B).  
Finally, we investigated the localisation of hypoxia associated factor (HAF aka SART1800). 
This protein has been demonstrated to interact with HIF-2α (Koh et al., 2011). However 
immunofluorescent imaging found that only 16% of endogenous HAF co-localises with HIF-
2α and 12.5% of HIF-2α co-localises with HAF (Figure 4.8B).  
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Figure 4.8 ǀ Co-localisation HIF-2α and other nuclear proteins. A) Immunolfuorescenct images of 
HIF-2α and other nuclear proteins that are known to localise into nuclear bodies. First image in each 
panel (far left) is endogenous HIF-2α labelled with Alexa Fluor® 555 (red, psuedocolour). Second image (green, 
pseudocolour) is a nuclear protein labelled with Alexa Fluor-488® (SC35, HAF) or YFP (PML and HDAC5). Merge = 
HIF-2α (red) image superimposed onto the image (green) of the adjacent nuclear protein. Coloc = co-localisation 
channel calculated using ImageJ plugin Co-localisation Threshold. White indicates pixels where both red and 
green signal is found i.e. co-localisation. Overlay = Merge image with coloc image superimposed. Inlay = 
magnified region (white square). White arrows highlight regions of co-localisation. Scale bar = 5 μm. 
Abbreviations: PML = Promyelocytic leukemia protein, HDAC5 = histone deacetylase 5 , HAF = hypoxia associated 
factor, YFP = yellow fluorescent protein.B) Immunofluorescent images (Figure 4.7) were analysed using ImageJ 
plugin Coloc Threshold with uses the Coste et al method to automatically create a threshold prior to calculating 
the Manders coefficient for both proteins i.e. the percentage of protein A (HIF-2α) that co-localised with protein 
B (other nuclear protein of interest) and vice versa.  
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Overall, the results here indicate that a small proportion of HIF-2α co-localises with each of 
the nuclear proteins investigated. It is difficult to determine how significant these results 
are and whether they have any biological relevance. In some instances it is possible that the 
nuclear bodies are actually separate entities, but diffraction limited microscopy cannot 
resolve the two so it appears as if they cohabit the same location (such as PML and HIF-2α). 
Furthermore, we didn’t determine what the majority of HIF-2α is co-localising with, if 
anything. It is possible that the HIF-2α speckles are a novel nuclear domain and / or that 
they are specific for HIF-2α (although most, if not all, nuclear speckles that have been 
described in the literature are cohabited by more than one protein).   
Admittedly, only a small range of proteins were investigated here. However, randomly 
picking proteins that happen to localise into nuclear speckles and performing 
immunofluorescent staining is a costly and somewhat “needle in a haystack” approach, so 
we moved on to other methods that could provide information on the function of these 
speckles. For further co-localisation studies, a more targeted approach should be taken 
such as performing mass spectrometry on a pull down of HIF-2α or EGFP-HIF-2α. From the 
resulting list of proteins, suitable candidates (e.g. nuclear proteins reported to localise into 
speckles etc.) could be identified and then investigated using immunofluorescence.  
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 4.1.4 Molecular Mobility 
Next, we investigated the mobility of HIF-2α at the single molecule level. Molecular mobility 
could provide insight into the function of these speckles, for example no movement of 
molecules between speckles could indicate a storage or sequestration whereas molecule 
mobility between the speckles and the rest of the nucleus could indicate a release or a 
change in protein availability / activity such as being released from storage sites. 
 4.1.4.1 Nuclear proteins and FRAP 
FRAP has been key in determining kinetic information (such as chromatin binding time) of 
over 50 transcription factors (TFs) (Mazza et al., 2012). Interestingly, it has been found that 
TFs are highly dynamic and bind transiently to target binding sites within genes leading to 
an overhaul of the longstanding model that TFs form stable complexes (Hemmerich et al., 
2011;Mazza et al., 2012). 
FRAP has also been used to study the dynamics of RNAPII in the nucleus. Kimura et al. 
(2002) found that 75% is highly mobile and 25% is immobile, additionally they found that 
these two fraction correlate with inactive and actively transcribing RNAPII, respectively. 
These data back up the theory that active RNAPII is present at transcription factories (see 
chapter 1.5.1) whilst the inactive form is freely diffusing through the nucleoplasm. 
Photobleaching has also been used to study PML bodies. PML and SP100, which co-
localised at PML bodies, show no recovery following bleaching within the nucleoplasm or 
PML bodies themselves whereas CBP, that also localises to PML bodies under certain 
conditions, is highly mobile and was shown to move in and out of PML bodies rapidly 
(Boisvert et al., 2001). Thus supporting the conclusion that PML and SP100 play a structural 
role in PML bodies but also highlighting that components of the same nuclear body can 
have different mobility, which can correlate with function.  
 4.1.4.2 Molecular mobility of HIF-2α 
Firstly, FRAP experiments were performed on HeLa cells ectopically expressing EGFP-HIF-2α 
in normoxia, hypoxia and 6 h after treatment with 0.5 mM DMOG. This was achieved by 
bleaching half the nucleus and measuring the fluorescence levels in this region over time 
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(Figure 4.9). The fractional recovery curve of HIF-2α was determined and fitted using a one 
component exponential equation (see Methods). The mobile fraction (the amount of 
molecules freely diffusing) and half time (the time taken for the fluorescence in the 
bleached region to reach half the eventual recovery) of HIF-2α was extrapolated from the 
fitted curves (see Methods). 
 
 
Figure 4.9 ǀ EGFP-HIF-2α FRAP. A series of confocal images of HeLa cell ectopically expressing EGFP-HIF-2α in 
the nucleus that has been photobleached. Images at different time points showing gradual recovery of 
fluorescence into the bleached region (outlined in white). 
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Figure 4.10 ǀ Comparing EGFP-HIF-2α mobility in different conditions. A) The percentage of mobile 
EGFP-HIF-2α molecules (mobile fraction) per nucleus. The average (± SD) mobile fraction of EGFP-HIf-2α was 
0.95 ± 0.15 (n=89) in normoxia, 0.99 ± 0.16 (n=115) hypoxia and 0.94 ± 0.13 (n=43) following treatment with 
DMOG. For HIF-2α-DM-EGFP mobile fraction was 0.9 ± 0.15 (n=23). B) The time taken for recovery to reach half 
the final recovery (half time / tHALF) per nucleus in normoxia, hypoxia and DMOG. The average (± SD) half time 
was 0.56 ± 0.46 (n=89) minutes, 0.68 ± 0.36 (n=115) minutes and 0.40 ± 0.18 (n=43) minutes, respectively. The 
half time for HIF-2α-DM-EGFP was 0.44 ± 0.31 (n=23) minutes Independent t-test (α=0.05) was used to compare 
the mean normoxic half time to those from the hypoxic (t202=2.122, p=0.35) and hypoxia mimic (t130=2.156, 
p=0.033) conditions. Average represented by black line on graph. 
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It was found that the average mobile fraction across the three conditions was 96% (Figure 
4.10A) suggesting that a significant amount of HIF-2α molecules are freely diffusing through 
the nucleus. The average half time was calculated to be 34, 41 and 24 seconds in normoxia, 
hypoxia and hypoxia mimic, respectively (Figure 4.10B). Although the results from the 
statistical test suggest that the average half times in hypoxia and DMOG for wild type 
HIF-2α are significantly higher than that for the normoxic sample, the actual values are only 
marginally different therefore are unlikely to have a great biological impact.  
In line with the observation that hypoxia or DMOG has little effect on HIF-2α mobility, FRAP 
was performed on a constitutively stable HIF-2α (the two prolyl residues within the ODD 
domain have been substituted for alanines and so cannot undergo PHD-dependent 
degradation) and the mobile fraction and half time was found to be very similar to that of 
wild type HIF-2α treated with DMOG.  
To confirm the observations made for wild type HIF-2α, a complimentary photo-
perturbation technique, Fluorescence loss in photobleaching (FLIP), was used. In FLIP 
experiments the GFP positive cells are continually bleached in the same region and the 
fluorescent signal in the non-bleached region is measured (Figure 4.11A), therefore 
measuring the signal decay in the non-bleached region. This technique can be used to 
determine molecular mobility (like FRAP) but also provides information on the movement 
of  molecules around and between cellular compartments (Mueller et al., 2013). In the case 
of the HIF-2α speckles, continual bleaching in a specific region of the nucleus resulted in 
loss of fluorescent signal in the non-bleached region in all three conditions within 15 
minutes (Figure 4.11B). The fluorescence loss data were plotted in Matlab and fitted using a 
one component exponential equation. The resulting curve was used to determine the half 
times of EGFP-HIF-2α (Figure 4.11C). Overall these results show no difference in the 
molecular mobility of EGFP-HIF-2α between the three conditions. However, it does 
highlight that HIF-2α must be continually moving in and out of the speckles (and 
throughout the nucleus) to have complete loss of fluorescent signal.  
It is worth noting that, although not significantly different based on statistical testing, the 
half time values from the FRAP (Figure 4.10C) and FLIP (Figure 4.11B) experiments follow 
the same pattern across the three conditions. This could be of biological interest however 
further experiments would be required to confirm whether this is a coincidence.  
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Figure 4.11 ǀ Molecular mobility of HIF-2α measured using FLIP. A) Confocal images of a HeLa cell 
ectopically expressing EGFP-HIF-2α that has been continually bleached in one region (red box). Nucleus outlined 
in yellow. White arrow highlights the loss of fluorescence in the non-bleached region of the nucleus. B) Overview 
of the average trend of fluorescence loss in normoxia, hypoxia and DMOG. Y-error bars represent standard 
deviation. The data was grouped (“binned”) based on time and the X-error bars represent the standard deviation 
of these bins. C) Half time values were extrapolated from the curves fitted (as in B) for each cell in the three 
conditions. Average half time (represented by black line on graph) ± SD: Normoxia = 3.47 ± 1.98 (n=53), Hypoxia 
= 3.96 ± 1.61 (n = 36), DMOG = 2.88 ± 0.88 (n = 23). 
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 4.1.4.3 Molecular mobility of HIF-2α compared to HIF-1α 
The molecular mobility of HIF-2α was compared to that of HIF-1α. FRAP experiments were 
only performed on HIF-1α-EGFP in hypoxia or following DMOG treatment, as there is no 
detectable fluorescent protein in normoxia (Bagnall, 2011).  
It was found that the mobile fraction of HIF-1α-EGFP was 92% in both conditions (Figure 
4.12A). This mobile fraction is significantly lower than that of EGFP-HIF-2α in hypoxia (99%, 
Figure 4.10A). This could be due to HIF-1α activating genes as part of the hypoxic response. 
It has been proposed that HIF-1α is the dominant transcription factor in the acute response 
to hypoxia whereas HIF-2α is responsible for regulation of genes in chronic hypoxia (>48 h). 
As FRAP looks at the whole population of molecules, if sufficient HIF-1α is bound at 
promoters then a global effect on the mobility could be observed. The difference is 
significant but small (7%).  
Conversely, the difference in half time is much greater (Figure 4.12B). These measurements 
suggest that HIF-1α-EGFP is more than 10-fold and 5-fold faster than EGFP-HIF-2α in 
hypoxia and hypoxia mimic conditions, respectively. The rapid recovery of HIF-1α is typical 
of that seen with other transcription factors (Hager et al., 2009). The slower recovery of 
mobility of HIF-2α is unusual but could simply be explained by the fact that it is in nuclear 
speckles which physically impedes its mobility whereas HIF-1α-EGFP is dispersed 
homogenously throughout the nucleus with only obstructions (such as chromatin) and 
molecular crowding to hinder its movement. 
It should also be noted that although tests were performed in our lab to establish that the 
orientation of the GFP fusion protein (whether at the N- or C-terminus of the protein of 
interest) had little influence on the transcriptional activity of HIF-1α or HIF-2α (Bagnall, 
2011) the mobility results could be affected by the fluorophore orientation; here the 
fluorophore is attached at different ends of the two proteins of interest. Wotzlaw et al. 
(2011) demonstrated using FRET that the orientation of the fluorescent tag can influence 
hetero-dimerisation of HIF-1α and HIF-1β, so there is a chance that the orientation of the 
fusion protein could also impact physical interactions of HIF-2α, which would in turn affect 
molecular mobility.  
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Figure 4.12 ǀ Comparing EGFP-HIF-2α and HIF-1α-EGFP mobility. The average (± SD) mobile fraction and 
half time for EGFP-HIF-2α are the same as in figure 4.9. Only hypoxia and DMOG conditions are compared as 
HIF-1α-EGFP can’t be observed in normoxia and so can’t be photobleached. A) Mobile fraction of EGFP-HIF-2α 
compared to HIF-1α-EGFP. The average (±SD) mobile fraction of HIF-1α-EGFP per nucleus was 0.92 ± 0.11 (n=31) 
hypoxia and 0.92 ± 0.12 (n=29) following treatment with DMOG (0.5 mM, 6 h). Independent t-test (α=0.05) 
revealed that the mobile fraction of HIF-1α-EGFP in hypoxia is significantly less than EGFP-HIF-2α (t144=2.412, 
p=0.017). B) The half time of EGFP-HIf-2α compared to that of HIF-1α-EGFP in hypoxia and DMOG. The average 
(±SD) half time was 0.06 ± 0.04 (n=31) minutes and 0.06 ± 0.03 (n=29) minutes, respectively. In both hypoxic 
(independent t-test: t144=9.532, p<0.001) and DMOG (independent t-test: t70=10.278, p<0.001) conditions the 
half time of HIF-1α-EGFP was significantly less than EGFP-HIF-2α. Average values represented by black line on 
graph.  
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For all FRAP experiments, a large variation in the shapes of the recovery curves was 
observed. This could be due to the inherent heterogeneity of protein expression often seen 
within a population of transfected cells. A clonal cell line stably expressing a fluorescently 
tagged HIF-2α or a tuneable expression system where the expression can be increased to 
desired level using a drug would remove this issue. In addition to this, a major drawback of 
photobleaching experiments is that only the photo-physical properties are altered via the 
photobleaching, meaning that the protein of interest is still present and presumed to be 
functional but can no longer be seen. Therefore, it would be beneficial to utilise photo-
convertible proteins such as Dendra2. Here, instead of turning the fluorescent signal off by 
photobleaching, the signal is changed from green to red using a specific wavelength of light. 
Using a system such as this would result in the speckles and molecules remaining visible yet 
distinguishable from the non-converted molecules, therefore providing bi-directional data 
i.e. one can monitor molecules moving out of the photo bleached region as well as those 
moving in. 
We have performed some spatial analysis on the FRAP experiments by tracking the speckles 
during bleaching and have observed some cases of recovery in the same place 
(Supplemental movies M5, M6 and M7), complementing the SMSS data and the possibility 
that these speckles might be tethered structures in specific locations. However, photo-
convertible proteins would allow the switched speckles to remain visible during recovery, 
thus allow continued monitoring of speckle location and provide more conclusive evidence.  
 Finally, it would be worth comparing both N- and C-terminally tagged HIF-2α and HIF-1α to 
make sure that this does not have an influence on the molecular mobility.  
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 4.2 Conclusion 
Here we have shown that both endogenous and exogenous HIF-2α display heterogeneous 
distribution in the nucleus. We observed a small change in the number and movement of 
these speckles when comparing different conditions. Although statistically significant, the 
differences are marginal and the biological relevance of these results is difficult to 
determine. Photobleaching experiments revealed that HIF-2α is freely diffusing in and out 
of the speckles and throughout the nucleoplasm. Finally, there is some indication that these 
could be domains that are associated with or ‘tethered’ to a structure such as the nuclear 
matrix. ascertain 
Hendzel et al. (2001) proposed that there are “transcription factor-enriched foci” within the 
nucleus that act to: concentrate functionally-related proteins in order to streamline 
assembly of macro-molecular complexes; and, control the concentration of the proteins / 
complexes in the nucleoplasm. One thought was that the HIF-2α speckles could have a 
purpose similar to the latter. Stemming from the fact that both endogenous and ectopically 
expressed HIF-2α is detectable in normoxia (HIF-1α is not), we hypothesised that perhaps 
HIF-1α is regulated in an oxygen-dependent manner via protein stability (as widely 
accepted) but HIF-2α is regulated spatially i.e. the alpha subunit accumulates in nuclear 
speckles and is physically impeded from activating genes in normoxia. However, this has 
proved somewhat difficult to verify.  
In this study, we have shown that EGFP-HIF-2α is continuously moving in and out of 
speckles, regardless of oxygen levels or PHD enzyme activities. Therefore, it would seem 
unlikely that these speckles are storage sites, as one would expect a change in the mobile 
fraction as HIF-2α is released to find and bind to promoters of hypoxia inducible genes. 
However, it is possible that HIF-2α is localising at a number of sites that have different 
functions. CREB binding protein (CBP) has been shown to localise with p300 in small foci in 
the nucleus (Hendzel et al., 2001) but also to transiently localise at PML bodies (Boisvert et 
al., 2001). So, if one imagines that there are different sub-populations of HIF-2α e.g. some 
are activating genes, some are forming transcriptional complexes and some are being 
sequestered, then the results from the co-localisation study become more meaningful.  
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To probe the function of the HIF-2α speckles further, more advanced techniques such as 
single molecule tracking (SMT) should be employed which forms the basis of the following 
chapter. 
 Chapter 5: Development of tools for 
single molecule tracking in living cells 
Single molecule tracking 
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We have utilised advanced confocal microscopy techniques, FRAP and FLIP, to investigate 
the dynamics of HIF-2α and found no considerable changes in the molecular mobility under 
different conditions. However, these techniques look at the global behaviour of the protein 
being studied and the ‘averaging effects’ of these methods may be masking the dynamics of 
individual molecules. In addition to this we have not established the residence time of 
HIF-2α molecules in the speckles and whether this changes with oxygen potential. 
Therefore, the aim was to label HIF-2α with gold nanoparticles and image in the nucleus of 
living cells, using photothermal heterodyne imaging (PHI). This methodology facilitates the 
tracking of single gold nanoparticles (and, therefore, single molecules), as demonstrated by 
Duchesne et al. (2012). The single molecule data generated using this technique would 
provide information on: the movement of HIF-2α between speckles; movement in and out 
of the nucleus / speckles; and, provide information on velocity and degradation. All of 
which, could contribute to the elucidation of the function of the HIF-2α nuclear bodies. 
As discussed in the introduction (Section 1.7.2.5), SMT can be performed using 
fluorescently probes such as dyes, proteins or semi-conductor nanocrystals (aka quantum 
dots), however, this approach has drawbacks. Firstly, probes such as fluorescent dyes and 
proteins photobleach and only short trajectories of ~10 s can be acquired, even with very 
careful illumination. Secondly, quantum dots emit a fluctuating and sporadic fluorescent 
signal. This temporary loss of signal causes issues when tracking molecules (Kuno et al., 
2001). Moreover, for optimum results, as much out of focus light as possible must be 
removed during acquisition, which has led to research groups using more specialist custom-
built microscopes, such as those reviewed in Mueller et al. (2013)  .  
Gold nanoparticles are a useful and complementary alternative to fluorescent labels. They 
have several features that makes them ideal for SMT. Firstly, they are optically stable and 
do not suffer from the equivalent of photobleaching. Single nanoparticles can be imaged 
for as long as required (or as long as the stability of the microscope permits) without loss of 
any signal (Lasne et al., 2006). Secondly, the photothermal signal from gold nanoparticles is 
continuous. Thirdly, the photothermal signal from gold nanoparticles has little or no 
background, except for a weak and distinguishable signal from mitochondria (Lasne et al., 
2007). Taken together, all these features make gold nanoparticles an ideal probe for single 
molecule tracking.  
Single molecule tracking 
115 
Gold nanoparticles also offer imaging versatility as they can also be visualised with an 
electron microscope, thus providing more information on sub-cellular localisation at 
molecular scale resolution. More importantly, however they can be specifically and 
stoichiometrically functionalised, as described in Duchesne et al. (2008),   Duchesne et al. 
(2012) and Nieves et al. (2014). Briefly, gold nanoparticles require passivation i.e. the 
synthesis of a monolayer composed of small ligands (peptides, alkane thiol ethylene glycols 
with or without peptidols) on their surface that prevents non-specific binding (Lévy et al., 
2004;Duchesne et al., 2008). The self-assembled ligand shell can also be functionalised by 
inserting other biological molecules, such as a nuclear localisation sequence (NLS) that will 
target the gold nanoparticles to the nucleus. Here the aim was to insert a ligand (Halotag 
ligand) that will allow the attachment of a protein of interest (POI) via the Halotag protein, 
facilitating the single molecule dynamics to be monitored by tracking the gold 
nanoparticles.  
Single molecule imaging using gold nanoparticles has previously been successfully utilised 
in Liverpool to measure how fibroblast growth factor-2 (FGF2) moves through the 
extracellular matrix via its heparan sulphate binding sites (Duchesne et al., 2012;Nieves et 
al., 2015). Purified, recombinant HisTag-FGF2 was attached to gold nanoparticles via 
Tris-Ni2+NTA. Although this method was able to provide useful insight into the single 
molecule dynamics of FGF2, the Tris-Ni2+NTA on the surface of the gold nanoparticles can 
be prone to exchange with histadine patches on the surface of endogenous proteins, 
thereby disrupting the bond between the POI and the probe and so confounding single 
molecule tracking results. Therefore, the aim here was to utilise the Halotag® as a means to 
develop a novel method for covalent and stoichiometric (1:1) conjugation of proteins to the 
surface of a gold nanoparticles.  
The Halotag® (Promega) is a modified haloalkane dehalogenase protein that has been 
designed to bind synthetic ligands that carry a chloroalkane (Los et al., 2008). This reaction 
is highly specific, as there is no corresponding activity in mammalian cells, and irreversible, 
since a mutation (His272Phe) in the catalytic centre means that the reaction proceeds no 
further than the covalent intermediate of substrate-enzyme (Los et al., 2008). The strategy 
was to incorporate the Halotag ligand (a chloroalkane ligand, see Appendix 1.5) onto the 
surface of the gold nanoparticle and react this with a Halotag fusion protein. Figure 5.1 
gives an outline of the approach.  
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Figure 5.1 ǀ Overview of GNP-Halotag plan. Flow chart highlighting the key steps to tracking single 
molecules in living cells. 1) The aim is to incorporate the Halotag ligand into the ligand shell of gold 
nanoparticles (10 nm gold core) and 2) express and purify recombinant Halotag fusion protein. 3) The GNP-
Halotag and Halotag fusion will react to form GNPs carrying the protein of interest (GNP-Halotag-POI). 4) The 
GNP-Halotag-POI will be delivered to the cells. For extracellular proteins such as FGF-2 (used for proof of 
principle experiments), the GNP-Halotag-FGF2 are added to the medium and bind to the surface of cells. For 
intracellular proteins such as HIF-2α, this requires delivery into the cells via microinjection. 5)  The single GNPs 
are visualised and imaged over time using photothermal microscopy. Individual GNPs are tracked allowing the 
molecular dynamics of the proteins to be determined. 
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The initial challenges were:  
 1) The synthesis of gold nanoparticles carrying the Halotag ligand 
 2) The conjugation of the gold nanoparticles to a protein of interest  
 3) The expression and purification of a full length recombinant HIF-2α  
The work described in this chapter was a collaborative effort between me and members of 
both Prof. D. G. Fernig’s and Dr R. Lévy’s research groups (University of Liverpool, UK). The 
contributions by each individual were: 
 Changye Sun 
 Together we expressed and purified Halotag-FGF2 
 Made the pET14B-Halotag-FGF2 construct 
 Provided advice and guidance on expression of Halotag-HIF-2α and 
contributed to troubleshooting 
 Contributed reagents 
 Dr Umbreen Shaheen 
 Made GNPs carrying Halotag ligand for Halotag-FGF2 work 
 Guided me in making Halotag ligand GNPs for Halotag-HIF-2α work 
 Dr Raphaël Lévy 
 Contributed reagents and equipment  
 Provided advice about gold nanoparticle synthesis and conjugation 
 Prof Dave Fernig 
 Contributed reagents and equipment 
 Provided advice and guidance regarding protein expression and 
chromatography 
 Dr Daniel Nieves 
 Performed photothermal imaging 
 Provided advice and guidance on protein purification and gold nanoparticle 
synthesis 
 Dr Joanna Wnetrzak (CCI, University of Liverpool) 
 Performed microinjection 
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 5.1 Can the Halotag be used for conjugation of a 
protein to a gold nanoparticle? 
 5.1.1 Testing the Halotag approach for labelling a protein of 
interest with gold nanoparticles 
To investigate whether the Halotag can be used to conjugate a protein of interest to a gold 
nanoparticle, we employed an N-terminal Halotag-fibroblast growth factor 2 (FGF2) fusion 
protein. We chose to use FGF2 to carry out preliminary experiments, as our collaborator 
Prof. D. G. Fernig (University of Liverpool) and his research group have substantial 
experience in expressing and purifying recombinant FGFs (in particular FGF2). Since FGF2 is 
an extracellular protein that binds to components of the extracellular matrix such as 
heparan sulfate, obtaining biological validation is easier, as it does not require delivery into 
the cell. As a proof of principle, we would express and purify Halotag-FGF2, synthesise gold 
nanoparticles carrying the Halotag ligand and conduct experiments to test whether FGF2 
can be labelled with gold-nanoparticles via the Halotag reaction. The work on the 
production of Halotag-FGF2 has been published (Sun et al., 2015). 
 5.1.1.1 Expressing recombinant Halotag-FGF2 
A bacterial expression vector, pET14B-Halotag-FGF2, encoding the Halotag fused to the N-
terminus of full-length FGF2 via a linker region was made by Changye Sun (Prof. D. G. Fernig 
research group, University of Liverpool). Figure 5.2A illustrates the key characteristics of the 
Halotag-FGF2 fusion protein. 
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Figure 5.2 ǀ Halotag-FGF2 recombinant protein. A) Schematic diagram of Halotag-FGF2 recombinant 
protein expressed from the pET14B-Halotag-FGF2 construct. The Tobacco Etch Virus (TEV) protease cleavage site 
is highlighted. Calculated molecular weight and isoelectric point values are shown for the whole fusion protein 
and individual Halotag / FGF2 proteins. B) SDS-PAGE analysis of expression of recombinant Halotag-FGF2 
expressed in C41 DE3 E. coli. One mM IPTG was added once cultures reached an OD600 of 0.6 and incubated for a 
further 4h at 37°C. The induced samples (I1 & I2) were combined, harvested by centrifugation and the resulting 
pellet lysed via sonication. To separate the insoluble (P) and soluble (S) proteins the sample was centrifuged at 
8000 rpm, 30 min, 4 °C (Sorvall RC6+ Centrifuge; SS34 fixed angle rotor). (C = control, no IPTG added, I = induced 
protein expression, P = pellet / insoluble protein, S = supernatant / soluble protein). Arrows indicate the band 
corresponding to the expected size of HT-FGF2. First lane = Molecular weight marker, numbers represent kDa. 
Although Prof Fernig's group have worked with many recombinant FGFs, the addition of the 
Halotag can affect both the bacterial expression and purification of the recombinant 
protein. Cultures of C41 DE3 E. coli, a strain commonly used for expression of recombinant 
proteins, transformed with the Halotag-FGF2 construct were incubated for 4 h at 37 °C 
following the induction of protein expression (via the addition of IPTG) (Xu et al., 2012). 
Analysis by SDS PAGE and coomassie staining showed a large induced band close to 50 kDa 
in both samples (Figure 5.2B, lanes labelled I) compared to the control culture (no IPTG 
added, lane C).  
In order to determine the solubility of the expressed Halotag-FGF2, the bacteria (induced 
sample) were lysed via sonication. Following centrifugation, the soluble (supernatant) and 
insoluble (pellet) proteins were analysed by SDS PAGE. A band at 50 kDa was observed in 
both the pellet and supernatant suggesting that both soluble and insoluble Halotag-FGF2 is 
present (Figure 5.2B, lanes P and S, white arrows). Taking together the fact that the 
purification of soluble protein is a more straightforward process compared to that of 
insoluble proteins and that there was good expression of Halotag-FGF2 in the soluble 
fraction, the fusion protein was purified from the supernatant (Figure 5.2, lane S).  
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 5.1.1.2 Optimisation of Halotag-FGF2 purification protocol 
Purification of FGF2 utilises its affinity for heparin, so heparin affinity chromatography was 
employed for the initial purification of the Halotag-FGF2 fusion protein. Figure 5.3 shows 
preliminary chromatography of the soluble protein fraction. Analysis via SDS PAGE shows 
that a protein corresponding to the expected size of Halotag-FGF2 is present in each eluted 
fraction and that the contaminants are gradually removed resulting in a final eluate that 
was judged to be reasonably pure Halotag-FGF2 (Figure 5.3B, Blue Box).  
 
 
Figure 5.3 ǀ Trial purification of Halotag-FGF2. A) The steps taken to purify Halotag-FGF2. B) The soluble 
protein fraction was applied to Heparin Affinity Gel (BioRad, UK). The eluted protein underwent buffer exchange 
via gel filtration (G25) chromatography and then applied to a CM cation-exchange column (IEX). Finally, the 
eluate from IEX was applied to a second heparin affinity column and eluted with a gradient of NaCl (using a 
Biorad Econo pump (EP-1) fitted with UV monitor; set up as follows: 0-70%, 70 minutes. Buffer B = PBS set at 6%, 
Buffer A = 1.4M NaCl) 29 fractions were collected, fractions 5-29 contained with protein (eluted at approximately 
34-68%) and were combined for analysis via SDS PAGE (H(2)). (S = soluble fraction, FT = flow through, W = wash 
with 0.5 M NaCl, E = fraction eluted with 1.4 M NaCl, GF = Sample following buffer exchange via gel filtration 
chromatography, IEX = Sample eluted from CM resin column with 0.4 M NaCl, white arrows =Halotag-FGF2, 
black arrows = contaminants, blue box = reasonably pure Halotag-FGF2) 
 
To investigate further the binding of Halotag-FGF2 and to determine which additional 
chromatography steps could be used and the sequence to use them in to further purify the 
fusion protein, small–scale purification was then performed on the Halotag-FGF2 (Figure 
5.3B, blue box). Three chromatography methods: heparin affinity, cation-exchange (CM 
resin, negatively charged) and anion-exchange (DEAE resin, positively charged), were 
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tested. Each of these purification methods exploits a different feature of the recombinant 
protein, namely the binding affinity of FGF2 to heparin, the strong positive charge / very 
basic pI of FGF2 and, the negative charge / acidic pI of the Halotag. The chromatography 
was performed with Halotag-FGF2 and TEV-digested Halotag-FGF2.  
Analysis via SDS PAGE shows that the Halotag-FGF2 bound to heparin, DEAE and CM resins 
(Figure 5.4) highlighting that all three methods can be used for purification of the fusion 
protein. The samples digested with TEV show that these results are due to FGF2 binding to 
the heparin and CM resin (Figure 5.4A and B, red arrows), and the Halotag binding to the 
DEAE resin (Figure 5.4C, yellow arrow), as predicted.   
Based on these findings the Halotag-FGF2 was purified using all three chromatography 
steps in the following order: heparin affinity, anion-exchange and cation-exchange 
chromatography. Details of the final protocol can be found in Sun et al. (2015). 
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Figure 5.4 ǀ Halotag-FGF2 purification tests. Halotag-FGF2 was incubated with TEV protease overnight 
(digested) and applied to a heparin column (A). Digestion results in additional bands of approximately 30 kDa, 
27 kDa and 18 kDa, which represent the Halotag, TEV enzyme and FGF2. Samples of undigested and digested 
Halotag-FGF2 samples were applied to a CM (B) resin column (FT = flow through, W = PBS wash, 0.3 M = 0.3 M 
NaCl wash, 2 M = 2 M NaCl wash) and DEAE (C) resin column (FT = flow through, W1=PB wash, W2 = PBS wash, 
0.3 M = 0.3 M NaCl wash, 2 M = 2 M NaCl wash).  
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 5.1.1.3 Testing the functionality of purified Halotag-FGF2  
Following purification, it was important to determine that both parts of the fusion protein 
were folded correctly and had retained their function. The fact that the protein bound to 
heparin and eluted similarly to native FGF2 indicated that the FGF2 possessed an intact 
primary heparin binding site. Since this is formed from amino acids that are physically 
adjacent in the tertiary structure, but distant in the protein sequence, it was likely that the 
FGF2 was correctly folded. Other data demonstrating that the HaloTag-FGF2 protein retains 
the same activity as the native FGF2 such as stimulating the phosphorylation of p42/44MAPK 
are described in Sun et al. (2015). 
 
Figure 5.5 ǀ Testing the activity of Halotag-FGF2. A) Halotag-FGF2 and Halotag-FGF2 digested with TEV 
protease were labelled with Oregon Green fluorescent Halotag ligand and analysed via SDS PAGE. The 
fluorescently labelled protein was visualised with an ImageQuant LAS 4000 imager (Sybr green settings). B) 3 µM 
Halotag-FGF2 was labelled with the red fluorescent (TMR Halotag) ligand (7.5 µM) for 30 minutes at room 
temperature. The TMR-Halotag-FGF2 was added to Rama 27 fibroblasts (final concentration 2 nM), incubated at 
room temperature for 1 hour and imaged using a Zeiss LSM 710 confocal microscope. The images here were 
taken with C-apochromat 63×/1.20 Oil immersion objection, 2.1 zoom. Scale bar represents 10 µm. 
To determine whether the Halotag is functional, the Halotag-FGF2 and Halotag-FGF2 
digested by TEV were labelled with a Halotag ligand conjugated to a fluorescent dye 
(Oregon Green). Figure 5.5A shows a fluorescent band at approximately 50 kDa in the 
undigested sample and a one at 30 kDa following digestion with TEV, which represent the 
Halotag-FGF2 and Halotag, respectively. This highlights that the Halotag is functional (i.e. 
can bind its ligand) when it is part of the Halotag-FGF2 fusion protein and after cleavage 
from FGF2. 
As it was determined that both parts of the chimeric protein were functional, the Halotag-
FGF2 was reacted with a Halotag ligand carrying a fluorescent dye (TMR) before labelling 
Rama 27 cells. Figure 5.5B shows that the TMR-Halotag-FGF2 associated with the surface of 
the cells. The lack of signal in the regions in between the cells highlights that the TMR-
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Halotag-FGF2 has specially bound to the cells, likely through the binding of FGF2 to heparan 
sulfate present in the pericellular matrix.  
Following the acquisition of these images, the cells were washed with 2M NaCl to see if the 
interactions between FGF2 and heparan sulfate could be disrupted. Images were acquired 
using the same settings and a reduction in TMR-Halotag-FGF2 signal was observed, further 
contributing to the suggestion that the labelling of the cells observed in Figure 5.5B is due 
to FGF2 binding heparan sulfate.  
 5.1.1.4 Labelling Halotag-FGF2 with gold nanoparticles via the Halotag 
ligand 
Since it was shown that TMR-Halotag-FGF2 could bind to the pericellular matrix of cells, the 
next step was to substitute the fluorescent label with gold nanoparticles. Gold 
nanoparticles carrying Halotag ligands (chloroalkane, see Appendix ) on the surface were 
prepared by Dr U. Shaheen (Raphaël Lévy group, University of Liverpool). Following 
conjugation, approximately 5 nM Halotag-FGF2 labelled with gold nanoparticles (GNP-
Halotag-FGF2) was added to the medium of Rama 27 cells (Labelling protocol same as for 
TMR-Halotag-FGF2). Figure 5.6 (right panel) shows the cells clearly labelled with the gold 
nanoparticles. As a control, Rama 27 cells were also incubated with nanoparticles lacking 
Halotag-FGF2 and almost no photothermal signal was observed (Figure 5.6, left panel). 
These results strongly suggest that the Halotag can be utilised as method of conjugating a 
recombinant protein of interest to gold nanoparticles, thus providing a platform for single 
molecule imaging. 
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Figure 5.6 ǀ Photothermal images of FGF2-Halotag-nanoparticles. Photo thermal images of Rama 27 
cells labelled with unconjugated nanoparticles (Control; left) or Halotag-FGF2 conjugated gold nanoparticles 
(GNP-Halotag-FGF2; right). The control GNPs or the Halotag-FGF2-GNPs were added to the medium and after 1 
hour the cells were washed and imaged on a photothermal microscope (imaging carried out by Dr D. Nieves, 
Raphaël Lévy group, University of Liverpool, UK). Scale bar represents 10 µm.  
 
In this section, it has been shown that: Halotag-FGF2 can be expressed in C41 DE3 E. coli 
and purified using a three step chromatography protocol; both the FGF2 and Halotag parts 
of the purified protein are functional; and, FGF2 can be labelled via the Halotag with 
fluorescent dyes and most importantly GNPs. The work described here contributed to a 
paper entitled: “Halotag is an effective expression and solubilisation fusion partner for a 
range of fibroblast growth factors” (Sun et al., 2015).  
 5.2 Expression & purification of Halotag-HIF-2α 
The next step was to follow the strategy used for FGF2 with HIF-2α. By expressing and 
purifying Halotag-HIF-2α from E.coli it would then be possible to conjugate it to gold 
nanoparticles carrying the Halotag ligand. 
A DNA vector (pFN21AB4384) containing the Halotag-HIF-2α gene was purchased from 
Kazusa DNA Research Institute, Japan. In order to check the spatial localisation of the 
Halotag-HIF-2α in cells, this plasmid was transiently transfected into HeLa cells and labelled 
with the Oregon-Green Halotag ligand (Promega, WI, USA). Figure 5.7A shows that the 
Halotag-HIF-2α fusion protein localises into discrete foci in the nucleus, as observed with 
fluorescent protein fusions and endogenous HIF-2α. Figure 5.7B shows analysis of protein 
extracts from HeLa cells transiently transfected with CMV-Halotag-HIF-2α via SDS PAGE and 
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western blot. The samples were labelled with the Oregon Green Halotag ligand prior to 
separation on SDS PAGE and fluorescent bands were observed at 150 kDa (Figure 5.7B, top 
panel). Following this, the proteins were transferred onto nitrocellulose membrane and 
probed with a HIF-2α antibody. Western blot revealed one band at around 100 kDa and 
another at 150 kDa, representing endogenous HIF-2α and the ectopically expressed 
Halotag-HIF-2α, respectively (Figure 5.7B, bottom panel). These data show that the 
Halotag-HIF-2α ectopically expressed in mammalian cells is 150 kDa, can react with the 
Halotag ligand and exhibits HIF-2α immuno-reactivity. Further to this, confocal microscopy 
confirmed that fluorescent labelled Halotag-HIF-2α and EGFP-HIF-2α co-localise. All of 
these results suggest that the Halotag is functional and does not interfere with the spatial 
localisation of HIF-2α. 
 
 
Figure 5.7 ǀ Halotag-HIF-2α recombinant protein in HeLa cells. A) Live HeLa cell transfected with the 
Halotag-HIF-2α plasmid and labelled with the fluorescent Oregon Green Halotag Ligand. Fluorescence is 
localised in nucleus in speckles. Scale bar = 5 μm. B) Protein extracted from HeLa cells transfected with pFN21A-
Halotag-HIF-2α. Samples were labelled with the fluorescent Oregon Green Ligand and analysed via SDS PAGE. (N 
= normoxia, H = hypoxia, D = 0.5 mM DMOG). C) Confocal images of HeLa cells co-transfected with EGFP-HIF-2α 
and Halotag-HIF-2α and labelled with the TMR conjugated Halotag ligand.  
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 5.2.1 Expressing Halotag-HIF-2α in bacteria 
pETM-11-Halotag-HIF-2α was transformed into three bacterial strains that are commonly 
used for protein expression: C41 DE3, BL21 DE3 and BL21.pLysS DE3. Figure 5.8 shows gels 
stained for total protein (left panel) and HIF-2α (western blot, anti-HIF-2α, right panel) for 
the three strains tested. Different protein expression conditions (variation in temperature 
and time post induction with IPTG) were trialled. The coomassie staining (Figure 5.8, left) 
shows no strong induction of protein expression in the cultures treated with 1 mM IPTG 
compared to the control cultures in all three bacterial strains. Immuno-reactivity was 
detected in some, but not all, of the induced samples across the three strains. Two bands 
very close in size are detected at approximately 150 kDa, the expected size for Halotag-HIF-
2α, and some additional bands at lower molecular weights (Figure 5.8, right). The 29.8 °C, 
16 h sample in the BL21 and BL21.pLysS E.coli showed very strong immuno-reactivity, yet 
this was not correlated with any signal obtained by coomassie staining, suggesting that 
there is little Halotag-HIF-2α protein present.  
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Figure 5.8 ǀ HIS-Halotag-HIF-2α expression in bacteria. HIS-Halotag-HIF2α recombinant protein 
expression in C41 DE3 (A), BL21 DE3 (B) and BL21.pLysS DE3 (C) under various conditions. Left coomassie, right 
western blot (anti-HIF-2a). 
 
A faint induced band could be seen at around 120 kDa (Figure 5.8, left, black arrows), which 
is slightly smaller than the expected size of Halotag-HIF-2α. However, analysis of bacteria 
transformed with different pETM11 constructs shows an induced band at around 120 kDa 
in all samples treated with IPTG, which suggests that this band corresponds to an 
endogenous protein (Figure 5.9). 
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Figure 5.9 ǀ Induction of protein expression from different pETM-11 constructs. BL21.pLysS DE3 E.coli 
transformed with an empty pETM-11, pETM-11-Halotag-HIF-2α and pETM-11-FGF1 were incubated for 4 h at 
37 °C, post induction of protein expressing via addition of IPTG.  An additional condition of 16 h at 29.8 °C was 
included for Halotag-HIF-2α. A control sample of Hela cells ectopically expressing Halotag-HIF-2α was run 
alongside the samples. A) Coomassie Yellow arrows = induced protein. B) Fluorescent Oregon Green Halotag 
ligand. Image inverted to aid visualisation of the bands. Red arrows = proteins labelled with Halotag ligand. 
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Although a band corresponding to recombinant Halotag-HIF-2α cannot be seen with 
coomassie staining, analysis via western blot with an anti-HIF-2α antibody highlights that 
there is potentially some Halotag-HIF-2α present, albeit in small amounts (Figure 5.10A & 
B). Samples from the soluble (supernatant) and insoluble (pellet) fractions of BL21.pLysS 
(37 °C, 4 h) were labelled with the fluorescent Oregon Green Halotag ligand and analysed 
by SDS PAGE (Figure 5.10C). The fluorescent bands on the gel suggest that there is protein 
present that reacts with the Halotag ligand, but none of these are the expected size of 150 
kDa (Figure 5.10C). There is a strong band at around 40 kDa which is likely to be the Halotag 
(Figure 5.10C, Lane S, black arrow). In the insoluble fraction (lane P) there are multiple 
bands (Figure 5.10C, white arrowheads), suggesting either the expression of proteins of 
different sizes or protein degradation or incomplete transcription/translation. Either way, 
these results indicate that the Halotag is being expressed, but the HIF-2α part of the fusion 
protein is not complete.   
 
Figure 5.10 ǀ BL21.pLysS DE3 E.coli expression and solubility test. BL21.pLysS DE3 E.coli incubated at 
37 °C for 3 h post IPTG addition (+). Control sample (-) = no IPTG added but incubated in the same conditions. A) 
Coomassie stained SDS Page. B) Protein was transferred to nitrocellulose membrane and probed with anti-HIF-
2α antibody. C) The induced BL21.pLysS culture was sonicated and the soluble (supernatant) and insoluble 
(pellet) proteins were separated by centrifugation. Samples from the pellet (P) and the supernatant (S) were 
labelled with Oregon Green Halotag ligand and analysed via SDS PAGE. Black arrow = fluorescent bands likely to 
correspond to the Halotag. Image inverted to aid visualisation of the bands. White arrowheads = fluorescent 
bands likely to correspond to several truncated versions of Halotag-HIF-2α.  
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In the three bacterial expression systems used here it appears that several things could be 
happening. Firstly, full length recombinant HT-HIF-2α is expressed at such low quantities 
that it can only be seen via western blot and although small amounts of protein could 
potentially be purified, for the envisaged application it would not be sufficient. Secondly, it 
is being degraded due to endogenous proteases. Or, truncated forms are being translated, 
possibly due to the high number of codons rarely used by E. coli in the coding region of 
HIF-2α.  
 5.2.1.1 Bacterial Expression System: Troubleshooting 
To address some of the potential causes of the poor Halotag-HIF-2α protein expression 
discussed above we tried several other strains of E. coli. 
E. coli have different preferences for codons compared to mammals (Zhang et al., 1991). 
Many codons found in mammalian genes are rarely found in bacterial genomes hence the 
term ‘rare codons’. RosettaTM DE3, a strain of BL21 E. coli engineered for the expression of 
eukaryotic proteins containing a high proportion of rare codons (Merck Millipore, 
Germany), was tried. Figure 5.9A shows the total protein for induced (I) versus non-induced 
(C) for each condition, with an induced band at approximately 150 kDa. The sample grown 
at 37 °C following induction was further analysed. The bacteria were lysed, centrifuged and 
the proteins present in the pellet and supernatant separated via SDS PAGE. A band at 
around 150 kDa is present in both fractions, suggesting that there is both insoluble and 
soluble protein (Figure 5.11A, Lane P & S).  
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Figure 5.11 ǀ HIS-Halotag-HIF-2α expression in Rosetta DE3 E.coli. 5 mL cultures of Rosetta DE3 
transformed with the pETM-11-Halotag-HIF-2α vector were incubated for 18 h at 16 °C or 4 h at 37 °C. A) 
Coomassie stained SDS PAGE. (C = control, I = induced protein expression with 1 mM IPTG, P = pellet / insoluble 
proteins, S = supernatent / soluble proteins). White arrowheads highlight induced protein observed at around 
150 kDa. B) Trial purification was performed on a sample of the supernatant (S). A column was prepared with 0.6 
mL ProBond
TM
 nickel-chelating resin (Invitrogen, CA, USA), the resin was washed with 300 mM imidazole and 
sonication buffer prior to adding the sample. 3 mL of filtered supernatant was applied to the column and the 
flow through (FT) collected, any additional unbound protein was removed from the column with PBS washes and 
the bound fraction (E) eluted with 300 mM Imidazole. The eluted protein (E) was then applied to a column of 
heparin agarose (as described for Halotag-FGF2). Samples (20 µL) were labelled with 4 µL Oregon Green Halotag 
ligand (50 µM) and analysed by SDS PAGE. Left = coomassie, right = fluorescence SDS PAGE. Orange box = faint 
fluorescent band at around 150 kDa. Red box = several strong fluorescent bands around 40 kDa.  
 
Trial purification of the protein from lane S (Figure 5.11A) was performed. The bacterial 
expression plasmid, into which the Halotag-HIF-2α gene was cloned, resulted in the 
addition of a poly-histidine tag to the N-terminal end of the recombinant protein, allowing 
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it to bind to a nickel chelation resin. The supernatant was filtered and applied to a nickel 
chelation column. The eluted fraction (presumed to contain Halotag-HIF-2α) was then 
applied to a heparin column, due to the presence of a DNA binding domain HIF-2α should 
bind to this sulfated polysaccharide. The flow through (FT) and eluted (E) fractions were 
labelled with the fluorescent halotag ligands and analysis by SDS PAGE from which two 
observations can be made. Firstly, a 150 kDa protein (presumed to be Halotag-HIF-2α) was 
present in the supernatant and the flow through of the nickel column (Figure 5.11B, Orange 
box) indicating that this protein did not bind to the nickel resin, suggesting that either the 
Halotag-HIF-2α is missing the poly histidine tag or the tag is not exposed. Secondly, several 
fluorescently labelled proteins of varying sizes between 35 – 40 kDa (Figure 5.11B, red box) 
were observed in the supernatant. These bands were also present in the fraction eluted 
from the nickel column, but were in the flow through from the heparin column, indicating 
that these proteins were able to bind the Halotag ligand and to the nickel resin but not 
heparin, suggesting that these are truncated or partly degraded forms of the His-Halotag-
HIF-2α protein where the His-tag and Halotag portion has remained intact and functional.   
Even though there appears to be some protein that is of the predicted size that binds the 
Halotag-ligand, the amount of protein is very low. This is a problem, as during protein 
purification the yield of protein tends to diminish with increasing chromatography steps, 
therefore, it is best to start with a large amount of target protein. In this case, it is likely 
that the protein yield after protein purification would be far too low for the experiments 
planned.  
Other bacterial strains, such as Lemo21, useful for difficult (e.g. toxic, membrane, insoluble) 
proteins and SoluBL21(DE3), were used. However, the yield of full-length Halotag-HIF-2α 
could not be improved.  
 5.2.1.2 Expression of Halotag-HIF-2α in E.coli: Conclusion 
To conclude, the expression of recombinant Halotag-HIF-2α in bacteria did not yield 
sufficient protein for further purification and analysis. Possible reasons for this could be due 
to degradation by endogenous bacterial proteolytic enzymes. For instance, the full length 
recombinant protein could be expressed, but the protein is being degraded from the HIF-2α 
end, leaving the Halotag intact. However, this contradicts the fact that the bacteria used for 
protein expression tend to be engineered to have fewer endogenous proteases to prevent 
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this from happening. Another, (possibly more likely) scenario is that the bacteria are 
expressing truncated forms of the recombinant protein, i.e. the translation starts at the 
poly-histidine / Halotag end and proceeds unperturbed until the ribosome reaches the 
HIF-2α region where translation is stalled. Furthermore, it is likely that the induced band 
observed at around 120 kDa is a bacterial protein involved in transcription or translation, as 
this band is only present in cultures that have been induced with IPTG and is present 
regardless of the recombinant protein being expressed.  
In the interest of time and due to exhausting a substantial number of routes for bacterial 
protein expression, it was decided to express Halotag-HIF-2α by other means.   
 5.2.2 Cell-free protein expression  
A second approach for the expression of recombinant proteins was tested, the PureExpress 
in vitro system (NEB), was tested. This kit contains all the components (as purified 
recombinant his-tagged proteins) from bacteria that are required for protein expression, 
thus removing any chance of proteolysis. Although this system gives a lower yield than 
bacteria, it may produce sufficient amounts of full-length Halotag-HIF-2α for the present 
purpose.  
Figure 5.12(1) shows a western blot of the products of the in vitro translation. There was 
immuno-reactivity to the HIF-2α antibody at around 150 kDa. However, the fluorescent 
Oregon Green Halotag ligand signal was detected at a range of sizes. To test whether this 
was non-specific binding due to using a high concentration of Halotag ligand, the reaction 
was re-run and samples were labelled with various concentrations of ligand ranging from 
2 µM to 8 µM. All concentrations showed a similar band pattern (data not shown). These 
results suggest that the protein is being translated, but some products are truncated, i.e. 
the Halotag part is being translated and then the ribosome is stopping or falling off before 
reaching the end of the coding part of the mRNA, so full length HIF-2a is not produced. This 
could result in many truncated proteins that react with the Halotag ligand, but only a few 
that will exhibit immuno-reactivity against the HIF-2α antibody. This method of protein 
production was, therefore, also abandoned.  
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Figure 5.12 ǀ PureExpress in vitro Protein Expression System (NEB). in vitro expression analysed via 
western blot (1) and fluorescent SDS PAGE (2). The sample was labelled with 10 µM Oregon Green ligand.  
 5.2.3 Mammalian expression system 
As previously shown, the Halotag-HIF-2α can be expressed in mammalian cells (Figure 5.7). 
However, using mammalian cells for recombinant protein expression has drawbacks, such 
as it is more expensive, the yield of protein is much lower and purification is difficult due to 
the vast number of endogenous proteins present. Therefore, we chose to take a slightly 
different approach that does not involve purification of the protein via chromatography, 
which I have termed in vitro and in vivo conjugation (Figure 5.13). Briefly: the HL-GNPs 
would be added to the cell lysate of HEK293t ectopically expressing Halotag-HIF-2α (in vitro 
conjugation), following incubation to allow conjugation to occur the lysate would be 
centrifuged to “pull down” the GNP-labelled protein, which would then be microinjected 
into cells for imaging. Alternatively, live HeLa cells expressing Halotag-HIF-2α would be 
microinjected with HL-GNPs and imaged (in vivo conjugation). 
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Figure 5.13 ǀ Plan for conjugation of mammalian expressed Halotag-HIF-2α. An overview of two 
strategies for conjugating Halotag-HIF-2α to HL-GNPs. in vitro conjugation: labelling of Halotag-HIF-2α before 
injection into cells for imaging i.e.HEK293t cells ectopically expressing Halotag-HIF-2α are lysed and HL-GNPs 
added, unbound protein is removed and the nanoparticles are injected into cells. in vivo conjugation: labelling of 
Halotag-HIF-2α occurs inside the cells that are to be imaged i.e. cells ectopically expressing Halotag-HIF-2α are 
injected with the HL-GNPs and the cells are imaged directly.  
 5.2.3.1 in vivo conjugation 
The protocol for in vivo conjugation has several drawbacks such as once injected it relies on 
the nanoparticles finding and reacting with the Halotag-HIF-2α in the cells. Also, there is no 
way to control non-specific interactions. However, the primary issue was identifying cells 
for microinjection, as the pFN21A-Halotag-HIF-2α construct does not have a fluorescent 
marker. To overcome this, a fragment of DNA encoding an internal ribosome entry site 
preceding the fluorophore dTomato (IRES-dTomato) was inserted at the C-terminus of 
Halotag-HIF-2α to create a construct that expresses the Halotag-HIF-2α and dTomato 
separately (Figure 5.14). Thus providing a way to identify cells to be microinjected with 
HL-GNPs and bypass the need for co-transfection. 
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Figure 5.14 ǀ Halotag-HIF-2α-IRES-dTomato. HeLa cell ectopically expressing Halotag-HIF-2α-IRES-dTomato 
labelled with 5 μM Fluorescent Halotag Ligand (Oregon Green). i) Halotag-HIF-2α-IRES-dTomato, ii) Oregon 
Green, iii) Merge, iv Magnification of highlighted region (white square). 
 5.2.3.2 in vitro conjugation 
Figure 5.15 shows a protein sample taken from HEK293T cells transiently transfected with 
pFN21A-Halotag-HIF-2α that has been analysed by SDS-PAGE, western blot and 
fluorescence. A strong band of the expected size (150 kDa) that exhibits immuno-reactivity 
against the anti-HIF-2α and anti-Halotag antibody was observed. The lysate was incubated 
with the fluorescent (Oregon Green) Halotag ligand prior to denaturation and analysis by 
SDS PAGE. The fluorescent band in lane 1 (Figure 5.15) indicates that a functional Halotag 
makes up part of this the 150 kDa.   
 
Figure 5.15 ǀ Halotag-HIF-2α expressed in HEK293T cells. pFN21A-Halotag-HIF-2α was transfected into 
HEK293T cells. Protein extraction was carried out and samples taken for analysis. Oregon Green Halotag ligand 
(1), Halotag antibody (2) and HIF-2α antibody (3).  
 
Gold nanoparticles carrying the Halotag ligand were incubated with the lysate of HEK293T 
cells that were transfected with Halotag-HIF-2α (transfected lysate). As a control HL-GNPs 
were also incubated with the lysate of non-transfected cells (control lysate) or with just PBS 
(- Lysate). Samples from each condition were spotted onto nitrocellulose membrane and 
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probed for HIF-2α. Alongside these experiments, gold nanoparticles with a ligand shell 
consisting of only polyethylene glycol (PEG-GNPs) were tested as negative controls. The dot 
blots in figure 5.16 show that there is HIF-2α non-specifically bound to HL-GNPs and PEG-
GNPs in the transfected and control lysate pre-wash. However, following a wash step to 
remove weakly bound proteins, a faint signal is only seen for the sample from the HL-GNPs 
incubated with the transfected lysate, suggesting that HIF-2α has specifically bound to the 
surface of the gold nanoparticles via the Halotag ligand (Figure 5.16C, red circle). 
To confirm the size of the protein attached to the surface of the nanoparticles, the ligand 
shell was stripped from the gold core with DTT (Chen et al., 2012) and analysed via western 
blot. Following several washes, to remove aspecifically bound proteins, the nanoparticles 
were treated with 50 mM DTT for 36 h. Figure 5.16D shows that upon stripping, a strong 
HIF-2α immunoreactivity at 150 kDa was observed (Lane labelled DTT), suggesting a clear 
conjugation of HIF-2α to gold nanoparticles (last lane). As a control, samples of from the 
transfected cells (size control for HT-HIF-2α) and from the wash steps were separated on 
the same gel. HIF-2α was detected only in the first wash, suggesting any non-specifically 
bound HIF-2α was removed by subsequent washes.  Altogether, these results suggest that 
Halotag-HIF-2α is covalently bound to the gold nanoparticles via the Halotag ligand that is 
incorporated into the ligand shell. 
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Figure 5.16 ǀ Conjugation of HL-GNPs to Halotag-HIF-2α from mammalian cell lysate. A) Lysates from 
HEK293T cells not expressing (control) and expressing Halotag-HIF-2α were spotted onto a nitrocellulose 
membrane and probed with a HIF2α antibody (Abcam, UK). B) Fluorescence image of 200 μg of lysates from (A) 
labelled with 10 μM of HaloTag Oregon Green ligand resolved via SDS PAGE. C) Nanoparticles after overnight 
incubation with lysates from (A) or without lysate were spotted onto nitrocellulose membrane and probed with 
anti-HIF2α (Abcam, UK). Dot blot shows before (pre) and after (post) four washes with PBST to remove unbound 
/ weakly bound protein. D) To determine the size of the protein attached to the gold nanoparticles the ligand 
shell and, therefore, anything bound, was stripped from the gold core and analysed via western blot. HL-GNPs 
were incubated with HT-HIF-2α lysate. The nanoparticles were washed four times in PBST to removed weakly 
bound proteins. After washing, the nanoparticles were incubated with 50 mM DTT for 36 h. The ligand shell was 
separated from the gold via centrifugation and the presence of HT-HIF-2α was determined immunoblotting 
(anti-HIF-2α). 
 
Although this result was very promising, we observed variability in success rates of 
conjugation between different batches of HL-GNPs and experienced difficulties in 
consistently reproducing the results observed in figure 5.16. Taking this into consideration, 
along with the development of new approaches for nanoparticle conjugation to proteins 
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(Leduc et al., 2013), we decided to pursue a different strategy for coupling HIF-2α to gold 
nanoparticles.  
 5.2.3.3 Anti-GFP Nanobodies: A compromise?  
Nanobody is a term that refers to a single variable domain (VHH) derived from heavy chain 
only antibodies (IgG) found in camelid species such as alpaca (Hamerscasterman et al., 
1993;Muyldermans et al., 1994;Muyldermans & Lauwereys, 1999). These nanobodies are a 
fraction of the size of conventional antibodies (full length 160 kDa), with a molecular weight 
of around 15 kDa (Doshi et al., 2014). Their small size, 2.5 x 4.2 nm, gives them certain 
advantages over antibodies (Revets et al., 2005;Muyldermans et al., 2009), such as a much 
smaller minimal linkage distance between the tag and the target, which is of particular 
value for super-resolution imaging and single molecule tracking (Ries et al., 2012;Leduc et 
al., 2013)  
Leduc et al. (2013) have already shown that nanobodies to GFP can be used as a means for 
labelling proteins of interest with gold nanoparticles (Leduc et al., 2013). This method 
requires an EGFP fusion of the protein of interest, which we already had available for 
HIF-2 and was, therefore, appealing to enable the study of HIF-2α at the single molecule 
level.  
 
Figure 5.17 ǀ Labelling cells expressing EGFP-HIF-2α with anti-GFP nanobodies. HeLa cells transiently 
transfected with EGFP-HIF-2α were fixed, permeabilised and labelled with anti-GFP nanobodies. i) nuclear stain 
(Hoechst), ii) EGFP-HIF-2α, iii) ATTO594 conjugated anti-GFP nanobodies, iv) merge of ii & iii. Yellow indicates 
colocalisation. 
Preliminary experiments show that highly specific labelling of EGFP-HIF-2α with GFP 
nanobodies (conjugated with fluorescent dye ATTO594) can be achieved using standard 
immuno-fluorescent protocols (Figure 5.15). Figure 5.16 shows an example of a HeLa cells 
ectopically expressing EGFP-HIF-2α that has been microinjected with the anti-GFP-ATTO594 
nanobodies. Nuclear colocalisation between the green and red channels can be observed 
(Figure 5.16iv.). These promising results suggest that ectopically expressed EGFP-HIF-2α 
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could potentially be labelled with GNPs via anti-GFP nanobodies in live cells using 
microinjection as the delivery method.  
 
Figure 5.18 ǀ Microinjection of anti-GFP nanobodies into cells ectopically expressing EGFP-HIF-2α. 
Live HeLa cells transiently transfected with EGFP-HIF-2α were injected with anti-GFP nanobodies.i) Brightfield, ii) 
EGFP-HIF-2α, iii) anti-GFP ATTO594 nanobodies, iv) merge of ii & iii. 
 
Incorporation of the anti-GFP nanobodies onto the surface of the gold nanoparticles 
requires a different protocol to that of the Halotag-ligand which would need optimisation. 
As I was approaching the end of my time in the laboratory, and the size and scope of this 
work was unknown, the GFP-nanobody project was passed onto another member of the 
laboratory and is currently under development. 
 5.3 Conclusion 
The aim of the work described in this chapter was to develop a method of labelling single 
molecules of HIF-2α with gold nanoparticles to facilitate their tracking in live cells. The 
initial plan was to use the Halotag, an enzyme that specifically and irreversibly binds to 
chloroalkanes. In collaboration with Promega, a Halotag ligand was specifically designed so 
that it could be incorporated into the ligand shell of a gold nanoparticle but protrude far 
enough so that it could react with a Halotag fusion protein.  
Preliminary ‘proof of principle’ experiments were conducted with fibroblast growth factor-2 
(FGF2). Recombinant Halotag-FGF2 was expressed in bacteria and purified using a three-
step chromatography protocol. We showed that FGF2 could be coupled to gold 
nanoparticles via the Halotag technology.   
However, when we moved on to the protein of interest, HIF-2α, several issues were 
encountered. Despite work published in Sun, C. et al (2015) suggesting that having the 
Halotag at the N-terminal of the fusion protein can aid bacterial expression of recalcitrant 
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protein and although many different bacterial strains and variations of protocols were 
trialled, expression of full-length recombinant Halotag-HIF-2α in useful amounts was not 
achieved.  The poor expression observed could be due to the large size of the protein or the 
large proportion of rare codons in the coding sequence HIF-2α. The latter interpretation is 
supported by the marginal improvement in expression observed in the Rosetta strain. At 
present there are no crystal structures of full length HIF-2α available, only structures of the 
HIF-2α PAS-B domain (Erbel et al., 2003;Card et al., 2005;Scheuermann et al., 2009;Key et 
al., 2009;Scheuermann et al., 2013;Rogers et al., 2013;Guo et al., 2015), suggesting that 
others may have also struggled to express full-length recombinant HIF-2α. 
Secondly, we encountered problems with reproducibility with regards to nanoparticle 
production / conjugation. Although it was shown that FGF2 could be conjugated to gold 
nanoparticles via the Halotag, we were unable to consistently conjugate HIF-2α to HL-GNPs. 
One possible reason for this is that the Halotag-FGF2 / nanoparticle conjugation reaction 
occurred in more favourable conditions (in vitro) i.e. as we are able to express & purify 
recombinant Halotag-FGF2, the reaction occurred in excess of Halotag-FGF2 and with no 
interference from other proteins. In the case of Halotag-HIF-2α, we seemingly could on 
express full-length Halotag-HIF-2α in mammalian cell. However, any protein expressed was 
only visible via western blot (an amplification technique) and not on an SDS PAGE stained 
with coomassie blue. It is difficult to calculate the concentration of fusion protein that is 
present in the lysate, but we can be sure that it is far less than that of the purified Halotag-
FGF2. In addition to this, there is competition from other endogenous proteins that may 
non-specifically interact with the surface of the nanoparticle, blocking Halotag-HIF-2a from 
reacting with the Halotag-ligand. Both of these factors would reduce the chances of 
successful conjugation.  
Another explanation for this could be that the Halotag ligand is inaccessible to the Halotag 
protein. The Halotag ligand was designed to protrude far enough out of the ligand shell so 
that it can react with the Halotag protein, however, there are hydrophobic regions along 
the ligand (for ligand structure see Appendix 1.5) and it is possible that this causes the 
Halotag ligand to reorient itself so that these regions are immersed in the ligand shell, thus 
resulting in the Halotag protein being unable to react with the chloroalkane part of the 
ligand. 
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Despite lack of reproducibility, the results presented here suggest that it is possible to 
conjugate HIF-2α to gold nanoparticles via the Halotag protein. With improvements to the 
design of the Halotag ligand and optimisation of a robust protocol for making Halotag 
ligand gold nanoparticles, this would be an invaluable technique for labelling proteins of 
interest for single molecule tracking.  
Nanobodies are another promising and versatile method for labelling a protein of interest 
with gold nanoparticles. The anti-GFP nanobodies can be used with any GFP (and GFP 
derivative)-fusion proteins. They have been shown to have uses in numerous microscopy 
techniques, not only for single molecule tracking but also for super-resolution microscopy 
(Leduc et al., 2013;Ries et al., 2012)  
 
 Chapter 6: Discussion 
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In this thesis, we have demonstrated that the HIF-1α subunits transiently stabilise in 
hypoxia and that this dynamic accumulation is the result of a negative feedback mechanism 
that ensures a controlled HIF response and is specifically controlled by PHD2. We have 
further demonstrated that HIF-1α and HIF-2α exhibit different sub-nuclear distributions, 
with HIF-2α being localised in nuclear foci. I have shown that HIF-2α freely diffuses in and 
out of the nuclear speckles and through the inter-speckle space. We initially hypothesised 
that HIF-2α might be regulated by molecular availability, as opposed to protein stability, yet 
my results show no clear difference in HIF-2α molecular availability or diffusion rate in 
normoxia and hypoxia. However, the diffusion of HIF-2α molecules is much slower than 
HIF-1α irrespective of oxygen tension. All these results were obtained using live cell imaging 
and for this project, I have generated several useful tools for imaging from the nano-scale 
to the cellular scale. I have developed a method for conjugating gold nanoparticles to a 
protein of interest for single molecule tracking and I have also created several lentiviral 
plasmids and stable cell lines for quantitative imaging of HIF-1α/ 2α. 
 6.1 Utilising fluorescent confocal microscopy to 
investigate protein dynamics in living cells: 
Reflection and future prospects 
 6.1.1 Stable cell lines 
We have utilised fluorescent fusion proteins to monitor and quantify a protein of interest. 
This method however has drawback, for example: delivery of the construct encoding the 
fusion protein which can be variable and lacks control; the fusion protein is under the 
control of an exogenous promoter such as the CMV promoter which can provide 
heterogeneous levels of expression between experiments and cell types (Smith et al., 
2000); and, it is not the endogenous protein that is being observed.  
To overcome some of these problems we have endeavoured to make cell lines stably 
expressing fluorescent fusions of HIF-1α and HIF-2α. Although some success was had via 
the use of a BAC for HIF-1α, the resulting cell lines were still less than ideal as the signal was 
very weak. Many of the drawbacks of BACs were discussed in chapter 3, one of which is the 
lack of control over where the transgene integrates into the genome. One way around this 
is to utilise genome editing nucleases such as zinc finger nucleases (ZFNs), Transcription 
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activator-like effector nucleases (TALENs) or clustered regularly interspaced short palindromic 
repeats (CRISPr). These technologies facilitate directed integration of the transgene into the 
host’s genome. There are two options: (1) insert an exogenous fusion of the protein of 
interest (e.g. HIF-1α-EGFP) at a predetermined site (e.g. AAVS1 locus) or (2) insert an 
exogenous tag (e.g. EGFP or Halotag) downstream of the gene of interest.  The latter option 
means that the endogenous protein is transcribed with the tag attached under the control 
of endogenous promoter; it also means that any other regulatory elements are also still 
having an effect and therefore any observations made are more physiologically relevant. 
 6.1.2 Data analysis 
One difficulty with microscope experiments, particularly time-lapse experiments, is turning 
the qualitative information in to quantitative data that can be analysed and interpreted. A 
particular problem with analysing live cells is that they can move and / or change shape 
over the course of the experiment. So in order to measure the fluorescent signal from the 
nucleus of one cell, one has to track the nucleus through the time course. If the protein of 
interest is not visible for the entirety of the experiment (such as HIF-1α), then automated 
detection and tracking is difficult as the loss of signal means software (such as Imaris, 
Bitplane) loses the object during these periods. This can be overcome by using a nuclear 
marker, however with regards to the HIF-1α-GFP BAC cell line, finding a spectrally suitable, 
non-toxic nuclear marker that will last the duration of the experiment (>24 h) proved 
difficult. This meant that for these experiments there was no way to automatically track the 
region of interest, resulting in the tedious task of manually drawing the boundaries of each 
cell nuclei and moving through each frame of the time-lapse checking for cell movement 
and adjusting the boundaries accordingly. To make the analysis of future experiments less 
laborious, I would create a construct encoding either lamin or histone-2b (H2B) fused with a 
red fluorescent protein such as dTomato or mCherry. 
 6.1.3 Investigating molecular dynamics 
Although work continues with investigating methods (e.g. nanobodies) of labelling HIF-2α in 
vivo with gold nanoparticles, it would be worth considering other methods of SMT. I believe 
a useful tool for investigating the molecular dynamics of the HIF-α subunits would be a 
fusion of HIF-1α or HIF-2α with a photo-switchable / convertible protein. This could provide 
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more comprehensive information for FRAP such as bi-directional diffusion and can be 
utilised for super-resolution techniques such as fPALM and single molecule tracking.  
Continually, the Halotag can be specifically and irreversibly labelled with a cell-permeable 
Halotag ligand carrying a synthetic dye (e.g. TMR) and has been utilised by several groups 
for SMT (Abrahamsson et al., 2013;Mazza et al., 2012). So we could utilise the 
Halotag-HIF-2α construct and the TMR ligand for SMT in living cells. This work would also 
benefit from the opportunity to use the equipment at the Advanced Imaging Centre (AIC) at 
Janelia Farm, USA. This facility has many custom-built state of the art pieces of equipment 
designed for super-resolution single molecule tracking and throughout the year they run a 
call for proposals where external researchers can bring their own samples to the facility for 
imaging.  
 6.2 HIF-1α versus HIF-2α 
 6.2.1 Normoxic stabilisation of HIF-2α 
The literature suggests that both HIF alpha subunits are regulated in an oxygen-dependent 
manner whereby they are hydroxylated by the PHD enzymes, which results in association 
with VHL and subsequently degradation via the proteasome. However, in contradiction 
with this model, we observe normoxic stabilisation of both endogenous and ectopically 
expressed HIF-2α in a variety of cells line (HeLa, HEK, SK-N-AS cells) via different methods 
(live cell imaging, immunofluorescence and western blot) and so are confident that is that 
this is not an artefact.  
One possibility is that the cell lines used have reduced activity of the components involved 
in the oxygen-dependent hydroxylation and VHL-dependent degradation, such as the co-
factors required for hydroxylation of the prolyl residues located within the ODD domain 
(Figure 6.1). However, as we do not observe normoxic stabilisation of HIF-1α this is unlikely 
to be the case. This also suggests that it is something specific to HIF-2α. 
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Figure 6.1 | PHD enzymatic reaction. The reaction that takes place when the PHD proteins hydroxylate the 
prolyl residues located within the ODD domain. Essential co-substrates and co-factors are highlight in the blue 
box.  
There is evidence that there are deubiquitinases (DUBs) that modify HIF-1α (e.g. ubiquitin 
specific peptidase 29 / USP29) and positively influence its stability (Edurne Berra,CIC 
bioGUNE, Spain; unpublished; communication at the Hypoxia: From Basic Mechanisms to 
Therapeutics (E3) Keystone meeting 2015). If there are also DUBs that specifically modify 
HIF-2α, then this would result in evasion of proteasomal degradation and give rise to 
normoxic stabilisation (Figure 6.2). It could also be possible that there is an enzyme that 
reverses the actions of the PHD enzymes, which would prevent association of pVHL with 
the alpha subunit and the subsequent targeting to the proteasome. Lastly, there could be a 
protein similar to a chaperone protein that protects HIF-2α from degradation by physically 
preventing PHDs or pVHL interacting with and modifying the subunit. 
 
Figure 6.2 | Theory of normoxic stabilisation of HIF-2α.  
 
 6.2.2 Not just a backup system 
For a long time HIF-2α has been considered the "under-study" of HIF-1α. However, interest 
in HIF-2α is growing as there is more and more evidence that this isoform is not just 
HIF-1α's fall back, but that it has specific roles and unique target genes. However, one of 
the main conundrums is how does gene specificity arise. David Mole and colleagues have 
performed genome wide analysis of HIF (HIF-1α/HIF-1β or HIF-2α/HIF-1β) and found that 
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when comparing HIF-1 (HIF-1α + HIF-1β) and HIF-2 (HIF-2α + HIF-1β) specific binding sites 
there is no obvious difference in the consensus sequence and proximal sequences, 
therefore the specificity does not lie within the sequence that the two isoforms bind to 
(Schödel et al., 2011). Peter Ratcliffe and colleagues have found that when HIF-1α and 
HIF-2α are both present, then certain genes will be preferentially bound by HIF-1α, but 
when HIF-1α is knocked down then HIF-2α is found to bind these genes. This highlights that 
both isoforms can bind to the “HIF-1α-specific gene” but there is competition for binding 
(Peter Ratcliffe, University of Oxford, unpublished, communication at the Hypoxia: From 
Basic Mechanisms to Therapeutics (E3) Keystone meeting 2015), suggesting that gene 
specificity arises due to HIF-1α having a stronger affinity for these genes or due to mobility 
i.e. HIF-1α diffuses more quickly than HIF-2α so arrives at the gene first, which would fit 
with our FRAP results.  
 6.3 Final remarks 
The hypoxia signalling pathway is a vital oxygen deprivation survival mechanism that plays a 
role in many normal physiological and developmental processes. It has also been implicated 
in various diseases and there is a large focus on HIF as a potential therapeutic target in 
cancer, stroke and transplant rejection (for example). Therefore, it is important to gain a 
full understanding of how these two transcription factors and their activity is regulated and 
so further investigation is a needed into what causes the discrepancies, such as gene 
specificity, protein stabilisation and spatial localisation, between HIF-1α and HIF-2α. 
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 Appendix 
1.1 Amino acid sequences of each domain for HIF-1α and HIF-2α 
>bHLH_HIF1a 
RRKEKSRDAARSRRSKESEVFYELAHQLPLPHNVSSHLDKASVMRLTISYLRVR 
 
>bHLH_HIF2a 
RRKEKSRDAARCRRSKETEVFYELAHELPLPHSVSSHLDKASIMRLAISFLRTH 
 
>PAS-A_HIF1a 
KAQMNCFYLKALDGFVMVLTDDGDMIYISDNVNKYMGLTQFELTGHSVFDFTHPCDHEEMREMLTHRNGLVKK
G 
 
>PAS-A_HIF2a 
DQQMDNLYLKALEGFIAVVTQDGDMIFLSENISKFMGLTQVELTGHSIFDFTHPCDHEEIRENLSLKNGSG 
 
>PAS-B_HIF1a 
PHPSNIEIPLDSKTFLSRHSLDMKFSYCDERITELMGYEPEELLGRSIYEYYHALDSDHLTKTHHDMFTKG 
 
>PAS-B_HIF2a 
QHPSHMDIPLDSKTFLSRHSMDMKFTYCDDRITELIGYHPEELLGRSAYEFYHALDSENMTKSHQNLCTKG 
 
>NTAD_HIF1a 
FKLELVEKLFAEDTEAKNPFSTQDTDLDLEMLAPYIPMDDDFQLR 
 
>NTAD_HIF2a 
LKIEVIEKLFAMDTEAKDQCSTQTDFNELDLETLAPYIPMDGEDFQL 
 
>CTAD_HIF1a 
SMDESGLPQLTSYDCEVNAPIQGSRNLLQGEELLRALDQVN 
 
>CTAD_HIF2a 
SFESYLLPELTRYDCEVNVPVLGSSTLLQGGDLLRALDQAT 
 
>NLS_HIF1a(711-730) 
LALQNAQRKRKMEHDGSLFQ 
 
>NLS_HIF2a(731-750) 
STSHLMWKRMKNLRGGSCPL 
 
>ODD_HIF1a 
APAAGDTIISLDFGSNDTETDDQQLEEVPLYNDVMLPSPNEKLQNINLAMSPLPTAETPKPLRSSADPALNQEVALK
LEPNPESLELSFTMPQIQDQTPSPSDGSTRQSSPEPNSPSEYCFYVDSDMVNEFKLELVEKLFAEDTEAKNPFSTQDT
DLDLEMLAPYIPMDDDFQLRSFDQLSPLESSSASPESASPQSTVTVFQ 
 
>ODD_HIF2a 
TQTDFNELDLETLAPYIPMDGEDFQLSPICPEERLLAENPQSTPQHCFSAMTNIFQPLAPVAPHSPFLLDKFQQQLES
KKTEPEHRPMSSIFFDAGSKASLPPCCGQASTPLSSMGGRSNTQWPPDPPLHFGPTKWAVGDQRTEFLGAAPLGP
PVSPPHVSTFKTR 
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1.2 Alignment of HIF-1α and HIF-2α ODD domain protein sequence 
 
Sequence alignment of ODD domains using BlastP: 
 
 
 
 
 
 
 
 
Sequence alignment of ODD domains using MUSCLE: 
 
 
 
  
Appendix 
175 
1.3 Explanation of macro used for tracking HIF-2α speckles 
Tracking macro (step-by-step) 
1) User Input 
 Get user input. 
o calibration in x & y [xyCalib] 
o z [zCalib] 
o temporal interval [tCalib] 
o minimum track length [intMinTrackLen] 
 
2) Pre-processing 
 Find number of trajectories (from last trajectory number in Column B) 
[intTotalTracks] 
 For each trajectory 
o Check if trajectory is shorter than intMinTrackLen. If so, move onto next. 
o If longer, Copy Trajectory out to a new sheet named [tXX] where XX is 
trajectory number 
 
3) Analysis of Trajectory for tau=1 
 If absent add a summary sheet 
 Spatially calibrate the data (x,y,z) 
 For each timepoint: 
o Calculate the euclidean distance (displacement) between the coordinates 
of t (x,y,z) and t+1 (x1, y1, z1).  
  √(    )  (    )  (    )  
o Record a running sum of displacements for dx where x=1 to 6 
 Record the trajectory length [trajectoryLength] 
 Calculate the whole trajectory displacement (using equation above with start and 
finish coordinates) 
 Calculate the instantaneous velocity for a given window [intWindow] as the sum of 
step distances divided by the calibrated time.  
 
4) Calculate Displacements for tau>1 
 For each time window (tau) from 2 to trajectoryLength-1, calculate the 
displacements and (as above) record the running sum of displacements for dx 
where x=1 to 6 
 Divide the running sums by the number of frames to get the moments of the mean 
displacements (i.e. mean displacement, mean squared displacements, mean cube 
displacements ...) 
 Make a note of the MSD with the calibrated time. 
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5) The Moment Scaling Spectrum 
 Plot a double log graph of Tau vs Moment for moments 1-6 
 Calculate the Scaling Coefficients from the slopes of the double log plots and plot 
(below) and calculate the slope of the moment scaling spectrum (sMSS) by fitting a 
trendline.  
Note: Variables used in macro given in brackets 
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Figure 1. Analysis of individual trajectory. Screenshot of the output generated by the macro 
for a single trajectory.  
Appendix 
178 
 
Figure 2. Depiction of the difference between distance and displacement (left) and what “Tau 
= x” represents.  
 
 
Figure 3. Graphs calculated by macro. A) Mean squared displacement. B) Log/log plot. C) Moment 
scaling spectrum. 
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1.4 Matlab code for FRAP analysis 
 
%%FRAP ANALYSIS 
  
% For analysis of FRAP data in excel spreadsheet format or CSV 
format with  
% Time, Bleached Regoin,Non-bleached Region and Background.  
% By using the code, the end product 
% will be the value of Y at time infinity, the rate of the  
% and goodness of fit of the curve. 
  
%--                                             Written By Si Seet 
Chan, March 2015 
%--                                             v5+ Revisions by 
Dave Mason [dnmason@liv.ac.uk] 
  
%-- VERSION HISTORY 
% 
% v3: Added ability to read in csv, xls, xlsx, txt files 
% v4: Final version for SiSeet's project. Can process multiple 
sheets at once. 
% v5: Added option for a master log of results 
% v6: v5 breaks with multisheet excel files - reads xls and xlsx 
with "xlsread" and others (csv, txt) with  
%       importdata as v5. Also changed figure background to white on 
initialisation. Altered title to include filename  
%       (without extension) and cancel Latex Interpretation. 
% v7: Reduced bleach threshold to 30% 
% v7.1: Error messages changed to start with 'Dave says' 
% Clear the workspace and command history 
clear all 
close all 
clc 
  
%-- Ask if there's a master file 
useMaster=questdlg('Do you have a master file? Select No to make a 
new one or Cancel not to bother','Master'); 
if strcmp(useMaster,'Yes') 
    [mastFile,mastPath]=uigetfile('*','Select Master File'); 
    %-- Load in existing data 
    [~, ~, mastData]=xlsread([mastPath mastFile]); 
elseif strcmp(useMaster,'No') 
    mastPath=uigetdir('Select a folder in which to make a new Master 
File'); 
    mastFile='masterFRAP.xls'; 
    %-- No file, so store a new header 
    mastData={'Timestamp','Path','Filename','Plateau','Rate','R 
squared'}; 
end  
%-- catch empty master path here if useMaster is no or cancel 
####### 
  
  
% To get data from the workspace 
% In the form of Time, Bleach (ROI1), Control (ROI2) and Background 
(ROI3) 
% Find data in different format 
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[inFile, 
inPath]=uigetfile({'*.*';'*.xls';'*.txt';'*.csv';'*.xlsx'},'select 
file(s)','multiselect','on'); 
if inPath<0; 
    disp('DAVE SAYS - Error in finding file') 
    return 
end 
  
% For multiselection of files to occur, need code to see whether is 
it 
% multiple files or single files. Multiple files = char, single file 
= cell 
if iscell(inFile) 
    for n=1:length(inFile) 
  
         
%-- Get extension then test. If Excel, only import first sheet 
[tempPath tempFile tempExt]=fileparts([inPath inFile{n}]); 
if strfind(tempExt,'xls')>0 
    D=xlsread(fullfile([inPath inFile{n}]),1); 
    Data=D(:,1:4); 
else 
    D=importdata(fullfile([inPath inFile{n}])); 
    Data=D.data; 
end 
     
    Time=Data(:,1);  
    ROI1=Data(:,2); 
    ROI2=Data(:,3); 
    ROI3=Data(:,4); 
         
% csv, old xls and txt format is 3, xlsx format is 4 (the code count 
the 
% number to delete to replace the format 
        h=length(inFile{n})-strfind(inFile{n},'.'); 
% Set Variables 
% Number of PREBLEACH values 
for i=1:size(ROI1,1)-1 
    NUM_PREBLEACH=i; 
   if (ROI1(i)-ROI1(i+1))/ROI1(i)>0.3 
       break 
   end 
       if NUM_PREBLEACH>round((0.5*(size(ROI1)))) 
           disp('DAVE SAYS - Error in finding prebleach value') 
            return 
       end 
end 
  
% NUM_PREBLEACH=input('How many pre-bleach values?'); 
  
%Find the mean of Background 
        Mean_ROI3=mean(ROI3); 
  
% Background Substraction for ROI1 and ROI2 
        BGSUB_ROI1=ROI1-Mean_ROI3; 
        BGSUB_ROI2=ROI2-Mean_ROI3; 
  
% Pre-bleach values for both ROI1 and ROI2 
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        Pre_ROI1=ROI1(1:NUM_PREBLEACH); 
        Pre_ROI2=ROI2(1:NUM_PREBLEACH); 
  
% Mean of Pre-bleach value for both ROI1 and ROI2 
        Mean_PreROI1=mean(Pre_ROI1); 
        Mean_PreROI2=mean(Pre_ROI2); 
  
%Divide BG substraction for ROI1 and ROI2 with mean of Pre-bleach 
value 
        Norm_ROI1=BGSUB_ROI1/Mean_PreROI1;  
        Norm_ROI2=BGSUB_ROI2/Mean_PreROI2; 
  
% Correct for non-specfic bleachng (Rt) 
        Rt=Norm_ROI1./Norm_ROI2; 
  
% First Post Bleach Value (Rp) 
        Rp=Rt(NUM_PREBLEACH+1); 
  
% Correct for Bleach Function 
        Bleach_Fraction=(Rt-Rp)/(1-Rp); 
  
% Correct time for value after bleaching 
        Norm_Time=Time(NUM_PREBLEACH+1:end)-Time(NUM_PREBLEACH+1); 
  
% Get the Norm recovery data from first post bleach value till end 
        Norm_Recovery=Bleach_Fraction(NUM_PREBLEACH+1:end); 
  
% Curve Fitting 
        Equation='(a-b)*exp(-c*x)+b'; 
% where a= Value of Y where line cross Y axis 
% b= Value of Y a infinity 
% c= rate constant for graph 
  
% Plotting of graph and set the starting point for the equation to 
fit the 
% graph for normalised recovery 
        
[fit1,fit1_gof,fit1_alg]=fit(Norm_Time,Norm_Recovery,Equation,'Start
Point',[1 1 0.01]); 
  
% Flagged low Rsqaure value (less than 0.7 percent) 
% plot residuals here against NormTime - don't forget to label axes 
and 
% give the graph a title - use Figure to make a new figure 
fit1_alg.residuals 
        if fit1_gof.rsquare<0.7 
             figure('Color',[1 1 1]); 
            plot(Norm_Time,fit1_alg.residuals); 
            xlabel('Time (min)'); 
            ylabel('Residuals'); 
            title(['Residuals - ' inFile{n}(1:end-(h+1))], 
'Interpreter','none'); 
            legend('Residuals','location','northeast') 
            axis('square') 
            disp('DAVE SAYS - Low Rsquare value for graph') 
            F=getframe(gcf); 
            imwrite(F.cdata,[inPath inFile{n}(1:end-(h+1)) 
'_residuals.png'],'png'); 
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       end 
% Flagged negative Rsquare value 
        if fit1_alg.exitflag<0 
            disp('DAVE SAYS - Fail to fit equation') 
            return 
        end 
     
% Plotting of graphs (Raw Data and Normalised Recovery) 
% Put both graphs into one plot 
         figure('Color',[1 1 1]); 
        % Set the figure position and size of the figure 
set(gcf,'position',[100 100 960 430]) 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't 
cut off (or including other windows) when exporting 
  
% Plotting Raw Data - plot(Time,ROI1,Time,ROI2,Time,ROI3) 
% Labeling of graph and axis, graphs are in square format so that it 
is 
% easier to look at datapoints 
        subplot(1,2,1); 
        plot(Time,ROI1,Time,ROI2,Time,ROI3); 
        title(['FRAP Data - ' inFile{n}(1:end-(h+1))], 
'Interpreter','none'); 
        xlabel('Time (min)'); 
        ylabel('Fluorescence Intensity (a.u.)'); 
        legend 
('Bleach','Control','Background','location','northeast') 
        xlim('auto') 
        ylim('auto') 
        axis('square') 
  
% Plotting Normalised Recovery graph - 
plot(fit1,Norm_Time,Norm_Recovery) 
% Labeling of graph, axis and setting limits to y axis 
% Putting the graphs in square format so that it is easier to look 
at the 
% datapoint 
        subplot(1,2,2); 
        plot(fit1,Norm_Time,Norm_Recovery); 
        title(['Normalised Recovery Graph - ' inFile{n}(1:end-
(h+1))], 'Interpreter','none'); 
        xlabel('Time (min)'); 
        ylabel('Fractional Recovery'); 
        legend('Normalised Recovery','Curve 
Fitting','location','southeast') 
        xlim('auto') 
        ylim([0 1.2]) 
        axis('square') 
         
% Save figure in png format 
        F=getframe(gcf); 
        imwrite(F.cdata,[inPath inFile{n}(1:end-h),'png']); 
  
% Save workspace in mat format 
        save([inPath inFile{n}(1:end-h),'mat']); 
  
%-- If selected, write out data to master 
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if strcmp(useMaster,'Yes') || strcmp(useMaster,'No') 
    c=fix(clock); 
    c=strcat(int2str(c(1)),'-',sprintf('%02d',c(2)),'-
',sprintf('%02d',c(3)),'-
',sprintf('%02d',c(4)),sprintf('%02d',c(5))); 
    %-- Append new data 
    mastData=vertcat(mastData,{c inPath inFile{n} num2str(fit1.b) 
num2str(fit1.c) num2str(fit1_gof.rsquare)}); 
    %-- Write out master 
    xlswrite([mastPath '\' mastFile],mastData); 
    %-- Running batch to a master file, you probably don't want the 
images to stay open so... 
    close all 
end   
         
% Report data needed for analysis 
        disp(['----- ' inFile{n} ' -----']) 
        disp(['Y value at time infinity = ' num2str(fit1.b)]) 
        disp(['Rate Constant =' num2str(fit1.c)]) 
        disp(['R Square value for fitness of the equation=' 
num2str(fit1_gof.rsquare)]) 
    end 
     
     
%-- Single file selected     
else 
%-- Get extention then test. If Excel, only import first sheet 
[tempPath tempFile tempExt]=fileparts([inPath inFile]); 
if strfind(tempExt,'xls')>0 
    D=xlsread(fullfile([inPath inFile]),1); 
    Data=D(:,1:4); 
else 
    D=importdata(fullfile([inPath inFile])); 
%     Data=D.data; 
end 
     
    Time=Data(:,1);  
    ROI1=Data(:,2); 
    ROI2=Data(:,3); 
    ROI3=Data(:,4); 
         
% csv, old xls and txt format is 3, xlsx format is 4 (make it into a 
% variable so that the code could find out whether is it csv,xls,txt 
or 
% xlsx format 
h=length(inFile)-strfind(inFile,'.'); 
  
% Set Variables 
% Number of PREBLEACH values 
for i=1:size(ROI1,1)-1 
    NUM_PREBLEACH=i; 
   if (ROI1(i)-ROI1(i+1))/ROI1(i)>0.3 
       break 
   end 
       if NUM_PREBLEACH>(0.5*(size(ROI1))) 
           disp('DAVE SAYS - Error in finding good prebleach value') 
            return 
       end 
end 
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% NUM_PREBLEACH=input('How many pre-bleach values?'); 
  
%Find the mean of Background 
Mean_ROI3=mean(ROI3); 
  
% Background Substraction for ROI1 and ROI2 
BGSUB_ROI1=ROI1-Mean_ROI3; 
BGSUB_ROI2=ROI2-Mean_ROI3; 
  
% Pre-bleach values for both ROI1 and ROI2 
Pre_ROI1=ROI1(1:NUM_PREBLEACH); 
Pre_ROI2=ROI2(1:NUM_PREBLEACH); 
  
% Mean of Pre-bleach value for both ROI1 and ROI2 
Mean_PreROI1=mean(Pre_ROI1); 
Mean_PreROI2=mean(Pre_ROI2); 
  
%Divide BG substraction for ROI1 and ROI2 with mean of Pre-bleach 
value 
Norm_ROI1=BGSUB_ROI1/Mean_PreROI1;  
Norm_ROI2=BGSUB_ROI2/Mean_PreROI2; 
  
% Correct for non-specfic bleachng (Rt) 
Rt=Norm_ROI1./Norm_ROI2; 
  
% First Post Bleach Value (Rp) 
Rp=Rt(NUM_PREBLEACH+1); 
  
% Correct for Bleach Function 
Bleach_Fraction=(Rt-Rp)/(1-Rp); 
  
% Correct time for value after bleaching 
Norm_Time=Time(NUM_PREBLEACH+1:end)-Time(NUM_PREBLEACH+1); 
  
% Get the Norm recovery data from first post bleach value till end 
Norm_Recovery=Bleach_Fraction(NUM_PREBLEACH+1:end); 
  
% Curve Fitting 
Equation='(a-b)*exp(-c*x)+b'; 
% where a= Value of Y where line cross Y axis 
% b= Value of Y a infinity 
% c= rate constant for graph 
  
% Plotting of graph and set the starting point for the equation to 
fit the 
% graph for normalised recovery 
[fit1,fit1_gof,fit1_alg]=fit(Norm_Time,Norm_Recovery,Equation,'Start
Point',[1 1 0.01]); 
  
% Flagged low Rsqaure value (less than 0.7 percent) 
% plot residuals here against NormTime - don't forget to label axes 
and 
% give the graph a title - use Figure to make a new figure 
fit1_alg.residuals 
if fit1_gof.rsquare<0.7 
     figure('Color',[1 1 1]); 
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    plot(Norm_Time,fit1_alg.residuals); 
    xlabel('Time (min)'); 
    ylabel('Residuals');    
    title(['Residuals - ' inFile{n}(1:end-(h+1))], 
'Interpreter','none'); 
    legend('Residuals','location','northeast') 
    axis('square') 
    set(gcf,'position',[100 100 450 450]) 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't 
cut off (or including other windows) when exporting 
    disp('DAVE SAYS - Low Rsquare value for graph') 
    F=getframe(gcf); 
    imwrite(F.cdata,[inPath inFile(1:end-(h+1)) 
'_residuals.png'],'png'); 
end 
% Flagged negative Rsquare value 
if fit1_alg.exitflag<0 
    disp('DAVE SAYS - Fail to fit equation') 
    return 
end 
     
% Plotting of graphs (Raw Data and Normalised Recovery) 
% Put both graphs into one plot 
 figure('Color',[1 1 1]); 
% Set the figure position and size of the figure 
set(gcf,'position',[100 100 960 430]) 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't 
cut off (or including other windows) when exporting 
  
% Plotting Raw Data - plot(Time,ROI1,Time,ROI2,Time,ROI3) 
% Labeling of graph and axis, graphs are in square format so that it 
is 
% easier to look at datapoints 
subplot(1,2,1); 
plot(Time,ROI1,Time,ROI2,Time,ROI3); 
%title('FRAP Data '); 
title(['FRAP Data - ' inFile(1:end-(h+1))], 'Interpreter','none'); 
xlabel('Time (min)'); 
ylabel('Fluorescence Intensity (a.u.)'); 
legend ('Bleach','Control','Background','location','northeast') 
xlim('auto') 
ylim('auto') 
axis('square') 
  
% Plotting Normalised Recovery graph - 
plot(fit1,Norm_Time,Norm_Recovery) 
% Labeling of graph, axis and setting limits to y axis 
% Putting the graphs in square format so that it is easier to look 
at the 
% datapoint 
subplot(1,2,2); 
plot(fit1,Norm_Time,Norm_Recovery); 
%title('Normalised Recovery Graph'); 
title(['Normalised Recovery Graph - ' inFile(1:end-(h+1))], 
'Interpreter','none'); 
xlabel('Time (min)'); 
ylabel('Fractional Recovery'); 
legend('Normalised Recovery','Curve Fitting','location','southeast') 
xlim('auto') 
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ylim([0 1.2]) 
axis('square') 
  
% Save figure in png format 
F=getframe(gcf); 
imwrite(F.cdata,[inPath inFile(1:end-h),'png']); 
  
% Save workspace in mat format 
save([inPath inFile(1:end-h),'mat']); 
  
%-- If selected, write out data to master 
if strcmp(useMaster,'Yes') || strcmp(useMaster,'No') 
    c=fix(clock); 
    c=strcat(int2str(c(1)),'-',sprintf('%02d',c(2)),'-
',sprintf('%02d',c(3)),'-
',sprintf('%02d',c(4)),sprintf('%02d',c(5))); 
    %-- Append new data 
    mastData=vertcat(mastData,{c inPath inFile num2str(fit1.b) 
num2str(fit1.c) num2str(fit1_gof.rsquare)}); 
    %-- Write out master 
    xlswrite([mastPath '\' mastFile],mastData); 
end   
  
% Report data needed for analysis 
disp(['----- ' inFile ' -----']) 
disp(['Y value at time infinity = ' num2str(fit1.b)]) 
disp(['Rate Constant =' num2str(fit1.c)]) 
disp(['R Square value for fitness of the equation=' 
num2str(fit1_gof.rsquare)]) 
end 
%-- Clear the variable used to write out 
clear mastData 
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1.5 Structure of Halotag ligand  
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1.6 Legends for supplementary movies 
M1: Timelapse of HIF-1α-GFP BAC cells in hypoxia. HIF-1α-GFP BAC HeLa cells were plated 
in a 35 mm glass-bottom dish and incubated on the microscope stage in 1 % O2. Images 
were taken every 5 min. Total length of movie is 17 h. Frame rate = 8 frames / s. 
M2: Timelapse of EGFP-HIF-2α speckles. HeLa cells were transiently transfected with EGFP-
HIF-2α and plated in a 35 mm glass-bottom dish 24h prior to imaging. Cells were placed on 
the microscope stage in normoxic conditions. Timelapse shows the movement of the 
HIF-2α speckles. 
M3: Example of EGFP-HIF-2α speckle trajectories (1). EGFP-HIF-2α speckle (highlighted by 
white circle) tracked using ImageJ and the trajectory recorded (white line). Highlights a 
speckle exhibiting more restricted / confined movement.  
M4: Example of EGFP-HIF-2α speckle trajectories (2). EGFP-HIF-2α speckle (highlighted by 
yellow circle) tracked using ImageJ and the trajectory recorded (yellow line). Highlights a 
speckles exhibiting less restricted movement. 
M5: Example of tracking locations of EGFP-HIF-2α speckles during photobleaching 
experiment. Location of EGFP-HIF-2α speckles during FRAP experiment was analysed using 
ImageJ. Speckles were identified prior to bleaching and tracked during experiment to 
determine if recovery of fluorescence occurs in the same location.   
M6 and M7: Example of individual speckles tracked during photobleaching experiments. 
Two examples that suggest that EGFP-HIF-2α recovers into pre-existing speckles (speckles 
that were present prior to bleaching). 
